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general introduction

Personalised medicine is a way to 
optimise treatment strategies by tailoring 
the treatment to the characteristics of 
an individual patient. These patient 
characteristics can include sex, age, 
height and weight, concomitant 
medication use or concomitant disease 
and biomarkers such as specific proteins 
in the blood. Also, information about 
a patient’s DNA can be used to predict 
drug response. Pharmacogenetics/
genomics is a research field that studies 
variations in DNA sequence and the 
relation with drug response 1. For the 
treatment of cardiovascular diseases 
several interactions between the DNA 
and drug response have been identified 2. 
This information can be used to predict 
the chance that patients have less efficacy 
or more adverse drug reactions and 
adjust the dose or prescribe a different 
drug accordingly. Pharmacogenetics of 
treatment for cardiovascular disease is not 
implemented in clinical practice on a large 
scale yet. Although the FDA recommends 
the use of pharmacogenetic tests in the 
warfarin label, many are still waiting for 
more evidence on the effectiveness and 
cost-effectiveness 3.
Pharmacogenetics is already used 
in clinical practice for several drugs. 
For example, genotyping patients for 
HLA B*5701 is shown to be a cost-
effective method to decrease the risk of 
a hypersensitivity reaction to abacavir, 
a human immunodeficiency virus-1 
(HIV-1) nucleoside-analogue reverse 
transcriptase inhibitor 4. Personalised 
medicine also appears to be useful in the 
treatment with coumarin anticoagulants. 
These oral anticoagulants have a narrow 
therapeutic range and a large variability 
in dose requirement among patients. A 
subtherapeutic dose may lead to therapy 
failure and thereby to an increased risk 
of stroke or systemic embolism, while a 
supratherapeutic dose leads to an increased 
risk of bleeding. Pharmacogenetic 
information can be used to predict the 
optimal dose before treatment initiation. 
During the late 1990s, an association 
between variations in the CYP2C9 gene, 
coding for the main metabolising enzyme 
of coumarin anticoagulants, CYP2C9, 
and the required dose of warfarin was 
shown 5,6. Later, genetic variations in other 
genes were also found to be associated with 
coumarin anticoagulant dose requirement. 
Variations in the CYP2C9 gene and in 
the VKORC1 gene (coding for the target 
enzyme of coumarin anticoagulants, 
VKORC1) together explain approximately 
one third of the dose variation 7,8. 
Genotyping patients before the start with 
coumarin anticoagulants is expected to 
help the physicians prescribe the right 
dose and thereby increase the efficacy 
and safety of the treatment. Whether 
this is also clinically relevant will be 
investigated in a large European clinical 
trial, the European Pharmacogenetics 
of Anticoagulant Therapy (EU-PACT) 
trial 9. In this trial the clinical utility of a 
pharmacogenetic-guided dosing algorithm 
will be investigated for acenocoumarol, 
phenprocoumon and warfarin in six 
European countries. The results from the 
EU-PACT trial will also be used to assess 
the cost-effectiveness of pre-treatment 
genotyping. It is important to study these 
economic issues because this information is 
required for implementation. For example, 
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health insurance companies often require 
information about the cost-effectiveness 
before reimbursement. The studies in 
this thesis were performed in preparation 
for the final EU-PACT analyses. The 
information provided in this thesis will 
be used as input for the cost-effectiveness 
analysis of the EU-PACT data.
objectives of this thesis
The subject of this thesis is personalised 
treatment with oral anticoagulant drugs. 
A first objective of this thesis is to study 
genetic and other determinants that explain 
the variability in response to coumarin 
anticoagulants. A second objective is to 
study the economic consequences of 
different options (personalised medicine 
or using new oral anticoagulant drugs) to 
improve anticoagulant therapy.
outline of this thesis
This thesis starts with a background paper 
(chapter 2) on the use and characteristics 
of different coumarin anticoagulants, 
current clinical challenges and the role of 
pharmacogenetics in the treatment with 
these drugs. Part I of this thesis focuses 
on different determinants of variation 
in response to coumarin anticoagulants. 
In Chapter 3, we investigate the effects 
of CYP2C9 and VKORC1 genotype on 
anticoagulation control over time after 
initiating acenocoumarol treatment. 
Chapter 4 describes a similar study on the 
effects of CYP2C9 and VKORC1 genotype 
on phenprocoumon anticoagulation 
control in different time periods. 
In Chapter 5, we study the effect of 
omeprazole and esomeprazole on the 
maintenance dose of phenprocoumon and 
include the effect of the use of these drugs 
on the required maintenance dosage in a 
genotype-guided and a non-genotype-
guided dosing algorithm.  In Chapter 6, the 
beliefs coumarin anticoagulant users have 
about their therapy with acenocoumarol 
or phenprocoumon are described. These 
beliefs include the concerns patients might 
have about the drugs (for example about 
the side effects) and also beliefs about 
whether it is necessary for their health to 
use the drugs. We also compare the beliefs 
about coumarin anticoagulants with the 
beliefs about other cardiovascular drugs in 
users of an antihypertensive drug or statin. 
Insight into the beliefs about medicines 
can help to identify patients with a high 
risk of non-adherence to the therapy.
Part II of this thesis focuses on the 
cost-effectiveness of pharmacogenetic-
guided dosing of coumarin anticoagulants, 
as well as the cost-effectiveness of new 
oral anticoagulants. Chapter 7 provides 
a review of cost-effectiveness studies 
on pharmacogenetic-guided coumarin 
dosing published up to the end of 2009. In 
Chapter 8, we evaluate a cost-effectiveness 
study on this subject, published in 2010, 
using the International Normalized Ratio 
(INR) as a surrogate endpoint to model 
the risk of adverse events. In Chapter 9, we 
use the model described in chapter 8 and 
adapt it to analyse the cost-effectiveness of 
10
pharmacogenetic-guided phenprocoumon 
dosing in The Netherlands. Chapter 10 
describes a review of current standards of 
coumarin anticoagulant therapy for atrial 
fibrillation and its associated costs in six 
different European countries. In Chapter 
11, we conduct a cost-effectiveness 
analysis comparing three new oral 
anticoagulants for stroke prevention 
in patients with atrial fibrillation with 
coumarin anticoagulants in in a country 
with specialized anticoagulation clinics 
(The Netherlands) and in a country 
where the treatment of many patients 
with coumarin anticoagulants occurs 
in a primary care setting rather than a 
specialised anticoagulation clinic (the 
United Kingdom). Lastly, we discuss our 
findings in Chapter 12, putting the results 
in a broader perspective and describe the 
implications for (future) clinical practice 
and decision making.
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abstract
Coumarin derivatives, such as warfarin, acenocoumarol and phenprocoumon are 
frequently prescribed oral anticoagulants to treat and prevent thromboembolism. Because 
there is a large inter-individual and intra-individual variability in dose-response and a 
small therapeutic window, treatment with coumarin derivatives is challenging. Certain 
polymorphisms in CYP2C9 and VKORC1 are associated with lower dose requirements 
and a higher risk of bleeding. In this review we describe the use of different coumarin 
derivatives, pharmacokinetic characteristics of these drugs and differences amongst the 
coumarin anticoagulants. We also describe the current clinical challenges and the role of 
pharmacogenetic factors. These genetic factors are used to develop dosing algorithms, 
and can be used to predict the right coumarin dose. The effectiveness of this new dosing 
strategy is currently being investigated in clinical trials.
introduction
Coumarin derivatives are oral anticoagulants 
that are prescribed frequently to treat and 
prevent thromboembolism 1. This group 
of drugs was discovered when several cows 
suffered fatal bleeding after eating stacks 
of spoiled sweet clover hay in the 1920s 2. 
After several years, researchers were able 
to isolate and synthesise the first coumarin 
dicumarol. A more potent form of this 
drug, warfarin, initially used as rat poison, 
was introduced as oral anticoagulant in 
the 1950s and is currently the most widely 
used oral anticoagulant. Because warfarin 
and other coumarin derivatives inhibit 
the vitamin K-dependent synthesis of 
biologically active clotting factors, they are 
also called Vitamin K antagonists.
In this review we will describe the 
use of different coumarin derivatives, 
pharmacokinetic characteristics of 
these drugs and differences amongst the 
coumarin anticoagulants. We will also 
describe the current clinical challenges 
and the role of pharmacogenetic factors. 
These genetic factors are included in 
dosing algorithms, which can be used to 
predict the right coumarin dose for an 
individual patient. The effectiveness of 
these new dosing algorithms is currently 
being investigated in clinical trials.
coumarin anticoagulants; indications
Coumarin anticoagulants are prescribed 
for different indications such as treatment 
and prevention of deep vein thrombosis 
or pulmonary embolism or prevention of 
systemic embolism or stroke in patients 
with prosthetic heart valves or atrial 
fibrillation 1. Atrial fibrillation is the most 
frequent indication and has an estimated 
prevalence in developed countries of 
1.5 to 2% 3. Patients with this cardiac 
arrhythmia have an increased risk of stroke 
and systemic embolism and warfarin use 
can reduce this risk by approximately 
60% 4. Anticoagulant therapy is therefore 
recommended in all patients with atrial 
fibrillation, except for patients with a very 
15
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low stroke risk (CHA2DS2-VASc score<1, 
i.e., patients with no other risk factors such 
as congestive heart failure, hypertension, 
age>65, diabetes mellitus, previous stroke 
or vascular disease) 3.
Patients with a prosthetic heart 
valve have an increased risk of 
thromboembolism, caused by an 
altered blood flow and activation of 
the coagulation system by exposure of 
the blood to artificial surfaces 5. In a 
systematic review of observational studies 
major embolism occurred at a rate of 4 per 
100 patient-years. This risk was reduced 
by approximately 75% when patients 
used a coumarin derivative 6. Warfarin 
is more effective in the prevention of 
thromboembolic events than platelet-
inhibitor therapy with aspirin 7. A 
combination of a coumarin derivative 
and an antiplatelet drug has been shown 
to be even more effective in reducing the 
risk of death and thromboembolism than 
a coumarin derivative alone 8.
Venous thromboembolism (deep vein 
thrombosis or pulmonary embolism) often 
occurs as a complication after knee or hip 
replacement surgery 9. The use of warfarin 
after discharge from the hospital reduces 
the risk of this complication 10. When 
patients develop a deep vein thrombosis 
or pulmonary embolism, treatment 
with an oral anticoagulant is also 
indicated. Because it takes some time 
before the normal coagulation factors 
are cleared from the plasma the effect 
of coumarin anticoagulants is achieved 
after a several days. Patients with venous 
thromboembolism should therefore also 
start with a low molecular weight heparin 
for the first few days 11.
current Practice
Because the dose-response can vary between 
patients (inter-individual variability) and 
varies over time within one patient (intra-
individual variability), frequent monitoring 
of the anticoagulant effect is required. This 
can be done by measuring the prothrombin 
time expressed as the International 
Normalised Ratio (INR) 12. For people not 
using any anticoagulant, this INR should be 
1.0. In most countries, the target INR range 
for patients with atrial fibrillation or venous 
thromboembolism is 2.0-3.0, which means 
that the in vitro coagulation takes 2 to 3 
times longer if compared to subjects not 
using coumarin anticoagulants 13. For some 
indications like prosthetic heart valves a 
higher target range is used (2.5-4.0) 14.
When patients have to initiate coumarin 
therapy, a standard loading dose is frequently 
prescribed for the first few days to reach the 
therapeutic concentration more rapidly. After 
a few days, the patient´s INR is measured 
to check the response to the coumarin 
anticoagulant and the dose is adjusted 
accordingly. When the patient has reached 
a stable INR within the target range and a 
stable dose, on average INR measurements 
will be repeated every 4-6 weeks.
In most countries treatment with 
coumarin derivatives is managed by the 
GP or in the hospital (routine practice). 
In some countries, for example Spain 
and the Netherlands, the treatment is 
managed by specialised anticoagulation 
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clinics 15,16. The quality of care, assessed as 
percentage time spent in the therapeutic 
range, is higher in anticoagulation clinics 
than in routine practice. In a systematic 
review and meta-regression in 2006, the 
percentage time spent in the therapeutic 
range was 58% in routine practice and 
66% in anticoagulation clinics 17. In the 
Netherlands all coumarin users when 
treated outside the hospital are treated by 
an anticoagulation clinic and the target 
range for patients with atrial fibrillation 
or venous thromboembolism is 2.0-3.5. 
The percentage time in this range was as 
high as 80% for patients using long-term 
anticoagulants in 2011 18. Management 
by anticoagulation clinics has been found 
to be cost-effective compared to routine 
practice 19.
Patients using long-term anticoagulant 
therapy can find it bothersome to visit the 
clinic often for INR measurement. Many 
of these patients prefer self-monitoring, 
which is possible using a finger prick point 
of care test. When a patient only self-tests, 
the result is forwarded to the physician 
who will determine the next coumarin 
dose. With patient self-management, 
the patients can also adjust the dose 
themselves, after sufficient training 20. 
challenges
Coumarin derivatives have a small 
therapeutic window. When the dose is too 
low, the risk of thromboembolic events 
remains high and the drug is not effective. 
When the dose is too high, the risk of 
bleeding is increased 21. Bleeding events are 
the most frequent serious adverse effects of 
coumarin derivatives. These events can vary 
from mild haematoma to life-threatening or 
fatal intracranial haemorrhage. In addition, 
there is a large inter-individual and intra-
individual variability in dose-response. 
Therefore, giving patients the right dose is 
challenging. The daily dose can vary up to 
10-fold between patients for warfarin (1.5 
to 14 mg) as well as for acenocoumarol (1 
to 9 mg) or phenprocoumon (0.75-9 mg) 22. 
Coumarin anticoagulant use therefore often 
results in drug-related hospitalisation 23,24. 
Which dose is required for a certain 
patient depends on several factors. The 
dose can vary between patients because 
of differences in, for example, age, height, 
weight, sex, concomitant medication and 
comorbidities 25-27. Older patients generally 
require a lower dose, taller or heavier patients 
a higher dose. Genetic factors also play an 
important role here, and will be discussed 
in detail later in this review. The required 
dose can also vary over time within one 
patient because of changes in concomitant 
medication, diet or health status (fever, 
vomiting etc.) 28-30. Many interactions with 
other drugs exist because of inhibition 
or induction of the CYP2C9 enzyme 31. 
Adherence changes of coumarins, as in many 
other drugs, also influence the response to 
the anticoagulants 32.
17
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PharmacoKinetics and differences between 
coumarin anticoagulants
In Europe, different coumarin derivatives 
are used of which warfarin, acenocoumarol, 
and phenprocoumon are most frequently 
prescribed 33. All coumarin derivatives 
are 4-hydroxycoumarins. Each coumarin 
anticoagulant has a single, chiral centre with an 
S- or an R-enantiomeric form. The drugs are 
administered as racemic mixtures consisting 
of 50% of each enantiomer 31. Although 
the working mechanism of these drugs is 
similar, there are some important differences 
in pharmacokinetics between warfarin, 
acenocoumarol and phenprocoumon.
All coumarin anticoagulants (except 
S-acenocoumarol) are absorbed from the 
gastrointestinal tract with almost complete 
oral bioavailability. S-acenocoumarol 
undergoes extensive first pass metabolism. 
Within a few hours, peak plasma 
concentrations are reached 31. Approximately 
98-99% of the coumarin anticoagulant is 
bound to plasma albumin 22. Metabolism into 
inactive metabolites takes place in the liver 
by various hydroxylation reactions, catalysed 
by cytochrome P450 (CYP) enzymes.
S-warfarin (the most active form) 
is mainly metabolised by CYP2C9. 
R-warfarin is metabolised by several other 
CYP isoforms 34. CYP2C9 is also the 
principal metabolising enzyme of both 
acenocoumarol enantiomers, but plays a 
less important role in phenprocoumon 
metabolism, where CYP3A4 is also 
involved 35,36. Of these three coumarin 
anticoagulants, phenprocoumon has the 
longest elimination half-life of 110-130 
hours 37. Warfarin half-life varies from 
24-33 hours for S-warfarin to 35-58 for 
R-warfarin 38. Acenocoumarol has the 
shortest half-life. Although the S-enantiomer 
is more active, the anticoagulation effect 
of acenocoumarol mainly depends on the 
R-enantiomer, because of the short half-life 
of S-acenocoumarol (1.8 hours). The 
elimination half-life of R-acenocoumarol is 
6.6 hours 39.
Pharmacogenetics 
Genetic variants play an important 
role in the large variation in dose 
requirements. Certain polymorphisms 
in two genes (CYP2C9 and VKORC1) 
can explain approximately one-third of 
the dose variation 40,41. The contribution 
of VKORC1 to the variation in dose 
requirement is larger (approximately 30%) 
than the contribution of CYP2C9 (usually 
less than 10%) 22. 
CYP2C9 - PharmacoKinetics
Soon after Rettie et al. identified CYP2C9 
as the main metabolising enzyme of 
warfarin in 1992 42, the effect of the *2 
polymorphism on the dose requirement 
was shown 43. Aithal et al. first described 
that both *2 and *3 allele carriers required 
a lower dose and had an increased risk 
of bleeding 44. Since publication of this 
study, many others investigated the effect 
of these polymorphisms on warfarin dose 
18
requirement and other related outcomes 
(overanticoagulation, bleeding etc.). 
Table 1 summarises some of the evidence 
on the association between CYP2C9 
genotypes and coumarin anticoagulant 
dose or bleeding risk. A meta-analysis 
of pharmacogenetic studies on warfarin 
revealed that the reduction in warfarin 
dose requirement varied from 20% for 
heterozygous carriers of a *2 allele to 
78% in homozygous carriers of a *3 
allele compared to wild-types 45. In the 
studies measuring bleeding risk, carrying 
one or more CYP2C9 variant alleles 
was associated with an approximate 
doubling of bleeding risk compared to 
the wild-type 46. Since CYP2C9 variants 
influence the pharmacokinetics of 
coumarin anticoagulant anticoagulants, 
it is possible that the risk of bleeding in 
patients carrying a variant allele is not 
only increased because of the lower dose 
requirement, but also because of a slower 
response to changes in dose.
Although less has been published about 
CYP2C9 genotypes and acenocoumarol 
dose than about warfarin, there are several 
studies confirming the associations 
found with warfarin, genotypes and 
bleeding risk for acenocoumarol. The 
presence of a CYP2C9 *3 allele reduces 
the metabolism of the normally clinically 
table 1. Association between CYP2C9 genotypes and dose or bleeding risk
reference country n study type association
Warfarin
Lindh 2009 45 Various 39 studies Meta-analysis Dose reduction:*1*2: 20%, *1*3: 34%, 
*2*2: 36%, *2*3: 57%, *3*3: 78%
Sanderson  
2005 46
Various 2 or 3 studies Meta-analysis Dose reduction *2: 17%, *3: 37%
Bleeding risk *2 RR: 1.91, *3 RR: 
1.77, *2 or *3: RR 2.26
Acenocoumarol
Tassies 2002 49 Spain 325 Observational Dose reduction *1*2: 16%, *1*3: 
36%, *2*2: 1%, *2*3: 27%
Schalekamp  
2004 47
The Netherlands 231 Observational Dose reduction *2: 1%, *3: 20%
Visser 2004 48 The Netherlands 1124 Observational Dose reduction *1*2: 13%, *1*3: 
20%, *2*2: 28%, *2*3: 40%
Visser 2004 51 The Netherlands 996 Observational Major bleeding risk variant carriers: 
HR: 1.83
Phenprocoumon
Hummers 2003 54 Germany 185 Observational Bleeding risk *2: OR 0.35, *3: OR 
3.10
Schalekamp  
2004 53
The Netherlands 284 Observational Dose reduction *2: 21%, *3: 25%
Visser 2004 48 The Netherlands 1124 Observational Dose reduction *1*2: 10%, *1*3: 
17%, *2*2: 33%. In *2*3 patients 
(n=3) dose increased by 9%
19
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inactive S-acenocoumarol and thereby 
increases the half-life of this enantiomer 39. 
Mean acenocoumarol dose requirement 
is therefore 19-29% lower in carriers 
of this allele than in wild-types 47, but 
also 13-15% lower in carriers of a *2 
allele 48,49. The risk of overanticoagulation 
is increased in *3 carriers 47,49,50. One study 
found an increased risk of major bleeding 
which was seen in *2 and *3 carriers with a 
hazard ratio of 1.83 51.
Because CYP2C9 is not the principal 
metabolising enzyme of phenprocoumon, 
one might expect that it would have a less 
pronounced effect in the pharmacogenetics 
of phenprocoumon than for warfarin or 
acenocoumarol 52. However, Schalekamp 
et al. found a 22-25% decreased dose 
requirement in CYP2C9 variant carriers 53. 
In one study, both minor and major bleeding 
risk was increased (OR 3.10) in *3 carriers 54.
VKORC1 - Pharmacodynamics
In 2004 the gene coding for the target 
enzyme of coumarin anticoagulant 
anticoagulants, Vitamin K epoxide 
reductase complex subunit 1 (VKORC1), 
was identified 55,56. Since 2005, many 
authors have studied the effect of 
VKORC1 polymorphisms on warfarin 
and other coumarin anticoagulant doses. 
A number of polymorphisms in this gene 
have been studied. Some rare mutations 
in VKORC1 are associated with warfarin 
resistance 57. More common are mutations 
that are associated with insensitivity 
through altered VKORC1 expression. The 
-1639G>A, in tight linkage disequilibrium 
with 1173C>T, is associated with 
the widest range of variation in gene 
expression and hence enzyme activity 
within a number of different populations 58. 
In a recent meta-analysis, the difference in 
warfarin dose in relation to genotype for 
the -1639 polymorphism was compared 
for a Caucasian and an Asian population 59. 
From their results we could calculate that 
Caucasian patients with one -1639 A allele 
required a 25% lower dose and patients 
with two -1639 A alleles a 50% lower 
dose than patients without this variant 
allele. This effect was also present in Asian 
patients, although it was smaller (14 and 
38% lower doses respectively). 
Several authors have shown that 
acenocoumarol dose is also influenced 
by VKORC1 genotype. Reitsma et al. 
already had shown in 2005 that Dutch 
patients carrying one or two variant alleles 
for the 1173 polymorphism required a 
28% and 47% lower dose, respectively, 
when compared to wild-types 60. In Greek 
acenocoumarol users, heterozygous 
carriers of a variant allele required a 19% 
lower dose and homozygous carriers a 63% 
lower dose 61. Similar percentages were 
found in a German and Austrian population 
(25% and 52%) 62, in a Serbian population 
(27% and 62%) 63 and amongst Lebanese 
acenocoumarol users (34% and 50%) 64.
Reitsma et al. also investigated the 
influence of VKORC1 polymorphism on 
the phenprocoumon dose. Patients with 
a CT genotype at position 1173 had a 
10% lower dose and patients with a TT 
genotype a 52% lower dose than wild-
types (CC) 60. This effect was also seen in 
20
several German and Austrian studies. The 
dose in phenprocoumon users with one 
variant VKORC1 allele was 19-31% lower 
than in wild-type users and 43-51% lower 
in users with two variant alleles 62,65-67.
Table 2 summarises the current 
evidence on the association between 
VKORC1 genotypes and coumarin 
anticoagulant dose or bleeding risk. 
Reitsma showed an increased bleeding 
risk in carriers of a VKORC1 T1173 allele. 
This effect was larger in phenprocoumon 
(OR 2.6) than in acenocoumarol (OR 
1.2) 60. Although VKORC1 genotype 
was associated with overanticoagulation 
in a study of warfarin users by Wadelius 
et al., no effect on bleeding risk was 
found for VKORC1 polymorphism 40. 
In a study by Montes et al. the risk of 
gastrointestinal bleeding was increased in 
acenocoumarol users carrying a VKORC1 
polymorphism 68. In a more recent study, 
the risk of bleeding was also increased in 
warfarin users with a VKORC1 variant 
allele (incidence of 4.9% in AA, 2.3% 
in AG and 0.47% in GG patients) 69. 
table 2. Association between VKORC1 genotypes and dose or bleeding risk
reference country n study type association
Warfarin
Wadelius 2009 40 Sweden 1496 Observational Bleeding risk: no difference between 
VKORC1 genotypes
Yang 2010 59 Various 19 studies Meta-analysis Dose reduction: Caucasians: AG: 25%, 
AA: 50%, Asians: AG: 14%, AA: 38%
Lund 2012 69 Scotland 557 Observational Bleeding incidence: GG 0.47%, AG 
2.3%, AA 4.9%
Acenocoumarol
Reitsma 2005 60 The 
Netherlands
330 Observational Dose reduction AG: 28%, AA: 47%
Bleeding risk: OR 2.6 in variant carriers
Markatos 2008 61 Greece 98 Observational Dose reduction AG: 19%, AA: 63%
Montes 2008 68 Spain 266 Observational Gastro intestinal bleeding risk AG: 
OR 1.18, AA: OR 1.51
Cadamuro 2010 62 Austria 206 Observational Dose reduction AG: 25%, AA: 52%
Kovac 2010 63 Serbia 200 Observational Dose reduction AG: 27%, AA: 62%
Esmerian 2011 64 Lebanon 133 Observational Dose reduction AG: 34%, AA: 50%
Phenprocoumon
Reitsma 2005 60 The 
Netherlands
330 Observational Dose reduction AG: 10%, AA: 52%
Bleeding risk: OR 1.2 in variant carriers
Qazim 2009 66 Austria 53 Observational Dose reduction AG: 29%, AA: 49%
Cadamuro 2010 62 Austria 206 Observational Dose reduction AG: 21%, AA: 51%
Puehringer 2010 65 Austria and 
Germany
185 Observational Dose reduction AG: 19%, AA: 43%
Geisen 2011 67 Germany 75 Observational Dose reduction AG: 31%, AA: 50%
21
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However, this increase in risk was limited 
to the first month of treatment. An 
increased risk of overanticoagulation (and 
thereby indirectly an increased bleeding 
risk) in VKORC1 variant carriers was also 
observed in phenprocoumon (limited to 
the first month also) and acenocoumarol 
(limited to the first 3-6 months) users 70,71.
A recent study showed that 
polymorphisms in VKORC1 -1639G>A 
also influence the response to acute vitamin 
K supplementation in over-anticoagulated 
patients. The INR decreased faster in 
patients carrying the G allele 72.
other genes
The association between coumarin 
anticoagulant dose and other genes 
besides CYP2C9 or VKORC1 has also 
been investigated. For example, an effect 
has been found for GGCX, encoding the 
enzyme catalysing the carboxylation of 
vitamin K dependent clotting factors 73, 
for APOE, encoding the vitamin K liver-
uptake facilitating ligand Apolipoprotein 
E 74, for PROC, encoding Protein C, which 
inactivates clotting factor Va and VIIIa 75, 
for CYP4F2, encoding the CYP enzyme 
that metabolizes vitamin K 76 and for 
GATA-4, encoding the transcription factor 
involved in the regulation of CYP2C9 77. 
However, these effects could not always be 
replicated, or explained only a very small 
part of the dose variation.
genotyPe-guided dosing algorithms for 
warfarin
The first dosing algorithms incorporating 
CYP2C9 genotype were published in 
2004 78-80. The algorithm by Gage et al. 
was the most extensive and included, 
in addition to CYP2C9 genotype, age, 
body surface area, sex, race, target INR, 
amiodarone use and simvastatin use. The 
algorithm explained 39% of the variation 
in daily warfarin dose. Since that time, 
more than 30 algorithms have been 
published based on both CYP2C9 and 
VKORC1 genotype (Table 3). Sconce et 
al. published one of the first algorithms, 
including CYP2C9 and VKORC1 
genotypes as well as age and height 81. This 
algorithm explained 54% of the warfarin 
dose variation in a British population. 
CYP2C9 genotype alone explained 
17.5% of the variation and VKORC1 
genotype 15%. The algorithm by Carlquist 
et al. was developed in an American 
population and included CYP2C9 and 
VKORC1 polymorphisms, age, weight 
and sex (R2 = 0.45) 82. In 2008, Gage et al. 
published an updated algorithm including 
CYP2C9 and VKORC1 genotype, but also 
age, body surface area, amiodarone use, 
target INR, race and smoking status 83. 
In a Caucasian population this algorithm 
explained 57% of the dose variation, but 
the predictive value was lower (31%) in 
African-Americans. Wadelius et al. were 
able to explain almost 59% of the variation 
in a Swedish population, using information 
22
on both genotypes, age, race, sex and the 
number of interacting drugs capable of 
increasing the INR 40. The univariate R2 
of CYP2C9 genotype was approximately 
12% and that of VKORC1 29%. The 
International Warfarin Pharmacogenetics 
Consortium (IWPC) created an algorithm 
in a more diverse population from 9 
countries in 4 continents 84. Forty-seven 
percent of the dose variation was explained 
by CYP2C9, VKORC1, age, height, weight, 
amiodarone use, race and number of CYP 
enzyme inducers. An alternative measure 
to the percentage of variation explained by 
the algorithm (R2) is the mean absolute 
error (MAE), although this is not reported 
for all algorithms. Table 3 also shows this 
measure for the studies where this measure 
was reported.
For warfarin, many more algorithms 
have been published in different 
populations from several countries, such 
as the USA 85, UK and Canada 86,87, 
Italy 88,89, Slovenia 90, Singapore 
91, Japan 92-94, Korea 95,96, China 97-100, 
Indonesia 101, India 102, Oman 103, Brazil 104 
and Puerto Rico 105. Most of these studies 
have included VKORC1 and CYP2C9 
genotypes, but some have also included 
CYP4F2, CCCG and APOE genotypes 89,99.
The formulas from these studies 
made it possible to calculate a warfarin 
maintenance dose. However, only a handful 
of studies have looked at algorithms for 
other types of coumarin anticoagulant 
doses. Avery et al. also described how to 
derive an initiation dose from an adapted 
version of the IWPC algorithm 106. Gong 
et al. reported both a pharmacogenetic 
loading and maintenance dose in their 
publication 86. When a patient initiates 
warfarin on a pharmacogenetic-guided 
dose, it is difficult to know how to adjust 
this dose after INR measurement. In 2010, 
a dose refinement algorithm was developed 
in a combined population from the USA, 
UK, Sweden and Thailand making use of 
the first INR measurement 107. Later, the 
same group published an algorithm using 
INR information from days 6 to 11 108.
genotyPe-guided dosing algorithms for 
acenocoumarol and PhenProcoumon
Considerably less has been published on 
pharmacogenetic-guided algorithms for 
acenocoumarol and phenprocoumon doses 
compared to warfarin doses (Table 3). Van 
Schie et al. developed a genotype-guided 
algorithm for both acenocoumarol and 
phenprocoumon in a Dutch population 27. 
The authors also provided loading doses 
related to the calculated maintenance dose 
and validated the acenocoumarol algorithm 
later in a different Dutch population 
which yielded an R2 of 52.7% 109. Other 
acenocoumarol algorithms were developed 
in Greek 61, Indian 110 and Spanish 111,112 
populations. For phenprocoumon, only one 
other study has developed an algorithm 67. In 
a small (n=75) German population VKORC1 
genotype, age and weight explained 48.6% of 
the daily phenprocoumon dose variability. 
CYP2C9 genotype was not associated with 
phenprocoumon dose in this study. In the 
study by van Schie et al. the predictive value 
of this gene was 4.5%, similar to that of 
acenocoumarol 27.
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Pharmacogenetic-guided dosing was first 
evaluated by Voora et al. 113. In this study 
the safety and feasibility of using the dosing 
algorithm of Gage et al. (2004) 79 was 
investigated in 48 patients. The authors 
found that this dosing regimen was 
feasible and improved the time to stable 
dose in carriers of a CYP2C9 variant allele. 
The risk of supratherapeutic INR values 
was not decreased in this group. A few 
months later, the first (pilot) randomised 
trial in 38 patients was published 114. 
These authors drew a similar conclusion, 
reporting that genotyping seemed to be 
feasible and acceptable to patients and 
providers. No differences were found in 
percentage time in INR range or the risk 
of supratherapeutic INR values. Another 
randomised trial with 191 patients also 
investigated the added value of a dose 
based on CYP2C9 genotype and found 
that the time to stable dose was decreased 
and the time spent in therapeutic range 
was increased in the intervention group 
versus the control group 115.
Anderson et al. 116 were the first to 
investigate the impact of genotyping for 
both CYP2C9 and VKORC1 genotypes, 
using the algorithm of Carlquist et 
al. 82 and a weighted overview of other 
observational studies. In this study, 220 
patients were included and the patients in 
the intervention arm required fewer INR 
measurements and dose adjustments than 
in the control arm. However, no effect on 
the number of out-of-range INR values 
could be demonstrated when looking 
at all patients. In wild-type patients and 
patients carrying multiple variant alleles, 
genotyping decreased the risk of out-
of-range INRs by 10%. In a randomised 
controlled study published in 2009, 121 
Chinese patients undergoing heart valve 
replacement surgery were included 97. 
Patients who received a dose based on 
the genotype-guided algorithm spent 
more time within the target range and 
required less time to reach a stable dose 
than patients receiving a standard dose. In 
China, the standard initiation dose is 2.5 
mg/day. Another Chinese randomised trial 
using the same algorithm was published 
in 2012 117. The group receiving a loading 
dose according to this pharmacogenetic 
algorithm (n=50) reached stable dosing 
faster than the group receiving a standard 
loading dose of 2.5 mg/day (n=51).
Several non-randomised prospective 
studies on pharmacogenetic-guided dosing 
of warfarin using both VKORC1 and 
CYP2C9 have also been published. Wen et 
al. showed that genotyping for these genes 
could help to decrease the time to stable 
dose, although this study did not have a 
control group 118. In the study by Lenzini et al. 
the percentage time in therapeutic range was 
higher in the genetic group and the risk of 
adverse events lower compared to the clinical 
control group 119. McMillin et al. 120 compared 
2 parallel cohorts, one receiving a standard 
dose and the other receiving a dose based on 
the algorithm by Sconce et al. 81, and found 
that the outcomes in the two parallel cohorts 
were not statistically significantly different. In 
another study, patients in a historical control 
cohort were more frequently hospitalized 
for bleeding or thromboembolism than 
patients whose genotype was reported to 
evaluation of effectiveness of genotyPe-
guided dosing 
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the physician 121. Gong et al. found that the 
differences in time to therapeutic range 
between genotypes were eliminated when 
patients were dosed according to a genotype-
guided algorithm, but a comparison with a 
control group was not possible 86.
In a more recent randomised controlled 
trial by Burmester et al., dosing using 
a pharmacogenetic algorithm was not 
compared with standard care, but to a 
clinical algorithm 122. In both arms, the 
initial warfarin doses were closer to the 
stable therapeutic dose than they would 
have been on a standard dose of 5 mg/day. 
No differences between the two arms were 
found for percentage time in therapeutic 
range. Also Anderson et al. compared two 
algorithms, but both genotype-guided, 
and could not find differences between the 
two groups 123. But in this study, patients 
dosed with any of the two pharmacogenetic 
algorithms (n=504) spent more time within 
the target range and had less out-of-range 
INRs than patients on standard care in a 
parallel cohort (n=1911). This is the largest 
study comparing genotype-guided dosing 
to standard care to date and probably the 
only one with sufficient statistical power 
to detect a significant difference between 
pharmacogenetic-guided care and standard 
treatment. However, none of the studies 
described above (and summarised in Table 4) 
were able to provide convincing evidence 
about the clinical significance of genotyping, 
either because of the small size of the study 
or a non-randomised comparison. Also, no 
trials have been published yet describing 
the impact of genotyping before initiating 
acenocoumarol or phenprocoumon 
treatment.
studies in Progress
Some additional clinical trials are currently 
recruiting patients or have just finished 
recruiting. In the Clarification of Optimal 
Anticoagulation through Genetics 
(COAG) trial, a double blind randomised 
clinical trial, the percentage time patients 
spend in the therapeutic INR range 
during the first 4 weeks of therapy will 
be investigated in two groups 124. The first 
group will receive a genotype-guided dose 
based on algorithms using clinical and 
genetic information. The second group 
will receive a clinical-guided dose based 
on algorithms using clinical information 
only. Patients are currently being recruited 
from several centres in the USA. The 
Genetics Informatics trail (GIFT) is a 
2x2 factorial design trial, comparing a 
pharmacogenetic algorithm with a clinical 
algorithm and a high INR target (2.5) with 
a lower INR target (1.8) 125. In this study, 
patients undergoing hip or knee surgery 
and receiving prophylactic warfarin are 
being included. The primary outcome is a 
composite of venous thromboembolism, 
major bleeding, INR values above 4 or 
death. Both the COAG trial and the GIFT 
trial aim to include more than 1000 patients. 
All aforementioned trials have focused on 
warfarin. Carcas et al. described the study 
protocol of a trial on acenocoumarol 126. 
In this Spanish multicentre, single blind, 
randomised trial, 240 patients with venous 
thromboembolism will be included and 
followed for three months. Patients in 
the control group will be dosed according 
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to common clinical practice; patients 
in the intervention group will be dosed 
according to the algorithm of Borobia et 
al. 111. The primary endpoint is whether 
or not the INR at day 7 of acenocoumarol 
therapy is in the therapeutic range. 
The European pharmacogenetics of 
anticoagulant therapy (EU-PACT) trial is a 
European trial investigating the added value 
of genotyping in warfarin, acenocoumarol 
and phenprocoumon 127. This trial includes 
patients with atrial fibrillation or venous 
thromboembolism initiating warfarin (in 
the UK and Sweden), acenocoumarol 
(in Greece and The Netherlands) or 
phenprocoumon (in The Netherlands, 
Austria and Germany). Patients are being 
randomised to either an intervention group 
or a control group. The acenocoumarol 
and phenprocoumon control group will 
receive a dose based on a clinical algorithm; 
the warfarin control group will receive a 
dose based on standardised clinical care. 
The dosing algorithms by van Schie et al. 
and by Avery et al. are used to calculate 
loading and maintenance doses 27,106. 
The primary outcome of this trial is the 
percentage time in therapeutic INR range 
during the first three months of therapy. 
Secondary endpoints include percentage 
time spent with INR of 4 or higher, time 
to stable dose, time to therapeutic INR, 
time to and number of adverse events 
(bleeding or thromboembolism) and cost-
effectiveness. A new method will be used 
to genotype patients for CYP2C9 and 
VKORC1 polymorphisms 128. This method 
is a point-of-care test, providing the results 
in approximately 1.5 h. This enables 
physicians to prescribe a pharmacogenetic-
guided dose before treatment initiation 
without delaying the start of the therapy.
cost-effectiveness
If and when pharmacogenetic-guided 
coumarin dosing has been shown to be 
effective and safe, clinical practice guidelines 
will probably recommend genotyping. 
But widespread implementation of the 
dosing strategy will also depend on its 
cost-effectiveness. The payer, for example a 
health insurance company, is an important 
stakeholder in this case. If the genetic test 
is not reimbursed, patients might not be 
willing or able to undergo this test and 
receive a genotype-guided dose. The 
insurance company may require proper 
information from cost-effectiveness 
analyses before considering reimbursement.
A cost-effectiveness analysis (CEA) 
involves the comparison of the total costs 
and effectiveness of two or more different 
treatment strategies. In such an analysis 
different costs are considered, including 
not only the costs of genotyping and the 
cost of monitoring, but also the costs of 
cardiovascular events that may occur later 
in time. The effectiveness of genotyping 
can be defined in different ways. It can be 
oriented around the reduction in adverse 
events, in which case the cost-effectiveness 
of genotype-guided dosing versus clinical-
guided (or standard) dosing will be 
expressed as the extra cost to avoid one 
adverse event. This is, however, very 
disease-specific and therefore difficult 
to compare with treatments in other 
diseases. For a health insurance company 
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comparability with other treatments may 
be very valuable when making ‘value for 
money’ or budget allocation decisions. 
For this reason, some payers require a 
cost-utility analysis (CUA), where the 
utility of the new treatment is usually 
expressed in Quality Adjusted Life Years 
(QALYs). The costs per QALY gained can 
be compared more easily with treatments 
in other diseases than the cost per adverse 
event avoided. Some authors have already 
investigated the cost per QALY gained 
by genotype-guided warfarin dosing, 
but there is still large uncertainty about 
the effectiveness of a pharmacogenetic-
guided algorithm 129,130. In the EU-PACT 
trial, the cost per QALY gained by 
pharmacogenetic guided dosing will be 
determined for warfarin, acenocoumarol 
and phenprocoumon 127. The costs of 
genotyping will have an important effect 
on cost-effectiveness. If the costs are low, 
genotyping could reduce overall costs if 
the rate of adverse events is decreased. 
conclusions
Genetic factors play an important role 
in the response to coumarin derivatives. 
Dosing algorithms including CYP2C9 
and VKORC1 genotypes and some 
clinical factors are able to explain more 
than half of the variation in coumarin 
dose requirements. A higher R2 of the 
algorithms than what has been found 
so far, is not expected when more 
polymorphisms are added, as CYP2C9 
and VKORC1 (and to a smaller extent 
CYP4F2) are consistently found as the 
most important determinants of coumarin 
dose in genome wide association 
studies 131-134. The algorithms can be used 
in clinical practice to predict the right 
coumarin dose before treatment initiation. 
The effectiveness of this pharmacogenetic-
guided dosing is still uncertain. Currently, 
novel oral anticoagulants (direct thrombin 
inhibitors and factor Xa inhibitors) have 
been developed, which might be good 
alternatives to coumarin derivatives. 
A meta-analysis of 5 large phase III 
trials revealed that these novel oral 
anticoagulants compared to coumarin 
anticoagulants reduced the risk of stroke 
or systemic embolism by 18% and the 
risk of haemorrhagic stroke by as much as 
49% in patients with atrial fibrillation 135. 
These results indicate that these drugs 
are a promising alternative to coumarin 
derivatives, especially because patients 
will not have to be monitored frequently, 
as is the case with coumarin derivatives. 
However, these novel oral anticoagulants 
also have some disadvantages. No 
biomarker is currently available to monitor 
the anticoagulant effect of the new drugs. 
This fact, together with the fact that some 
of the new drugs have to be taken twice 
daily, could reduce patient adherence. 
Secondly, in elderly patients with renal 
dysfunction, the risk of bleeding is 
increased because of prolonged half-lives 
in patients with renal insufficiency 136. In 
case of a bleed or if emergency surgery 
is needed, there is no antidote available 
yet. However, some studies have been 
done in healthy volunteers, suggesting 
Prothrombin Complex Concentrate 
as a possible antidote 137,138. Lastly, the 
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costs of novel oral anticoagulants are 
considerably higher than the costs of 
coumarin anticoagulants. The costs of the 
drugs represent only one part of the costs; 
one needs to consider the monitoring 
costs and complication costs etc. also. It is 
therefore also necessary to investigate the 
cost-effectiveness of these drugs. Shah et 
al. showed that a direct thrombin inhibitor 
was less cost-effective versus warfarin 
when patients spent more time within the 
therapeutic range 139. As pharmacogenetic-
guided dosing may increase the time 
spent within therapeutic range, it would 
also be very interesting to investigate 
the cost-effectiveness of the novel oral 
anticoagulants versus pharmacogenetic-
guided dosing of coumarin derivatives.  In 
a cost-utility analysis, You et al. concluded 
that the chance that pharmacogenetic-
guided coumarin dosing would be 
cost-effective would be high if the time 
spent in therapeutic INR range could 
be improved from 64% to 77% 140. The 
new oral anticoagulants are expected 
to be used more widely in the coming 
years. This might influence the role of 
anticoagulation clinics when these clinics 
have fewer patients to treat. This can 
increase the operating costs per patient 
and also influence the cost-effectiveness of 
pharmacogenetic-guided dosing.
In conclusion, pharmacogenetics play 
an important role in the interindividual 
and intra-individual variation in response 
to coumarin derivatives. Pharmacogenetic-
guided dosing algorithms could be used 
to predict the required coumarin dose 
before treatment initiation, but the best 
evidence of the effectiveness of genotype-
guided dosing is still forthcoming. After 
the clinical effect of genotyping is known, 
it will be important to consider the 
cost-effectiveness of genotype-guided 
coumarin dosing, also when comparing to 
the new oral anticoagulants.
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abstract
Background: The required acenocoumarol dose and the risk of underanticoagulation and 
overanticoagulation are associated with the CYP2C9 and VKORC1 genotypes. However, 
the duration of the effects of these genes on anticoagulation is not yet known.
Objectives: In the present study, the effects of these polymorphisms on the risk of 
underanticoagulation and overanticoagulation over time after the start of acenocoumarol 
were investigated.
Methods: In three cohorts, we analysed the relationship between the CYP2C9 and 
VKORC1 genotypes and the incidence of subtherapeutic or supratherapeutic International 
Normalised Ratio (INR) values (< 2 and > 3.5) or severe overanticoagulation (INR > 6) 
for different time periods after treatment initiation.
Results: Patients with polymorphisms in CYP2C9 and VKORC1 had a higher risk of 
overanticoagulation (up to 74%) and a lower risk of underanticoagulation (down to 45%) in 
the first month of treatment with acenocoumarol, but this effect diminished after 1–6 months.
Conclusions: Knowledge of the patient’s genotype therefore might assist physicians to 
adjust doses in the first month(s) of therapy.
introduction
Coumarin derivatives, such as 
acenocoumarol, phenprocoumon and 
warfarin, are widely used oral anticoagulants. 
These drugs are prescribed for the treatment 
and prevention of thromboembolic events 
in patients with, for example, venous 
thromboembolism or atrial fibrillation1. 
Because of the narrow therapeutic window 
of these drugs, patients need to be monitored 
frequently by measuring the prothrombin 
time, expressed as the International 
Normalised Ratio (INR). A large variability 
in dose-response exists among coumarin 
users, which is caused by several factors such 
as age, concomitant medication and diet, 
but genetic factors also play an important 
role2-6. Approximately one-third of the 
variation in coumarin dose requirements 
can be explained by polymorphisms 
in the CYP2C9 gene, encoding for the 
main metabolizing enzyme, cytochrome 
P450 2C9 (CYP2C9), and the VKORC1 
gene, encoding for the target enzyme 
Vitamin K epoxide reductase multiprotein 
complex 1 (VKORC1)6-9. Carriers of a 
CYP2C9 *2 or *3 or a VKORC1 T-allele 
require a lower coumarin maintenance 
dose compared with wild-type patients 
(CYP2C9 *1*1, VKORC1 CC)7,10. These 
patients often receive a supratherapeutic 
dose at the start of treatment, which 
may lead to overanticoagulation. Lower 
dose requirements, an increased risk of 
overanticoagulation in the first month(s) of 
therapy and delayed stabilization have been 
shown in carriers of a variant allele in CYP2C9 
and/or VKORC1 in several studies11-17. 
Moreover, the risk of haemorrhagic adverse 
events increases with an increased INR. 
Severe overanticoagulated patients (INR > 6) 
therefore have a considerably increased risk 
of a bleeding event18,19. However, when 
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the INR is below the therapeutic range, 
coumarin therapy is less effective, with a 
higher risk of (recurrent) thromboembolic 
events20. When physicians are unaware of 
the genotype of patients, it is conceivable 
that patients with wild-type genotypes 
are more often underanticoagulated than 
variant allele carriers and the latter group 
has a higher risk for overanticoagulation 
than the former group. This difference in 
dose requirements led to the hypothesis that 
CYP2C9 and VKORC1 wild-type patients 
have an increased risk of subtherapeutic INR 
values and that carriers of a variant allele have 
an increased risk of supratherapeutic INR 
values. Meckley et al.21 showed an increased 
risk of overanticoagulation in CYP2C9 
variant carriers in the first 6 months and in 
VKORC1 variant carriers in the first month 
of warfarin treatment. In several European 
countries, including the Netherlands, 
acenocoumarol or phenprocoumon are 
prescribed more frequently for anticoagulant 
therapy22. Schalekamp et al.15,16 showed an 
increased risk of severe overanticoagulation 
in carriers of a CYP2C9 or VKORC1 
polymorphism during the first 6 months 
of acenocoumarol and phenprocoumon 
treatment. In these previous studies, the 
first 6 months were not analysed separately, 
but as a whole. Teichert et al.17 showed an 
increased risk of severe overanticoagulation 
for VKORC1 variant alleles after an initial 
standard dose of acenocoumarol treatment.
Whether carriers of a CYP2C9 or 
VKORC1 polymorphism only have an 
increased risk of overanticoagulation in 
the first month of therapy or whether 
this effect is also seen after the initiation 
period is still unknown, as well as the 
possible risk of underanticoagulation in 
wild-type patients. The aim of the present 
study was therefore to investigate the 
association of the CYP2C9 and VKORC1 
polymorphisms with the risk of over and 
underanticoagulation after the initiation 
period of acenocoumarol.
methods
study population
For the present study, we looked at data 
from three different studies. First, data 
from the pre-EU-PACT study were used23. 
In this cohort study, patients who were 
using acenocoumarol in November 2009 
with a target International Normalised 
Ratio (INR) in the lowest intensity 
category (according to Dutch guidelines 
INR 2.0–3.5) were included. Schalekamp 
prospectively followed patients newly 
starting on acenocoumarol with a target 
INR in the lowest intensity category (2.0– 
3.5) for 6 months15. In this dataset we 
therefore could repeat the analyses for the 
first half year of treatment. In the Rotterdam 
study, patients on acenocoumarol were 
followed for their entire treatment period 
regardless of their target INR24. We selected 
only the patients with a target INR of 2.0 to 
3.5 for the present analyses.
The study protocols of the three studies 
were approved by the Medical Ethics 
Committee (Leiden University Medical 
Center, Leiden for pre-EU-PACT, Utrecht 
Medical Centre, Utrecht for the study of 
Schalekamp, and Erasmus Medical Center, 
Rotterdam for the Rotterdam study) and 
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patients provided informed consent before 
inclusion into the study. All procedures 
were conducted in accordance with the 
Helsinki Declaration.
The data of the three studies were 
combined to increase the power of the 
analyses. For the first 6 months, this dataset 
contains data from all three studies, but for 
the periods after 6 months only data from 
Pre-EU-PACT and the Rotterdam study 
were included.
data collection
For each participating patient, data on 
age and gender were obtained from 
the electronic registry databases of the 
anticoagulation clinics. INR measurements, 
prescribed doses and relevant co-
medication have been routinely collected 
and recorded in registry databases at each 
visit to the anticoagulation clinic in the 
Netherlands since 1983. Therefore, it was 
possible to obtain this information for 
each patient. Patients were genotyped 
for CYP2C9*2 (rs1799853), CYP2C9*3 
(rs1057910) and VKORC1 1173C>T 
(rs9934438). In the Pre-EU-PACT study 
and the Rotterdam study, also data on 
height and weight were available. More 
details on the three studies can be found 
elsewhere15,17,23.
statistical analyses
As the target INR for the participants 
was in the lowest intensity category (INR 
2.0–3.5), subtherapeutic INR values were 
defined as INR < 2 and supratherapeutic 
INR values as INR > 3.5. As the risk of 
bleeding events is considerably increased 
in severe overanticoagulated patients, we 
also investigated the occurrence of INR 
values > 618,19. In several time periods up 
to one and a half years after treatment 
initiation, the occurrence of at least 
one INR < 2, > 3.5 or > 6.0 was studied. 
When patients reach a stable dose, they 
require less frequent monitoring than 
before they were stable. Consequently, 
the mean number of INR measurements 
decreases over time. The time periods 
used in the present study were chosen 
so as to have a sufficient number of INR 
measurements in every period. Data from 
a patient were only included in the analysis 
of a specific period, if the patient was using 
the coumarin under study for this entire 
period. Data on the start of treatment 
were required for all included patients 
and follow-up started at the first week of 
acenocoumarol use.
The difference in risk of at least one 
INR < 2, > 3.5 or > 6.0 between the different 
CYP2C9 and VKORC1 genotypes was 
tested with a chi-square test. If the expected 
number of observations in a cell was below 
5, Fisher’s exact test was used. Patients 
with missing data were excluded from 
the analyses where this data was needed. 
Because the frequency of homozygous 
carriers of a variant CYP2C9 allele is low, the 
CYP2C9 genotype was grouped to increase 
the group sizes for our analyses. We grouped 
the *2 carriers together (*1*2 and *2*2) and 
the *3 carriers together (*1*3, *2*3 and 
*3*3). The combined effect of CYP2C9 
and VKORC1 was also investigated for 
the first month of acenocoumarol use, by 
combining the two genotypes in six groups, 
with every VKORC1 genotype divided into 
CYP2C9 wild-type patients and CYP2C9 
variant carriers.
In addition to the occurrence of 
at least one out-of-range INR during 
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the different periods, we also looked at 
the time within, below and above the 
therapeutic range. This method is more 
robust for the difference in number of 
INR measurements between patients. All 
analyses were performed using SPSS 16.0 
(SPSS Inc., Chicago, IL, USA).
results
Patient characteristics
In total, 1586 acenocoumarol users from 
the three studies15,23,25 were eligible for 
analyses in the present study. A flowchart 
of the selection of patients can be found in 
the Supplement (Figures S1A–C). From 
the 471 acenocoumarol users in the pre-
EU-PACT cohort23, 231 in the study of 
Schalekamp15 and 2065 in the Rotterdam 
study25, 275, 192 and 1119 patients 
were included in the present study. 
Patient characteristics and genotypes of 
all 1586 patients are shown in Table 1. 
Characteristics per study can be found 
in the Supplement (Tables S1–S3). Data 
on height and weight were only available 
in two studies (Pre-EU-PACT and the 
Rotterdam study). Mean age stratified 
by genotype varied between 73 and 75 
years and 38% to 42% of the participants 
were male. The most frequent indication 
for acenocoumarol treatment was atrial 
fibrillation. The treatment duration at the 
moment of data collection ranged from 0 
to 189 months.
A VKORC1 CC genotype was seen 
in 499 patients, a CT genotype in 696 
patients and 211 patients had a TT 
genotype. When the CYP2C9 genotype 
was grouped as wild type, *2 carriers and 
*3 carriers, the group sizes were 938, 312 
and 170, respectively. All genotypes were 
in Hardy–Weinberg equilibrium.
time periods
The following time periods were 
considered to ensure a sufficient number 
of INR measurements in every period: 
0–1 month (day 1–30), 1–3 months (day 
31–90), 3–6 months (day 91–180), 6–9 
months (day 181–270), 9–12 months (day 
271–360), 12–15 months (day 361–450) 
and 15–18 months (day 451–540) after 
treatment initiation. The average number 
of INR measurements ranged from 4.6 to 
6 for all periods. The INR of carriers of a 
VKORC1 variant allele was measured less 
frequently during months 1–3 and 3–6 than 
the INR of wild-type patients (P = 0.03 and 
P = 0.004, respectively, see Table 1).
Because the treatment duration at the 
moment of data collection was different 
among the patients, the number of patients 
decreased over time to 414 acenocoumarol 
users in the last period (15–18 months, Table 
1). Only data of patients using acenocoumarol 
during the entire period were included in the 
analysis of a specific period. The maximum 
follow-up in the study of Schalekamp study 
was 6 months. The distribution of the 
different genotypes remained similar in the 
different time periods.
subtherapeutic inr values
Figure 1 depicts the occurrence of at least 
one INR < 2 over the different periods in 
acenocoumarol users with the different 
VKORC1 and CYP2C9 genotypes. Figure 
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B: Subtherapeutic INR and CYP2C9 genotypes
1A illustrates that during the first month, 
73% (95% confidence interval [CI]: 
68%–77%) of acenocoumarol users with 
a VKORC1-CC genotype had at least one 
INR measurement < 2. This number was 
significantly lower among patients with a 
CT genotype (62%, P < 0.001, 95% CI: 
58%–66%) and with a TT genotype (45%, P 
< 0.001, 95% CI: 38%–52%). During months 
2–3, the risk of a subtherapeutic INR was 
49% (95% CI: 43%–54%) in CC patients, 
vs. 40% (95% CI: 36%–45%, P = 0.01) and 
39% (95% CI: 30%–48%, P = 0.05) in CT 
and TT patients, respectively. Differences 
between the VKORC1 genotypes were 
not significant after the third month of 
acenocoumarol use. CYP2C9 wild-type 
patients had a 65% (95% CI: 62%–68%) 
risk of an INR < 2 in the first month, vs. 64% 
(95% CI: 58%–69%, P = 0.27) and 54% 
(95% CI: 46%–62%, P = 0.005) in *2 and *3 
carriers, respectively. After the first month, 
no significant differences were found for 
CYP2C9 (Figure 1B).
figure 1. Percentage of patients (and 95% confidence intervals) with at least one International 
Normalised Ratio (INR) < 2 in the different time periods after coumarin initiation. A: VKORC1 
genotypes B: CYP2C9 genotypes.
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B: Supratherapeutic INR and CYP2C9 genotypes
supratherapeutic inr values
Figure 2 displays the occurrence of at least 
one INR > 3.5 over the different periods 
in acenocoumarol users with the different 
VKORC1 and CYP2C9 genotypes. A 
significant difference between the VKORC1 
genotypes was found up to the third 
month (Figure 2A). In the first month, 
supratherapeutic INR values occurred in 
30% (95% CI: 26%–35%) of the wild-type 
patients, vs. 45% (95% CI: 41%–49%, 
P < 0.001) and 74% (95% CI: 67%–80%, 
P < 0.001) in patients with a CT and TT 
genotype, respectively. This difference 
was smaller (40% (95% CI: 34%–45%)) 
for wild-type patients, vs. 43% (95% CI: 
38%–47%, P = 0.37) for CT and 62% (95% 
CI: 53%–70%, P < 0.001) for TT in months 
1–3. CYP2C9 wild-type patients had a 
41% (95% CI: 38%–44%) risk of an INR 
> 3.5 in the first month, vs. 50% (95% CI: 
44%–56%, P = 0.008) and 51% (95% CI: 
43%–59%, P = 0.01) in *2 and *3 carriers, 
respectively. No significant differences were 
figure 2. Percentage of patients (and 95% confidence intervals) with at least one International 
Normalised Ratio INR > 3.5 in the different time periods after coumarin initiation. A: VKORC1 
genotypes B: CYP2C9 genotypes
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B: Severe overanticoagulation and CYP2C9 genotypes
found between the CYP2C9 genotypes of 
acenocoumarol users after the first month 
(Figure 2B).
severe overanticoagulation
The risk of severe overanticoagulation 
(INR > 6) in acenocoumarol users with the 
different VKORC1 and CYP2C9 genotypes 
is shown in Figure 3 over the different 
periods. In the first month, 3% (95% CI: 
2%–5%) of the VKORC1 wild-type patients 
had an INR > 6, vs. 5% (95% CI: 3%–7%, 
P = 0.26) and 12% (95% CI: 8%–17%, P < 
0.001) in CT and TT patients, respectively. 
In all, 4% (95% CI: 3%–6%) of the CYP2C9 
wild-type patients had an INR > 6 in the 
first month, vs. 7% (95% CI: 4%–10%, 
P = 0.07) of the *2 carriers and 9% (95% CI: 
5%–14%, P = 0.01) of the *3 carriers. No 
significant differences were found between 
the VKORC1 and CYP2C9 genotypes after 
the first month (Figure 3A,B).
figure 3. Percentage of patients (and 95% confidence intervals) with at least one International 
Normalised Ratio INR > 6 in the different time periods after coumarin initiation. A: VKORC1 genotypes 
B: CYP2C9 genotypes.
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Figure 4 shows the risk of under- and 
overanticoagulation in the first month 
for the different combined genotype 
groups. The risk of underdosing in the 
first month was greatest (75%, 95% CI: 
69%–79%) in VKORC1 and CYP2C9 
wild-type patients. This risk decreased 
for every variant allele, with the lowest 
risk (44%, 95% CI: 35%–52%) existing 
in VKORC1 TT and CYP2C9 wild-type 
patients. The risk of overdosing increased 
as the number of variant alleles increased 
(28% [95% CI: 23%–33%] inVKORC1 
and CYP2C9 wild-type patients to 76% 
[95%CI: 67%–83%] in VKORC1 TT 
and CYP2C9 wild-type patients). Severe 
overanticoagulation in the first month 
of acenocoumarol use was relatively rare 
in VKORC1 CC patients and in VKORC 
CT/CYP2C9 wild-type patients (2%–4%) 
and higher in VKORC1 CT/CYP2C9 
variant carriers and VKORC1 TT patients 
(9%–16%).
analyses per subcohort
The present analyses of the combined 
dataset were also performed in the three 
separate studies. The results of these 
analyses were similar to the results in the 
combined dataset and can be found in the 
Supplement. Only some small differences 
in results were seen. In the pre-EU-PACT 
dataset, the risk of underanticoagulation 
was higher than in the other two datasets 
(Figures S2 and S3). In this dataset, a 
significantly different risk of an INR > 3.5 
between the VKORC1 genotypes could be 
demonstrated up to month 6 (Figure S4). 
The risk of severe overanticoagulation was 
relatively low (mostly below 10%) and 
the confidence intervals in the datasets of 
pre-EU-PACT and Schalekamp in these 
analyses were large. Therefore only in 
the Rotterdam dataset could the effect of 
VKORC1 on the occurrence of an INR > 6 
be demonstrated, although this trend was 
also seen in the other datasets (Figure S6).
The results of the analyses on time 
within, below and above the therapeutic 
figure 4. Risk of under- or overanticoagulation during the first month of coumarin treatment and 
combined VKORC1/ CYP2C9 genotypes.
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INR range were very similar to the results 
described above. In the first month, 
time below the therapeutic INR range 
was highest in VKORC1 and CYP2C9 
wild-type patients (up to 31%) and the 
time above therapeutic INR range was 
highest in VKORC1 TT and CYP2C9 
*3 carriers (up to 30%). For CYP2C9 
no difference was found after the first 
month, but the effect of VKORC1 on time 
below the therapeutic INR range lasted 
up to months 1–3 and on time above the 
therapeutic INR range up to months 3–6.
discussion
The present study demonstrates that in the 
first month of acenocoumarol therapy, the 
risk of underdosing is highest in patients 
with a VKORC1 wild type. This increased 
risk of a subtherapeutic INR was also 
seen in months 2 and 3, but not after 
the third month of coumarin treatment. 
In addition, the risk of overdosing was 
highest in patients with a VKORC1 TT 
genotype in the first 6 months. For severe 
overanticoagulation an effect of VKORC1 
was only seen in the first month. After the 
sixth month, no effect of polymorphisms 
in VKORC1 on the occurrence of out-of-
range INRs was found.
The effect of the CYP2C9 genotype 
on under or overdosing was smaller 
than the effect of VKORC1. Only when 
we combined three datasets together 
was a significant difference in the 
occurrence of subtherapeutic INR values, 
supratherapeutic values and severe 
overanticoagulation found between the 
wild- type patients and the *2 and *3 
carriers. However, this effect was only 
found in the first month of therapy and not 
after the initiation period.
An increased risk of overanticoagulation 
among warfarin users with a CYP2C9 
or VKORC1 polymorphism during the 
initiation period was also found in the 
previous study of Limdi et al.26. They 
found that patients with a variant allele 
had a higher risk of an INR above 4 during 
the first 30 days. In the present study, we 
found a larger influence of VKORC1 than 
of CYP2C9. This difference was also seen in 
the previous study of Schwarz et al.,27 who 
demonstrated that the initial variability 
in INR response to warfarin was more 
strongly associated with VKORC1 than 
with CYP2C9. However, none of these 
studies investigated the effect of genetic 
variation on the risk of overanticoagulation 
after the first month. We found no effect 
of CYP2C9 after the first month, but for 
VKORC1 we demonstrated an increased 
risk of overanticoagulation among variant 
carriers up to 6 months after treatment 
initiation.
The aforementioned studies 
focused on the risk of (severe) 
overanticoagulation, but not on the risk 
of underanticoagulation. We found an 
increased risk of a subtherapeutic INR in 
CYP2C9 wild-type patients during the first 
month and in VKORC1 wild-type patients 
during the first 3 months. If physicians 
fear to prescribe high doses, because of 
uncertainty whether the patient is sensitive 
or not, frequent underdosing of VKORC1 
and CYP2C9 wild-type patients is to be 
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expected. For these patients, the standard 
dose is often not high enough. The dose 
will then be adjusted after a couple of INR 
measurements, mainly during the first 
weeks of coumarin therapy. Our results 
thus correspond with these expectations. 
Patients with venous thromboembolism 
are often also treated with a low-molecular-
weight heparin (LMWH) during the first 
days, until an INR > 2 is obtained. For 
these patients the risk of a subtherapeutic 
INR is compensated by this LMWH 
during this period. This is not the case 
for patients with other indications, as for 
example atrial fibrillation.
Because the Pre-EU-PACT study 
selected patients using acenocoumarol in 
November 2009, patients in this cohort did 
not all have the same length of follow-up. At 
the time of data collection, some patients 
were already using acenocoumarol for 
years, whereas others had just started using 
acenocoumarol. This is a limitation to the 
present study, not only because of the lower 
numbers of patients in the later periods, but 
also because we might have missed very 
unstable patients. These patients often stop 
using acenocoumarol early and therefore 
might be underrepresented in this cohort. 
However, we do not believe this had a large 
influence on our results because the results 
in the pre-EU-PACT study were very 
similar to the results in the other studies 
and the follow-up time was not different 
among the different genotypes (Table 1). 
We also performed a survival analysis using 
the prospective data of Schalekamp, and we 
found no differences in loss to follow-up 
between the genotypes. Of the 192 patients 
included from this cohort, four patients 
(2%) stopped within the first month.
Patients in the three Dutch cohorts 
were treated with a therapeutic INR 
range of 2.0–3.5. This is standard care in 
the Netherlands, but differs from other 
countries where normally a range of 
2.0–3.0 is used. In the present study, we 
therefore defined supratherapeutic INR 
values as INR > 3.5. As we used this as 
a marker of instability and we obtained 
similar results in our analysis on time 
above therapeutic range, we believe our 
results are also relevant for other countries.
A difference in risk of out-of-range 
INRs was found between the three studies. 
The data have been collected in different 
clinics, and as clinics perform differently, 
this can explain this variation. However, 
the effect of the different genotypes and 
the trend over time remains similar across 
the different clinics/datasets. Because 
data from different clinics were used, we 
believe our study population reflects the 
Dutch population well.
The likelihood of a patient having 
an out-of-range INR value depends 
on how often the INR is checked. This 
could influence the results when we use 
occurrence of at least one INR below or 
above a certain value. In the Netherlands, 
patients are monitored frequently (on 
average 21 times per year), especially in 
the first year. However, we also studied the 
effect of the genotypes on the percentage 
time within, below and above the 
therapeutic INR range, and these analyses 
yielded similar results. Using this metric 
(% of time), the results are relatively robust 
for the frequency of INR monitoring.
Although we did not find an effect of 
being a carrier of CYP2C9 or VKORC1 
polymorphisms after the sixth month of 
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therapy, for VKORC1 we did find an effect 
on subtherapeutic and supratherapeutic 
INR values after the first month. This 
could mean that knowledge of the patient’s 
genotype could help to determine dose 
adjustments for acenocoumarol users. This 
might be useful if the patient has an out-of-
range INR. In this case, carriers of a variant 
allele could be treated with smaller dose 
adjustments than wild-type patients. This 
would not only be useful for the sensitive 
patients to prevent supratherapeutic 
INR values and thereby decrease the 
risk of bleeding, but also for wild-type 
patients. In the present study, we have 
shown an increased risk of underdosing 
in wild-type patients, which exposes them 
to an increased risk of thromboembolic 
events. Oake et al.28 investigated the risk 
of adverse events in different INR ranges 
and demonstrated that although the risk 
of bleeding or thromboembolic events 
was lowest with an INR between two and 
three, an INR just above three was safer 
(less events) than an INR below 2. The 
results from the present study suggest 
that sensitive patients could be treated 
with smaller dose adjustments, thereby 
decreasing their bleeding risk, and that 
wild-type patients could be treated with 
larger dose adjustments to decrease the 
time below therapeutic INR range, thereby 
decreasing their risk of thromboembolic 
events. This knowledge is especially useful 
in the first months of therapy, as in the 
months thereafter the physician more 
often uses the previous INRs and doses of 
a patient to determine the magnitude of 
dose adjustments.
In summary, the novel finding of 
the present study is that acenocoumarol 
users with the CYP2C9 and VKORC1 
wild type have an increased risk of 
underanticoagulation in the first period of 
therapy. This suggests that pre-treatment 
genotyping could not only be useful in 
preventing overanticoagulation in the 
limited group of carriers of a CYP2C9 and 
VKORC1 polymorphism, but also to prevent 
underanticoagulation in the larger group of 
patients without a CYP2C9 and VKORC1 
polymorphism. It has been suggested that 
pre-treatment genotyping could identify 
patients requiring a lower or higher coumarin 
dose, and thereby, reduce the risk of over 
anticoagulation or underanticoagulation 
in variant carriers and wild-type patients. 
Currently, the effectiveness and cost-
effectiveness of a genotype-guided dosing 
regimen is being investigated in clinical 
trials29-31. If the genotype of a patient is known, 
this might help to prevent subtherapeutic or 
supratherapeutic INRs in the first months 
of therapy and thereby reduce the risk of 
adverse events. The trade-off between the 
health gained through this risk reduction 
and the extra costs of genotyping should 
be investigated in a cost-effectiveness 
analysis. As the costs of a genetic test are still 
decreasing, we believe that genotyping could 
be an attractive option in the future32.
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Population Schalekamp
n=231
Included in this study
n=192
Not fulfilling in- and exclusion criteria: n=39
• Different target INR range: n=39
Pre-EU-PACT population
n=471
Eligible patients
n=354
Included in this study
n=275
Not fulfilling in- and exclusion criteria: n=117
• Has been treated in another anticoagulation clinic
(follow-up information incomplete): n=3
• Pregnancy: n=1
• Used phenprocoumon or had a different target INR
range during follow-up period: n=113
Data on the start of treatment incomplete: n=79
• No reliable information on startdate available: n=65
• INR on day 1 already 1.5 or higher: n=14
figure s1a. Selection of patients from Pre-EU-PACT
ERGO1 population
n=2065
Included in this study
n=1119
Not fulfilling in- and exclusion criteria: n=946
• Different target INR range: n=946
figure s1b. Selection of patients from the study of Schalekamp
figure s1c. Selection of patients from the Rotterdam study
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figure s2. Percentage of patients (and 95% confidence intervals) with at least one INR<2 in the different time 
periods after coumarin initiation – VKORC1 genotypes. A: Pre-EU-PACT, B: Schalekamp, C: Rotterdam.
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C: Subtherapeutic INR and CYP2C9 genotypes - Rotterdam
figure s3. Percentage of patients (and 95% confidence intervals) with at least one INR<2 in the different 
time periods after coumarin initiation – CYP2C9 genotypes.A: Pre-EU-PACT, B: Schalekamp, C: Rotterdam.
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figure s4. Percentage of patients (and 95% confidence intervals) with at least one INR>3.5 in the different 
time periods after coumarin initiation – VKORC1 genotypes. A: Pre-EU-PACT, B: Schalekamp, C: Rotterdam
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C: Supratherapeutic INR and CYP2C9 genotypes - Rotterdam
figure s5. Percentage of patients (and 95% confidence intervals) with at least one INR>3.5 in the different 
time periods after coumarin initiation – CYP2C9 genotypes. A: Pre-EU-PACT, B: Schalekamp, C: Rotterdam
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C: Severe overanticoagulation and VKORC1 genotypes - Rotterdam
figure s6. Percentage of patients (and 95% confidence intervals) with at least one INR>6 in the different time 
periods after coumarin initiation – VKORC1 genotypes. A: Pre-EU-PACT, B: Schalekamp, C: Rotterdam
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figure s7. Percentage of patients (and 95% confidence intervals) with at least one INR>6 in the different 
time periods after coumarin initiation – CYP2C9 genotypes. A: Pre-EU-PACT, B: Schalekamp, C: Rotterdam
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long-term anticoagulant effects 
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anthonius de boer, anke-hilse maitland-van der Zee 
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Anticoagulant treatment with 
phenprocoumon is challenging because 
of the narrow therapeutic range and the 
wide inter- and intra-patient variability 
in dose response. Frequent monitoring of 
the international normalised ratio (INR) 
is therefore required. Polymorphisms in 
two genes, CYP2C9 and VKORC1, explain 
approximately one-third of the variation in 
dose requirements 1-3. CYP2C9 encodes the 
main metabolizing enzyme of coumarin 
anticoagulants, the cytochrome P450 
2C9 enzyme (CYP2C9), while VKORC1 
encodes the pharmacodynamics target 
enzyme for coumarin anticoagulants, 
vitamin K epoxide reductase multiprotein 
complex 1 (VKORC1).
Earlier this year, we found that in the 
first month of acenocoumarol therapy, the 
risk of underdosing is highest in patients 
with a VKORC1 wild type 4. This increased 
risk of a subtherapeutic INR was also seen 
in months 2 and 3, but not after the third 
month of coumarin treatment. In addition, 
the risk of overdosing was highest in 
patients with a VKORC1 TT genotype in 
the first 6 months. The effect of CYP2C9 
genotype on under- or overdosing of 
acenocoumarol was smaller than the effect 
of VKORC1 and this effect was only found 
in the first month of therapy and not after 
the initiation period 4. This has not been 
investigated for phenprocoumon yet. The 
aim of this study was therefore to examine 
the association of CYP2C9 and VKORC1 
polymorphisms with the risk of over- and 
under-anticoagulation after the initiation 
period of phenprocoumon.
To investigate this, we looked at 
data from two different studies, the 
pre-EU-PACT study 5 and the study by 
Schalekamp et al. 6. The study protocols of 
both studies were approved by a Medical 
Ethics Committee (Leiden University 
Medical Center, Leiden, for the pre-EU-
PACT study, and Utrecht Medical Centre, 
Utrecht, for the study by Schalekamp) 
and patients provided informed consent 
before study inclusion. All procedures 
were conducted in accordance with the 
Helsinki Declaration. More details about 
the design and data collection in both 
studies can be found elsewhere 4.
We examined the occurrence of at least 
one INR < 2,> 3.5 or> 6.0 in several time 
periods up to 1.5 years after treatment 
initiation and tested for differences among 
the genotypes with chi-square analysis. 
The time periods we used were: 0–1 month 
(days 1–30), 1–3 months (days 31–90), 
3–6 months (days 91–180), 6–9 months 
(days 181–270), 9–12 months (days 
271–360), 12–15 months (days 361–450) 
and 15–18 months (days 451–540) after 
treatment initiation. We also looked at 
the time within, below and above the 
therapeutic range, because this method is 
more robust when the frequency of INR 
measurements differs between patients. 
All analyses were performed using SPSS 
18.0 (SPSS Inc., Chicago, IL, USA).
In total, 794 phenprocoumon users 
from the two studies 5,6 were eligible for 
analyses in this study. Patient characteristics 
and genotypes of all 794 patients are shown 
in the Supplement Table S1. Data on height 
and weight were only available in the Pre-
EU-PACT study (n = 486). The most 
frequent indication for phenprocoumon 
treatment was atrial fibrillation. The average 
number of INR measurements per time 
period ranged from 3.4 to 5.5. Only data 
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of patients using phenprocoumon during 
the entire time period were included in 
the analysis of that period. The maximum 
follow-up in the Schalekamp study was 6 
months (n = 308).
Significant differences in out-of-
range INR values between the genotypes 
were only found during the first month 
of phenprocoumon therapy. In the first 
month, 89% of the patients with a VKORC1 
wild type had at least one subtherapeutic 
INR. This frequency was significantly lower 
among patients with CT (76%, P < 0.001) 
and TT (50%, P < 0.001). Supratherapeutic 
INR values occurred in 33% of the 
VKORC1 wild-type patients, vs. 48% 
(P < 0.001) and 66% (P < 0.001) in patients 
with a CT or TT genotype, respectively. Of 
the wild-type patients, 3% had at least one 
INR > 6. This percentage was increased 
in patients with a TT genotype (17%, 
P < 0.001), but there was no statistically 
significant difference for patients with a 
CT genotype (6%, P = 0.12).
Occurrences of subtherapeutic 
INR values or INR values > 6 were not 
significantly different among the CYP2C9 
genotypes. However, INR values > 3.5 
occurred more often in carriers of a 
CYP2C9*3 allele (62%, P < 0.001) or a 
CYP2C9*2 allele (52%, P = 0.01) than 
in wild-type patients (40%). For both 
VKORC1 and CYP2C9 genotypes, no 
significant differences in out-of-range 
INRs were found after the first month. The 
risk of out-of-range INRs for the different 
periods and genotypes is shown in the 
Supplement (Figures S1–S4).
Similar results were obtained in the 
analyses of time within, below and above 
therapeutic INR range (Figure 1). In 
the first month, time below therapeutic 
INR range was longest in VKORC1 and 
CYP2C9 wild-type patients (up to 33%) 
and time above therapeutic INR range was 
longest in VKORC1–TT and CYP2C9*3 
carriers (up to 37%). The risk of having at 
least one INR < 2 did not vary significantly 
among the CYP2C9 genotypes, but the 
time spent below therapeutic INR range 
was significantly shorter in *2 carriers 
(19%) and *3 carriers (14%) than in 
wild-type patients (26%, P < 0.001). No 
significant differences were found after 
month 1 of the treatment.
Our study demonstrated that in the 
first month of phenprocoumon therapy, 
the risk of underdosing is highest in 
patients with VKORC1 and CYP2C9 
wild types. In addition, the risk of 
overdosing was highest in patients with 
a VKORC1 TT genotype or carriers of 
a CYP2C9 variant allele. These results 
correspond with the results we have seen 
for acenocoumarol users, as described in 
a previous article 4. However, the results 
beyond the first month of treatment are 
not similar. Specifically, while there were 
no differences in the risk of out-of-range 
INRs between the different genotypes 
after the first month of phenprocoumon 
therapy, there were differences in risk 
between the VKORC1 genotypes up to the 
sixth month of acenocoumarol treatment.
A limitation of this study is the 
fact that the Pre-EUPACT study 
contained retrospective data 5. The data 
of Schalekamp et al. 6, however, were 
collected prospectively. Data for a specific 
time period were only used in the analysis 
if the patient used phenprocoumon for 
this entire period. Because very unstable 
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patients are expected to stop the therapy 
early, this patient group might be under-
represented in our study.
Information about the patient’s 
genotype can be used to predict the right 
dose of phenprocoumon 5. Carriers of a 
VKORC1 or CYP2C9 variant allele require 
a lower dose and have an increased risk 
of supratherapeutic INR values. If these 
patients are genotyped before treatment 
initiation, they could be treated with a 
lower dose, thereby decreasing the risk of 
over-anticoagulation. In both this study 
and our previous study on acenocoumarol, 
we also found an increased risk of a 
subtherapeutic INR in VKORC1 and 
CYP2C9 wild-type patients during the first 
month. Information about the patient’s 
genotype could therefore also be used to 
identify patients who need a higher dose 
to decrease the risk of complications 
from underdosing. In this way, genetic 
information could be used to improve 
the safety and efficacy of anticoagulation 
treatment in both wild-type patients 
and variant carriers. The relevance 
0
10
20
30
40
50
60
70
<2 2.0-3.5 >3.5
%
INR
A: VKORC1 genotypes
CC
CT
TT
0
10
20
30
40
50
60
70
<2 2.0-3.5 >3.5
%
INR
B: CYP2C9 genotypes
*1*1
*2
*3
figure 1. Percentage time in different INR ranges during the first month of phenprocoumon use. 
A: VKORC1 genotypes, b: CYP2C9 genotypes.
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of pharmacogenetic information for 
phenprocoumon users, however, seems to 
be limited to the first month of treatment.
Phenprocoumon has a longer elimination 
half-life than acenocoumarol (110–130 h vs. 
6–8 h) 3,7. Treatment with phenprocoumon 
is therefore somewhat more stable and 
patients on phenprocoumon spend more 
time within the therapeutic INR range than 
patients on acenocoumarol 8. This might be 
a reason why only acenocoumarol users, and 
not phenprocoumon users, show differences 
between the genotypes in the risk of out-of-
range INRs after the first month of treatment.
The results of this study suggest 
that pharmacogenetic information 
might help to prevent subtherapeutic or 
supratherapeutic INRs in the first month 
of phenprocoumon therapy and thereby 
reduce the risk of adverse events. The value 
of this information after the first month 
of phenprocoumon treatment appears to 
be limited. Currently, clinical trials are 
underway to investigate the effectiveness 
and cost-effectiveness of a genotype-
guided dosing regimen vs. a standard 
dosing regimen 9,10.
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figure s1. Percentage of patients (and 95% confidence intervals) with at least one INR<2 in the 
different time periods after coumarin initiation. A: VKORC1 genotypes B: CYP2C9 genotypes
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figure s2. Percentage of patients (and 95% confidence intervals) with at least one INR>3.5 in the 
different time periods after coumarin initiation. A: VKORC1 genotypes B: CYP2C9 genotypes 
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figure s3. Percentage of patients (and 95% confidence intervals) with at least one INR>6 in the 
different time periods after coumarin initiation. A: VKORC1 genotypes B: CYP2C9 genotypes 
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the effect of omePraZole and 
esomePraZole on the maintenance dose 
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The response to vitamin K antagonists 
(VKAs) is determined by many different 
factors like age, weight, height, vitamin K 
intake and genetic polymorphisms 1. The 
proton pump inhibitors (PPIs) omeprazole 
and esomeprazole may enhance the effect 
of VKAs by inhibition of the hepatic 
metabolism of coumarin anticoagulants 2. 
Some isolated cases have been reported of 
clinically significant elevated INRs in 
patients concomitantly using omeprazole 
and phenprocoumon, a VKA frequently 
used in Europe 3. Practical experience 
suggests an interaction between omeprazole 
or esomeprazole and phenprocoumon, but 
scientific evidence is still lacking.
Van Schie et al. developed a dosing 
algorithm including age, gender, height, 
weight, CYP2C9 and VKORC1 genotypes 
and amiodarone use and a dosing 
algorithm without the genotypes to predict 
the phenprocoumon maintenance dose 4. 
Given the possibility that omeprazole use 
affects the stable phenprocoumon 
maintenance dose, we examined whether 
information about its use would improve 
the predictive value of a dosing algorithm.
Data from the pre-EU-PACT 
study were used to study the effect of 
omeprazole and esomeprazole on the 
stable phenprocoumon maintenance 
dose 4. More details about this study can 
be found elsewhere 4. The main outcome 
measure of the present study was the mean 
stable phenprocoumon maintenance dose 
in mg/day in the first stable period after 
initiation of phenprocoumon therapy. 
Only patients who reached a stable dose 
within 1 year were included in the analyses. 
Multiple linear regression analysis was 
used to develop a genotype-guided 
algorithm and a non-genotype-guided 
algorithm to estimate the square root of 
the weekly phenprocoumon maintenance 
dose. We included the same predictive 
variables used by van Schie et al. 4, but 
added an extra variable for omeprazole or 
esomeprazole use.
A stable maintenance dose was reached 
within 1 year by 597 patients. Of these, 46 
patients used omeprazole and 18 patients 
used esomeprazole. On average, non-users 
required 2.27 mg (SD 0.90) phenprocoumon 
per day, significantly higher than the average 
dose seen in both omeprazole users (1.78 
mg/day, SD 0.73, 95% CI of the difference 
0.22, 0.75) and esomeprazole users (1.88 
mg/day, SD 0.52, 95% CI of the difference 
0.12, 0.66)). Since the phenprocoumon 
dose was not significantly different
between omeprazole and esomeprazole 
users (95% CI of the difference -0.47, 0.28), 
we combined them into one group for 
inclusion in the algorithm. Five hundred 
and eighty-seven phenprocoumon users 
were included in the analysis of the non-
genotype-guided algorithm and 559 for the 
genotype-guided algorithm. Omeprazole/
esomeprazole use significantly influenced 
the phenprocoumon maintenance dose 
in the genotype-guided algorithm (P = 
0.002) and the non-genotype-guided 
algorithm (P = 0.001) (Table 1). 
The genotype-guided algorithm was as 
follows:
SQRT (maintenance dose (mg/
week)) = 2.870–0.254 (if CYP2C9*1/*2) 
– 0.356 (if CYP2C9*1/*3) – 0.431 (if 
CYP2C9*2/*2) – 0.708 (if CYP2C9*2/*3) 
– 0.693 (if CYP2C9*3/*3) – 0.594 (if 
VKORC1 CT) – 1.371 (if VKORC1 TT) 
– 0.015 x Age (years) + 0.034 (if female) 
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table 1. Algorithms to predict stable phenprocoumon maintenance dose
genotype-guided 
algorithm P value
non-genotype-
guided algorithm P value univariate r2
Intercept 2.870 1.659
CYP2C9 genotype <0.001 - 5.1
*1/*1 0 -
*1/*2 -0.254 -
*1/*3 -0.356 -
*2/*2 -0.431 -
*2/*3 -0.708 -
*3/*3 -0.693 -
VKORC1 genotype <0.001 - 34.3
CC 0 -
CT -0.594 -
TT -1.371 -
Age (years) -0.015 <0.001 -0.010 0.001 8.3
Gender, if female 0.034 0.579 0.109 0.174 2.3
Height (cm) 0.011 0.001 0.011 0.020 7.2
Weight (kg) 0.009 <0.001 0.013 <0.001 13.1
Amiodarone use, if yes -0.315 0.003 -0.304 0.032 0.4
Omeprazole/esomeprazole use, if yes -0.234 0.002 -0.323 0.001 2.5
Unadjusted r2 of the algorithm 56.7% 18.9%
NB, Dependent variable is the square root of the stable maintenance dose of phenprocoumon.
+ 0.009 x Weight (kg) + 0.011 x Height 
(cm) – 0.315 (if amiodarone use) – 0.234 
(if omeprazole/esomeprazole use).
With this genotype-guided algorithm, 
56.7% of dose variation could be 
explained, 0.8% more than in the study of 
van Schie et al. 4.With our non-genotype-
guided algorithm, the predictive value was 
18.9%, 1.6% more than the algorithm of 
van Schie et al. 4.
The information obtained in this study 
could help physicians determine the right 
phenprocoumon dose for patients. If a 
patient is already using omeprazole or 
esomeprazole when phenprocoumon 
treatment is started, the dosing algorithm 
can be used to predict the required dose. 
If a patient starts using omeprazole or 
esomeprazole during phenprocoumon 
treatment the dose of phenprocoumon 
should be lowered. This could help 
prevent overanticoagulation and thereby 
reduce the risk of bleeding events when 
phenprocoumon and omeprazole or 
esomeprazole are used simultaneously.
In this study we observed a lower 
phenprocoumon dose requirement in 
omeprazole and esomeprazole users and 
86
developed a dosing algorithm using this 
information. We only demonstrated the 
effect of omeprazole and esomeprazole. 
An interaction between phenprocoumon 
and other PPIs should be investigated in 
future research.
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abstract
Introduction: Adherence to the mostly complex regimen of coumarin derivatives is vital 
in order to keep patients in the adequate INR range.  Patients’ beliefs about medicines 
are associated with the level of therapy adherence. Our aim was to assess the beliefs 
about coumarin anticoagulants. Secondly we compared the beliefs about coumarin 
anticoagulants with the beliefs about other cardiovascular drugs.
Methods: The Beliefs about Medicines Questionnaire (BMQ) was used to assess 
medication beliefs. The BMQ was completed by users of coumarin anticoagulants 
indicated for venous thromboembolism or atrial fibrillation. A necessity and a 
concerns score was calculated for all patients. The analyses were repeated for users of 
antihypertensive drugs or statins (not using coumarin anticoagulants). 
Results: 320 patients were included in the analysis on the beliefs about coumarin anticoagulants. 
The mean necessity score was 15.3, the concerns score 12.3 and the necessity-concerns 
differential 3.0. Patients with venous thromboembolism (n=71) had higher necessity scores 
than patients with atrial fibrillation (n=249) (16.8 vs. 14.9, p<0.001). The mean necessity 
score in 493 users of other cardiovascular drugs was 16.1, the concerns score 13.5 and the 
necessity-concerns differential 2.6. The necessity score was higher in chronic cardiovascular 
drug users (n=192) than in new users (n=301) (17.9 vs. 14.9, p<0.001).
Conclusions: Coumarin users score higher on the necessity scale than on the concerns 
scale, which is also the case in users of other cardiovascular drugs. Patients with atrial 
fibrillation have a less positive attitude towards these drugs than patients with venous 
thromboembolism, and could therefore benefit more from specific attention. 
introduction
Patient beliefs about medicines are an 
important factor in the adherence to the 
therapy. Patients can have concerns about, 
for example, the side effects of the drug 
or they can believe that the drug is not 
really necessary for their health. Several 
studies have shown that higher concerns 
about medication as well as lower 
necessity beliefs are associated with higher 
non-adherence 1-5. Non-adherence is a 
significant challenge to clinical practice 
and for some patients extra education 
might be useful to increase adherence. 
Knowledge about patient beliefs might 
help to identify patients who would benefit 
from additional counselling. The Beliefs 
about Medicines Questionnaire (BMQ) 
was developed to simplify the wide range 
of beliefs that patients may have about 
their medication 6.
The BMQ has not yet been applied 
in studies focusing on anticoagulant 
therapy with coumarin derivatives. The 
coumarin derivatives acenocoumarol, 
phenprocoumon and warfarin are 
frequently used for the treatment and 
prevention of thromboembolic events in 
patients with, for example, atrial fibrillation 
or venous thromboembolism 7. These 
drugs have a narrow therapeutic range 
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and show large inter- and intra-individual 
variation in dose requirements. Frequent 
monitoring of the level of anticoagulation 
and adjusting the dose is required. This 
makes the treatment with coumarin 
anticoagulants more burdensome than 
most other cardiovascular drugs. On the 
other hand, it is possible that the therapy 
adherence is higher in these drugs than in 
other cardiovascular drugs, because of the 
frequent checks. Analysing the beliefs of 
patients using coumarin derivatives can 
provide insight into their attitude towards 
their treatment. The aim of this study 
was therefore: to assess the beliefs about 
acenocoumarol and phenprocoumon 
in patients initiating therapy with these 
drugs for atrial fibrillation or venous 
thromboembolism. A secondary aim was 
to compare the beliefs about coumarin 
derivatives with the beliefs about other 
cardiovascular drugs (antihypertensive 
drugs or statins).
materials and methods
Participants
The European pharmacogenetics of oral 
anticoagulation (EU-PACT) trial aims to 
assess the effectiveness of pharmacogenetic-
guided dosing of coumarin derivatives and 
includes patients starting acenocoumarol, 
phenprocoumon or warfarin therapy for 
either atrial fibrillation (AF) or venous 
thromboembolism (VTE) 8. Patients were 
recruited at four different anticoagulation 
clinics in The Netherlands. More details 
about the EU-PACT trial can be found 
elsewhere 8. After approximately one week 
of therapy with either acenocoumarol or 
phenprocoumon, patients were asked to fill 
in the BMQ questionnaire.
To compare the beliefs of coumarin 
users with users of other cardiovascular 
drugs, data from the study of van Geffen 
et al. were used 9. In this study users of an 
antihypertensive drug or a statin were 
included and they all received the BMQ 
questionnaire by mail. Patients using a 
coumarin derivative were excluded from 
the analysis. This study included new users 
who did not have any antihypertensive drug 
or statin in the previous 2 years and chronic 
users who had been prescribed at least 40 
prescriptions in the previous three years. 
More information about this study can be 
found elsewhere 9. Because all coumarin 
users in the EU-PACT study were new 
users, we looked at new and chronic users 
in the data of van Geffen et al. separately. 
beliefs about medicines Questionnaire
The BMQ-Specific used in this study 
focused on beliefs about acenocoumarol and 
phenprocoumon or other cardiovascular 
medicines. This questionnaire consists of 
two scales 6. The necessity scale is focused 
on patients’ beliefs about the necessity of 
using their medicines. The concerns scale is 
focused on the concerns that patients may 
have about their medicines. Each item is 
scored on a 5-point Likert scale: 1 (strongly 
disagree), 2 (disagree), 3 (uncertain), 4 
(agree) or 5 (strongly agree). The scores 
obtained from the individual questions in 
each scale were summed, divided by the total 
number of statements in the scale and then 
multiplied by 5 5. The range of possible scores 
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on each scale was 5 to 25. Higher scores 
represented stronger necessity or concern 
beliefs. A necessity-concerns differential was 
calculated by subtracting the concerns scores 
from the necessity scores (range -20 to 20).
statistical analysis
Data was analysed using SPSS version 19. 
Patients were excluded from the analysis 
if more than two answers of the BMQ 
were missing. Missing item scores of 
included patients were replaced by a score 
of 3 (uncertain) on the Likert-scale. To 
confirm the psychometric properties of 
this Dutch version of the BMQ used in 
coumarin users, a principal component 
factor analysis (PCA) was performed with 
varimax rotation. Internal consistency of 
different parts of the BMQ was estimated 
using Cronbach’s alpha. 
Mean and median necessity and 
concerns scores and the necessity- concerns 
differential were calculated for patients with 
AF and for patients with VTE. The scores 
for the necessity and concerns scales were 
split at the scale midpoint to create four 
belief groups: indifferent (low necessity 
beliefs, low concerns), accepting (high 
necessity beliefs, low concerns), skeptical 
(low necessity beliefs, high concerns) and 
ambivalent (high necessity beliefs, high 
concerns). These groups have been used 
in earlier studies also 5,9,10. Chi-square tests 
were used to compare the percentage of 
patients with a specific attitude for AF and 
VTE patients or new and chronic users.
results
Participants
In The Netherlands, 340 patients were 
included in the EU-PACT trial. Of these, 
20 patients did not complete the BMQ. 
One answer was missing (and replaced by a 
score of 3) in 2 (0.6%) patients, there were 
no patients with more than one answer 
missing. Table 1 shows the characteristics 
of the 320 patients included in this study.
beliefs about acenocoumarol and 
phenprocoumon
PCA confirmed the original structure 
with two components for necessity beliefs 
and concerns. Internal consistency was 
similar amongst the components (α = 0.66 
for concerns and α = 0.67 for necessity). 
Factor loadings are reported in Table 2.
The necessity and concerns scores 
and the necessity-concerns differential of 
acenocoumarol and phenprocoumon users 
are shown in Table 3. The mean necessity 
score for the entire population was higher 
than the scale midpoint (15.3) while the 
mean concerns score was lower than the scale 
midpoint (12.3). This led to a positive mean 
necessity-concerns differential of 3.0. The 
highest mean score was seen in the item ‘My 
health, at present, depends on my coumarin’. 
For this item, 49.7% of the patients agreed or 
strongly agreed. The lowest score was seen 
in the item ‘My coumarin disrupts my life’, 
for which 80.3% of the patients disagreed or 
strongly disagreed.
Patients with AF had significantly lower 
necessity beliefs (14.9) than patients with 
VTE (16.8, p <0.001). Also the necessity-
concerns differential was higher in VTE 
patients than in AF patients (4.9 vs. 2.4, 
p<0.001). 
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Figure 1 shows the necessity and 
concerns scores of patients with VTE or 
with AF and the percentage of patients in 
each belief group. Most patients had low 
concerns, 85% of the patients were either 
in the indifferent or in the accepting group. 
Fifty-eight percent of the patients with 
VTE were accepting, versus 34% of the 
patients with AF (p<0.001). AF patients 
were more frequently in the indifferent 
group (51% vs. 31%, p=0.003). 
comparison with beliefs about other 
cardiovascular drugs
Data of 578 patients were available from 
the study of van Geffen et al. 9. Of these, 
529 patients filled in all the questions or 
the BMQ. One answer was missing in 
18 (3.3%) patients; two answers were 
missing in 4 (0.7%) patients. In total, 
27 patients missed more than 2 items, 
and these patients were excluded from 
the present analyses. As we wanted to 
compare coumarin users with users of 
other cardiovascular drugs (and other 
table 1. Characteristics of included patients
characteristics
eu-Pact trial (n=320) van geffen study (n=493)*
af (n=249) vte (n=71)
new users 
(n=301)
chronic users  
(n=192)
Age in years, mean (range) 68 (37-90) 54 (22-83) 59 (19-88) 67 (39-98)
Sex, n (%)
Male 156 (62.7%) 37 (52.1%) 149 (49.5%) 111 (57.8%)
Female 93 (37.3%) 34 (47.9%) 152 (50.5%) 81 (42.2%)
Medication, n (%)
Acenocoumarol 119 (47.8%) 44 (62%) - -
Phenprocoumon 130 (52.2%) 27 (38%) - -
Other antithrombotic - - 57 (18.9%) 71 (37%)
No antithrombotic (one or more 
other cardiovascular drugs)
- - 244 (81.1%) 121 (63%)
Co-morbidity
Hypercholesterolemia 63 (25.3%) 3 (4.2%) 107 (37.5%) 101 (54.3%)
Hypertension 121 (48.6%) 14 (19.7%) 179 (61.1%) 148 (79.6%)
Diabetes 38 (15.3%) 3 (4.2%) 40 (13.7%) 74 (39.8%)
Angina pectoris 8 (3.2%) 0 (0%) 20 (7.6%) 41 (23.7%)
Myocardial infarction 21 (8.4%) 1 (1.4%) 12 (4.5) 22 (12.7)
Transient ischaemic attack 7 (2.8%) 1 (1.4%) 14 (5.3%) 15 (8.7%)
Stroke 7 (2.8%) 1 (1.4%) 11 (4.2%) 5 (2.9%)
* Coumarin users were excluded for this analysis
AF=Atrial fibrillation, VTE=Venous thromboembolism
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table 2. Principal component analysis using Varimax rotation.
concerns necessity
My health, at present, depends on my coumarin 0.673
Having to take coumarins worries me 0.548
My life would be impossible without my coumarin 0.692
I sometimes worry about the long-term effects of my coumarin 0.724
Without my coumarin I would be very ill 0.682
My coumarin is a mystery to me 0.400
My health in the future will depend on my coumarin 0.663
My coumarin disrupts my life 0.656
I sometimes worry about becoming too dependent on my coumarin 0.734
My coumarin protects me from becoming worse 0.542
This coumarin has unpleasant side effects 0.566
Factor loadings >0.30 are reported.
table 3. Mean scores (median) on the BMQ-specific
beliefs
eu-Pact trial (n=320) van geffen study (n=493)
af (n=249) vte (n=71) new users (n=301) chronic users (n=192)
Necessity 14.9 (15) 16.8 (17)a 14.9 (15) 17.9 (18) a
Concerns 12.5 (12.5) 11.9 (11.7) 13.3 (13.0) 14.1 (14.0) a
Necessity-Concerns 2.4 (2.2) 4.9 (4.5) a 1.5 (1.0) 3.8 (3.5) a
a p<0.05 for AF vs. VTE or new users vs. chronic users
antithrombotics), we excluded 58 
coumarin users from the van Geffen study. 
Table 1 shows the characteristics of the 493 
patients included in the analysis of the van 
Geffen study. PCA with Varimax rotation 
resulted in the same two‐component 
structure as in the EU-PACT study.
The necessity and concerns scores 
and the necessity-concerns differential of 
cardiovascular drug users are shown in 
Table 3. The mean necessity score of the 
entire population was higher than the 
scale midpoint (16.1) while the mean 
concerns score was lower than the scale 
midpoint (13.6). This led to a positive 
mean necessity-concerns differential of 
2.4. The highest mean score was seen in 
the item ‘My cardiovascular medicines 
protect me from becoming worse’. For 
this item, 59.2% of the patients agreed or 
strongly agreed. The lowest score was seen 
in the item ‘My cardiovascular medicines 
disrupt my life’, for which 77.7% of the 
patients disagreed or strongly disagreed.
Chronic users of cardiovascular drugs 
had significantly higher necessity scores 
(17.9 vs. 14.9, p<0.001), higher concern 
scores (14.1 vs. 13.3, p=0.046) and a 
higher necessity-concerns differential (3.8 
vs. 1.5, p<0.001) than new users. New 
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users of cardiovascular drugs did not have 
a significantly different necessity score 
than new users of coumarin derivatives 
(14.9 vs. 15.3, p=0.13). These patients 
did have a higher concerns score (13.3 
vs. 12.3, p=0.01) and a lower necessity-
concerns differential (1.5 vs. 3.0, p<0.001) 
than coumarin users.
Figure 2 shows the necessity and 
concerns scores of new and chronic users 
of cardiovascular drugs and the percentage 
of patients in each belief group. Most 
patients had low concerns, 69% of the 
patients were either in the indifferent or 
in the accepting group. Forty-six percent 
of the chronic users were accepting, 
versus 26% of the new users (p<0.001). 
New users were more frequently in the 
indifferent group (45% vs. 20%, p<0.001). 
New users of an antithrombotic were 
more often accepting than new users of 
other cardiovascular drugs (33% vs. 24%, 
p=0.136) and less often indifferent (32% 
vs. 48%, p=0.025).
5
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5 10 15 20 25
Concerns
Necessity
VTE
AF
Accepting: 39%
VTE: 58%, AF: 34%, p<0.001
Ambivalent: 7%
VTE: 9%, AF: 7%, p=0.640
Skeptical: 8%
VTE: 3%, AF: 9%, p=0.089
Indifferent: 46%
VTE: 31%, AF: 51%, p=0.003
figure 1. Scatter plot of the necessity and concerns scores by indication (Squares: venous 
thromboembolism (VTE), circles: atrial fibrillation (AF)). In the boxes, the percentage of VTE and AF 
patients that have the specific attitude towards the therapy is shown.
discussion
Users of coumarin anticoagulants display 
higher necessity beliefs compared to 
concerns, which is also the case in users of 
other cardiovascular drugs. Patients with 
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VTE score higher on the necessity scale 
and the necessity-concerns differential 
than patients with AF. This is also true 
for chronic users of antihypertensives or 
statins if compared to new users of these 
drugs. The fact that patients score higher 
on the necessity scale than on the concerns 
scale would indicate a positive attitude 
towards these drugs, the most positive 
attitude is found in coumarin users with 
VTE or chronic users of cardiovascular 
drugs. Patients with AF have a less positive 
attitude and might benefit from extra 
attention to improve their adherence.
A possible limitation to this study 
is that the beliefs about coumarin 
derivatives were measured among patients 
participating in a randomised controlled 
trial. This could have led to a selection 
bias, selecting more patients with a 
positive attitude towards the drugs. In 
this trial, however, no new drug was being 
investigated, but a new dosing strategy. 
On the other hand patients with more 
concerns about the adverse effects of 
coumarin anticoagulants could have been 
more willing to participate, hoping that 
genotype-guided dosing would reduce 
the risk of adverse events. The study of 
van Geffen et al. was an observational 
study 9. The results of the necessity and 
concerns scores in this study were similar 
to the results from the EU-PACT trial 
(necessity above scale midpoint, concerns 
figure 2. Scatter plot of the necessity and concerns scores by duration (Squares: new users, circles: 
chronic users). In the boxes, the percentage of new and chronic patients that have the specific attitude 
towards the therapy is shown.
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Concerns
Necessity
new user
chronic user
Accepting: 34%
New user: 26%, Chronic user: 46%, 
p<0.001
Ambivalent: 24%
New user: 20%, Chronic user: 31%, 
p=0.006
Skeptical: 7%
New user: 10%, Chronic user: 
3%, p=0.003
Indifferent: 35%
New user: 45%, Chronic user: 20%, 
p<0.001
97
6
Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users
below scale midpoint, necessity-concerns 
differential around 3). The comparability 
between the two studies could also be 
hampered by the difference in the way the 
questionnaire was administered (during a 
visit to the anticoagulation clinic vs. over 
mail). The effect of data collection method 
on the difference between these two 
groups remains unclear. 
To our knowledge this is the first study 
investigating the beliefs about coumarin 
derivatives. In the study by van Geffen et al., 
the beliefs about cardiovascular medication 
were investigated in relation to satisfaction 
with information 9. In their study, some 
coumarin users were also included, but not 
analysed separately. In our study, the mean 
necessity score was above scale midpoint. 
This is in agreement with the necessity 
scores in the other studies. In a study on the 
beliefs about inhaled corticosteroids in the 
Netherlands, the necessity score was 15.6, 
which is similar to the score of 15.3 in the 
present study 5. Necessity scores were even 
higher in a study on Norwegian patients with 
a mental disorder (17.2) 2 or in British patients 
with rheumatoid arthritis (19.2) 4. In these 
two studies, the concerns scores were also 
above midpoint (17.9 and 15.8 respectively). 
In other studies the concerns were lower, 
as in the present study 3,5,11. The necessity-
concerns differential is positive in most cases, 
except for patients with a mental disorder in 
which this differential was -0.70 2.
In many of these studies, the beliefs 
about medicines was shown to be related 
to the adherence 1-5,10. According to Clifford 
and colleagues, intentional non-adherence 
was associated with lower necessity beliefs 
and higher concerns 1. Unintentional 
non-adherence was not associated with 
the beliefs about medicines. Aikens et al. 
found that adherence was associated with 
the necessity-concerns differential and was 
highest in patients in the ‘accepting’ group 
(high necessity beliefs, low concerns) 10. 
Most of the coumarin users with VTE 
are in this group (58%). Coumarin users 
with AF however, are more often in the 
‘indifferent’ group (low necessity beliefs, 
low concerns). This could mean that 
patients with AF are at increased risk of 
poor adherence. Patients using coumarin 
anticoagulants for VTE generally have 
more complaints (pain) and therefore see 
the usefulness of coumarin anticoagulants 
more than patients using these drugs for 
AF. This could explain the higher necessity 
scores and necessity-concerns differential 
in this group. Although patients with AF 
often have complaints, these are generally 
controlled with rate or rhythm control. The 
additional antithrombotic treatment might 
therefore be perceived as less important. 
It would be interesting to look at the 
differences in beliefs between patients with 
complaints related to AF or with a previous 
TIA or stroke and patients without any 
complaints. In this study, this information 
was not available and the groups of patients 
with a previous TIA or stroke were too 
small to perform a subgroup analysis.
Van Geffen et al. showed that the beliefs 
about medicines were associated with 
the patients’ needs for information and 
counselling 9. The BMQ could be used to 
identify the patients who would benefit most 
from extra patient education. This education 
could address any questions they might 
have and dispel any misunderstanding or 
concerns. This could decrease the concerns 
and if the necessity of the treatment can be 
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explained clearly to the patient, this might 
increase the necessity beliefs.
Because warfarin is not used in 
the Netherlands, we did not include 
warfarin users in this study. However, no 
differences were found between the two 
coumarin anticoagulants investigated in 
this study and it is therefore likely that 
similar results would be seen for warfarin. 
The choice between acenocoumarol or 
phenprocoumon is in the Netherlands 
mainly based on the region, rather than 
on patient characteristics, so no selection 
bias is expected regarding the prescribed 
coumarin anticoagulant. All patients in 
this study attended an anticoagulation 
clinic, which is standard practice in The 
Netherlands. This might have caused a 
slightly different view on the drugs than 
patients treated by, for example, the general 
practitioner, because these clinics have 
considerable experience with the drugs 
and provide relevant information and 
education to patients. We also have no data 
on patients doing self-management or self-
monitoring of the treatment, which could 
change their beliefs about the treatment. 
The EU-PACT study took place in a stable 
socioeconomic environment and patients 
were well educated, which might make 
the results less transferable to a setting 
where these characteristics are different. 
However, socioeconomic factors have not 
consistently been linked to either beliefs 
about medicines or medication adherence.
Recently, new oral anticoagulant drugs 
(direct thrombin inhibitors and factor Xa 
inhibitors) have been developed and these 
are considered to be good alternatives to 
coumarin derivatives. These new drugs do 
not require monitoring as is the case with 
coumarin anticoagulants, which could lead 
to a higher risk of poor adherence. However, 
the adherence to these drugs has not been 
investigated extensively yet and is still reason 
for concern 12. Because the adherence in 
clinical trials is generally assumed to be higher 
than in clinical practice, the effectiveness 
of the new drugs could be less favourable 
than what is currently seen in these trials. 
The results of this study show that patients 
using coumarin derivatives generally have 
a positive attitude towards their therapy. 
Because of this positive attitude and the fact 
that frequent monitoring is required, the 
overall risk of poor adherence with coumarin 
derivatives is probably low. In some groups 
however, this risk is higher than in others (for 
example patients with AF, compared to VTE 
patients). Patients with AF could benefit 
from extra attention, with for example 
patient education.
Future studies can investigate the 
association of the beliefs with patient 
adherence in coumarin users or even with 
the time spent within the therapeutic INR 
range. The quality of INR control was 
shown to be associated with adherence in 
the past 13. In a larger study, the correlation 
with age, educational levels or presence 
of comorbidities could also be tested, as 
the subgroups in this study were small. In 
clinical practice, the BMQ could be used 
as a simple tool to measure patient beliefs 
and subsequently identify patients with a 
negative attitude towards anticoagulant 
therapy. Knowledge of the beliefs the 
patient has about the medication can be 
taken into account during contact with 
patients to improve their attitude towards 
the treatment and possibly subsequently 
improve their therapy adherence. 
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abstract
Anticoagulant therapy with coumarin derivatives is often sub- or supra-therapeutic, 
resulting in an increased risk of thromboembolic events or haemorrhage, respectively. 
Pharmacogenetic-guided dosing has been proposed as an effective way of reducing 
bleeding rates. Clinical trials to confirm the safety, efficacy and effectiveness of this 
strategy are ongoing, but in addition, it is also necessary to consider the cost–effectiveness 
of this strategy. This article describes the findings of a systematic review of published 
cost–effectiveness analyses of pharmacogenetic-guided dosing of coumarin derivatives. 
Similarities and differences in the approaches used were examined and the quality of the 
analyses was assessed. The results of the analyses are not sufficient to determine whether 
or not pharmacogenetic-guided dosing of coumarin anticoagulants is cost effective. More 
reliable cost–effectiveness estimates need to become available before it is possible to 
recommend whether or not this strategy should be applied in clinical practice.
introduction
Coumarin derivatives are a group of oral 
anti coagulants used to treat and prevent 
thrombo embolic events in patients with 
venous thrombo embolism, atrial fibrillation 
or a prosthetic heart valve 1. Among the 
coumarin anticoagulants, warfarin is the most 
commonly used, but there are differences in 
practice that vary across Europe, with aceno-
coumarol and phenprocoumon also being 
used frequently 2. Coumarin dosing requires 
mainte nance of the international normalised 
ratio (INR) within a narrow range, but as there 
is wide inter patient variability, the required 
dosage is difficult to predict. This means 
sub- and supra-therapeutic anticoagulation 
levels often occur, resulting in an increased 
risk of (recurrent) thromboembolic events 
or haemorrhage, respectively 3,4. Bleeding 
is a common adverse effect of coumarin 
anticoagulants; major bleeding events, such 
as intracranial haemorrhage, can cause high 
morbidity and mortality and are costly to 
manage 5. 
Coumarin dose requirements and the 
risk of over- or under-anticoagulation 
are dependent on several environmental 
and clinical factors, such as comorbidity, 
concurrent medication, diet, sex and age, but 
genetic factors also play an important role in 
the variability in response among patients 
treated with coumarin anticoagulants 6-9. 
Polymorphisms in both the CYP2C9 gene, 
cod ing for the main metabolizing enzyme, 
CYP2C9, and the VKORC1 gene, coding for 
the target enzyme VKORC1, are associated 
with coumarin dose requirements 8,10-12. 
Initial studies found that patients with a 
CYP2C9*2 or *3 allele variant had a lower 
dose requirement than patients with a 
wild-type variant, owing to reduced enzyme 
activity, and were therefore at increased 
risk of bleeding complications 13. Later, it 
became clear that variants in the VKORC1 
allele were also responsible for increased 
warfarin sensitivity 14. 
Currently, the initial coumarin dose 
is based on clinical characteristics. It 
has been sug gested that consideration 
of the genotype of the patient will lead 
to a more appropriate initial dose and 
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thereby improve the safety and effi cacy of 
therapy 10,15-17. The results of three small 
randomised trials support the notion that 
pharmacogenetic-guided initial dosing 
may improve the safety and efficacy of 
warfarin 18-20, and more trials are planned, 
or are ongoing, to investigate the added 
value of a genotype-guided dosing 
algorithm against standard (or non-
genotype-guided) dosing algorithms 21,22. 
Although genotyping patients prior 
to com mencing coumarin therapy might 
improve health outcomes, consideration 
of costs is also warranted. Therefore, in 
addition to estab lishing the effectiveness of 
this strategy, it is also necessary to consider 
whether or not a pharmacogenetic-guided 
dosing strategy is a cost-effective use of 
healthcare resources. Numerous economic 
evaluation studies have been performed in 
order to consider this, but these have not 
yet been reviewed systematically. Such a 
review is necessary to see whether valu able 
recommendations can be made to decision-
makers about this pharmacogenetic testing 
and whether current clinical practice should 
be changed or not.
The aims of this study were to 
systematically review and summarise the 
results of published economic evaluations 
of pharmacogenetic-guided dosing in 
relation to coumarin derivatives, and to 
identify differences and similarities among 
them. A further aim was to establish 
whether the available evidence is sufficient 
to recommend the implementation 
of pharmacogenetic-guided dosing of 
coumarin anticoagulants in routine practice. 
A comparison of the relevant studies in 
terms of the methodology used and their 
results can lead to recommendations 
about how economic evaluations should 
be designed to obtain valid and reliable 
estimates of cost–effectiveness.
materials & methods 
literature search 
Search strategy 
Literature was searched for relevant articles 
pub lished up to November 2009 using 
PubMed, Embase, Web of Science and the 
NHS Economic Evaluation Database (NHS 
EED). Three categories of search terms 
were com bined. The first category included 
the keywords ‘coumarin*’, ‘anticoagulant*’, 
‘acenocoumarol’, ‘phenprocoumon’ and 
‘warfarin’. The second and third categories 
consisted of pharmacogenetic and 
pharmacoeconomic terms, respec tively. 
All keywords were used as ‘free text’ terms. 
We did not apply a start date other than the 
standard start date in the databases. Papers 
published in languages other than English 
were excluded. More details on the search 
strategy are provided in the Supplement. 
Titles and abstracts were scanned to identify 
relevant studies, as were the reference lists 
of papers assessed for inclusion. A citation 
search of these papers was also performed 
using Web of Science. 
Selection criteria 
Studies were included if they met the 
following criteria: a full economic 
evaluation was described (defined as 
a study in which both the costs and 
outcomes of different strategies were 
com pared – i.e., a cost–benefit analysis, 
cost–utility analysis [CUA] or cost–
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effectiveness analysis [CEA]), one of the 
comparators was pharmaco genetic-guided 
dosing of coumarin derivatives and the 
language of the article was English. 
Data extraction 
Data were extracted on the following study 
characteristics: coumarin anticoagulant, 
genotype of focus, comparator, patient 
population, country, type of economic 
evaluation, perspective, price year, time 
horizon of analysis, outcome measure 
and clinical events included in the 
calculations, dis counting for costs and 
consequences, inputs and data sources 
used. Regarding the results, the diff erences 
in costs and effectiveness of genotyping 
versus no genotyping were collected, as 
were the cost–effectiveness ratios and the 
parameters assessed in sensitivity analyses. 
Quality assessment 
The quality of each study was assessed using 
the Drummond et al. ten-point checklist 23, 
modi fied for pharmacogenetic studies (Box 
1), which enabled the identification of 
both the strengths and weaknesses of the 
studies’ methodolo gies. The ten items were 
scored independently by two reviewers as 
‘yes’, ‘no’ or ‘cannot tell’, and disagreements 
were resolved by consensus. An indication 
of the quality was based on the number of 
box 1. Checklist for quality assessment of economic evaluations.  Adapted from 23.
Was a well-defined question posed in an answerable form? 
 • A research question that considered both costs and effects of genotype-guided dosing should have been stated 
Was a comprehensive description of the competing alternatives given? 
 • The comparator should have been mentioned and the new strategy should have been at least briefly described 
Was the effectiveness of the programs or services established? 
 • If the effectiveness of genotyping was established, the article should have mentioned whether this was 
based on studies (e.g., randomised controlled trial or meta-analysis) or on assumptions 
Were all the important & relevant costs & consequences for each alternative identified? 
 • All relevant costs and consequences to answer the research question should have been identified 
Were costs & consequences measured accurately in appropriate physical units? 
 • All of these costs and consequences needed to be included as well as measured accurately using the 
correct physical units or outcome measures 
Were costs & consequences valued credibly? 
 • The basis for all costs and consequences used in the model should have been documented, or when a 
value was assumed, this should have been justified 
Were costs & consequences adjusted for differential timing? 
 • If the time horizon was more than 1 year, discounting of costs and consequences was required 
Was an incremental analysis of costs & consequences of alternatives performed? 
 • Differences in the costs and health effects of the genotyping strategy versus the nongenotyping strategy 
should have actually been determined 
Was allowance made for uncertainty in the estimates of costs & consequences? 
 • A sensitivity analysis should have been performed, in order to examine the robustness of the models and 
assumptions in each study. In addition, justification should have been provided for the ranges of values 
that were used 
Did the presentation & discussion of study results include all issues of concern to users? 
 • At least the findings of the sensitivity analysis and the transferability of the results should have been discussed 
109
7
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing
positive answers to the ten items. We then 
subjectively examined if there was a rela-
tionship between the quality of the studies 
and the reported results.
figure 1. Literature search results
results 
search results 
A total of 349, 2784, 185 and 27 records 
were identified in PubMed, Embase, Web 
of Science and NHS EED, respectively. 
One additional study was identified by 
searching reference lists and citation 
searching 24. In total, nine met the 
inclusion criteria 24-32. Figure 1, based 
on the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses 
(PRISMA) guide lines 33, presents the 
number of studies included at each step of 
the systematic review. 
characteristics of the selected studies 
The general characteristics of the nine studies 
are described in Table 1. Eight examined 
the cost– effectiveness of pharmacogenetic 
testing in the USA 24-28,30-32 while the ninth 
examined its cost–effectiveness in The 
Netherlands 29. The US-based studies 
focused on warfarin, while the Dutch 
study focused on acenocoumarol. No 
study on phenprocoumon was found. The 
earlier studies (up to 2008) considered 
only polymorphisms in the CYP2C9 
gene 24,26,28-30, while all studies published 
after 2008 assessed the economic 
Records identified through database searching
Pubmed (n = 349)
Embase (n = 2784)
Web of Science (n = 185)
NHS EED (n = 27)
Additional records identified through
other sources
(n = 1)
Records after duplicates removed
(n =  2963)
Records screened
(n = 2963)
Records excluded
(n =  2954)
Full-text articles assessed
for eligibility
(n = 9)
Full-text articles excluded
(n = 0)
Studies included in
qualitative synthesis
(n =  9)
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n
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value of genotyping both CYP2C9 and 
VKORC1 25,27,31,32. 
As also shown in Table 1, all authors 
performed either a CEA 24,26,28-31 or a 
CUA 25,27,31,32. The number of bleeding 
events (or adverse events) averted was the 
most commonly used outcome measure 
24,26,28-31, followed by quality-adjusted life-
years (QALYs) gained 25,27,31,32 and life-years 
saved 31. Most evaluations analysed the costs 
from a healthcare sector perspective and 
used a time horizon of 12 months 24,28,30,31. 
Two studies applied a societal perspective 
(and thus considered all costs, regardless 
of who would incur these costs), as well as 
a lifetime time horizon 25,32. A third-party 
perspective was only adopted by Leey et 
al. 27. The major ity of the studies compared 
genotype-guided dosing with standard 
dosing (anticoagulation clinic) 24,25,28-32, but 
the comparator was not stated explicitly 
in two analyses 26,27. Variation in study 
population was also observed. Some studies 
focused only on a specific patient population 
(e.g., patients with atrial fibrillation) 25,27,32, 
while other studies included all patients on 
coumarin therapy 24,26,28-31. 
reported results 
The results of the cost analysis are 
presented in Table 2 & 3. Schalekamp 
et al. reported all costs in euros 29. To 
increase the comparability of the results, 
these costs have been converted into US 
dollars. The price year in this study was 
2004; therefore, we used a conversion 
rate of 1.2168 (exchange rate on 1 July 
2004) 101. The cost of genotyping varied 
from US$67 to US$350 for CYP2C9 
genotyping, and from US$200 to US$575 
for genotyping both VKORC1 and 
CYP2C9, and was subjected to sensitivity 
analysis in most instances. The cost of 
major bleed ing or thromboembolic events 
was reported by most, with some authors 
also assessing the costs of anticoagulation 
service 25,30,31 or coumarin tablets and INR 
monitoring 25,29,32. In total, five out of nine 
studies reported that a genotype-guided 
dosing strategy may increase healthcare 
costs 25,28-31. A reduction of the relevant 
costs was only found in the studies by 
McWilliam et al. 24 and Leey et al. 27. Leey 
et al. found that pharmacogenetic testing 
could reduce costs only if it reduced the 
risk of major bleeding, but provided 
no other results (i.e., specific values) 
regarding costs. 
Estimates of the effectiveness of 
genotyping were derived from the literature 
(based on one or more randomised 
controlled trials [RCTs] or a meta-analysis) 
in some instances 25,31,32, but based on 
assumptions in others 29,30. You et al. used 
data from a single RCT 31, while Patrick 
et al. applied the midpoint of the results 
from two RCTs 32; Eckman et al. derived 
an estimate of effectiveness from a meta-
analysis of three RCTs 25. Leey et al. did not 
use any data for effectiveness and, instead, 
identified a threshold for bleeding risk at 
which genotyping would no longer be cost 
effective 27. Another difference between the 
studies was the method used to esti mate 
the clinical impact of genotyping. Some 
studies modelled the effect of genotyping 
directly on adverse event rates 24,25,27-30. By 
contrast, others estimated the health effect 
of genotyping by estimating its impact 
on INR levels 31,32, since INR is known 
to be highly associated with the risk of 
(recurrent) thromboembolic events and 
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table 1. General characteristics of the economic evaluations.
study (year)
country  
of focus
Price 
year drug genotype type Perspective
time 
horizon events included outcome measure comparator
specific patient 
population ref.
Higashi et al. (2003) USA NM Warfarin CYP2C9 CEA NM NM Bleeding Bleeding event averted NM 26
You et al. (2004) USA NM Warfarin CYP2C9 CEA Healthcare 
providers
12 months Major bleeding, 
major TE
Bleeding event averted Standard  
AC care
Patients newly started 
on warfarin therapy
30
Schalekamp et al. (2006) The Netherlands 2004 Aceno-coumarol CYP2C9 CEA NM 12 months Major bleeding Bleeding event averted Standard  
AC care
29
McWilliam et al. (2006) USA NM Warfarin CYP2C9 CEA Healthcare 
sector
12 months Bleeding, stroke Bleeding and stroke 
events averted
Standard  
AC care
24
McWilliam  et al. (2008) USA NM Warfarin CYP2C9 CEA Healthcare 
sector
12 months Bleeding, stroke Bleeding events averted Standard  
AC care
28
Eckman  et al. (2009) USA 2007 Warfarin CYP2C9 & 
VKORC1
CUA Societal Lifetime Major bleeding, TE QALY gained Standard  
care
Nonvalvular AF patients 25
You  et al. (2009) USA 2008 Warfarin CYP2C9 & 
VKORC1
CEA & CUA Healthcare 
providers
12 months Major bleeding, 
major TE
QALY gained, adverse event 
averted and life-year saved
Standard  
care
Patients newly started 
on warfarin therapy
31
Patrick  et al. (2009) USA 2007 Warfarin CYP2C9 & 
VKORC1
CUA Societal Lifetime Haemorrhagic events, 
ischaemic stroke
QALY gained Standard A 
C care
Newly diagnosed AF 
patients
32
Leey  et al. (2009) USA 2003 Warfarin CYP2C9 & 
VKORC1
CUA Third-party 
payer
12 months Major bleeding, 
embolic stroke
QALY gained NM Elderly patients newly 
diagnosed with AF
27
AC: Anticoagulation clinic; CEA: Cost–effectiveness analysis; CUA: Cost–utility analysis; NM: Not 
mentioned; QALY: Quality-adjusted life-year; TE: thromboembolism;
AF: atrial fibrillation
haemorrhages. In these studies, available 
results or assumptions regarding the 
relationship between genotyping and the 
time spent in – or outside – the therapeutic 
INR range were com bined with the risk of 
clinical events at different INR levels. In the 
other studies, which modelled the effect of 
genotyping directly on adverse event rates, 
no information on time spent at increased 
risk or the time needed to reach a stable dose 
is described. It is possible that differences 
in the estimated cost–effectiveness of 
genotyping are partly due to differences in 
the methodology and assumptions used to 
estimate the effectiveness of genotyping. 
Regarding the final economic evaluation 
results, most of the studies reported base 
case incremental cost–effectiveness ratios 
in the form of costs per adverse event 
avoided, which ranged, where reported, 
from dominant 24 to US$170k 31. You et al. 
reported that geno type-guided dosing costs 
were US$1106k per life-year gained 31. Costs 
per QALY gained (where reported) ranged 
from US$171k 25 to US$347k 31. You et al. 
calculated the cost per QALY gained as 
well as the cost per adverse event averted 
and cost per life-year saved by performing 
both a CEA and a CUA 31. The authors 
of this study included both bleeding and 
thromboembolic events in the definition 
of adverse events. By contrast, other 
studies report ing the cost per adverse event 
avoided, consid ered only bleeding events as 
adverse events, justifying this approach by 
stating that it was unlikely that genotype-
112
table 1. General characteristics of the economic evaluations.
study (year)
country  
of focus
Price 
year drug genotype type Perspective
time 
horizon events included outcome measure comparator
specific patient 
population ref.
Higashi et al. (2003) USA NM Warfarin CYP2C9 CEA NM NM Bleeding Bleeding event averted NM 26
You et al. (2004) USA NM Warfarin CYP2C9 CEA Healthcare 
providers
12 months Major bleeding, 
major TE
Bleeding event averted Standard  
AC care
Patients newly started 
on warfarin therapy
30
Schalekamp et al. (2006) The Netherlands 2004 Aceno-coumarol CYP2C9 CEA NM 12 months Major bleeding Bleeding event averted Standard  
AC care
29
McWilliam et al. (2006) USA NM Warfarin CYP2C9 CEA Healthcare 
sector
12 months Bleeding, stroke Bleeding and stroke 
events averted
Standard  
AC care
24
McWilliam  et al. (2008) USA NM Warfarin CYP2C9 CEA Healthcare 
sector
12 months Bleeding, stroke Bleeding events averted Standard  
AC care
28
Eckman  et al. (2009) USA 2007 Warfarin CYP2C9 & 
VKORC1
CUA Societal Lifetime Major bleeding, TE QALY gained Standard  
care
Nonvalvular AF patients 25
You  et al. (2009) USA 2008 Warfarin CYP2C9 & 
VKORC1
CEA & CUA Healthcare 
providers
12 months Major bleeding, 
major TE
QALY gained, adverse event 
averted and life-year saved
Standard  
care
Patients newly started 
on warfarin therapy
31
Patrick  et al. (2009) USA 2007 Warfarin CYP2C9 & 
VKORC1
CUA Societal Lifetime Haemorrhagic events, 
ischaemic stroke
QALY gained Standard A 
C care
Newly diagnosed AF 
patients
32
Leey  et al. (2009) USA 2003 Warfarin CYP2C9 & 
VKORC1
CUA Third-party 
payer
12 months Major bleeding, 
embolic stroke
QALY gained NM Elderly patients newly 
diagnosed with AF
27
AC: Anticoagulation clinic; CEA: Cost–effectiveness analysis; CUA: Cost–utility analysis; NM: Not 
mentioned; QALY: Quality-adjusted life-year; TE: thromboembolism;
AF: atrial fibrillation
guided dosing would affect the risk of other 
adverse events, such as thromboembolic 
events. Instead of reporting incremental 
analyses, Patrick et al. reported how much 
of an increase (compared with usual care) 
in percentage time spent in the target INR 
range during the first 3 months of therapy 
would be needed in order for genotype-
guided dosing to be cost effective 32. They 
found that a 5% increase would be needed 
for the incre mental cost–effectiveness ratio 
(ICER) to be less than US$100,000 and a 
9% increase would be needed for the ICER 
to be less than US$50,000 per QALY gained. 
consideration of uncertainty 
Table 4 presents the various parameters 
imple mented in the sensitivity analyses. 
Univariate (one-way) or multivariate 
(two-way and three-way) sensitivity 
analyses were performed in all studies 
other than Higashi et al., which was a 
rudimentary analysis intended to illustrate 
the concepts of economic evaluation 
of pharmacogenetic testing 26. Their 
description of the study is brief, and the 
authors did not perform any sensitivity 
analysis. In the other eight studies, a range 
of factors were included in sensitivity 
analy ses; all included major bleeding event 
rates and consistently found that a higher 
baseline bleed ing risk would improve the 
cost–effectiveness of genotype-guided 
dosing 24,25,27-32. Seven of the eight studies 
considered the effectiveness of the 
genotype-guided strategy and the cost of 
geno typing; the only exception was Leey 
et al., who only varied the incremental 
effectiveness (i.e., diff erence in QALYs) but 
did not vary the costs of genotyping 27. As 
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expected, increased effective ness and lower 
costs of genotyping both improved the 
cost–effectiveness of a genotype-guided 
strat egy versus standard care. The accuracy 
of the genotyping method was only 
assessed in the two studies by McWilliam et 
al. 24,28. McWilliam et al. assumed that both 
the test specificity and test sensitivity were 
95% 24, while McWilliam et al. assumed 
that both were 99% 28. 
In five studies 24,25,28,31,32, a probabilis-
tic sensitivity analysis was also performed, 
whereby the values of many input 
parameters were sampled from distributions 
simultaneously. This approach makes 
it possible to calculate the probability 
that the strategy is cost effective given a 
particular threshold willingness to pay (e.g., 
a maximum of US$50,000 to gain one 
QALY). The probability that genotype-
guided dosing would be cost effective given 
a threshold of US$50,000 varied from 10% 25 
to 38% 31 and 42% 32. 
Quality of the economic evaluations 
The economic analyses were of variable 
quality (Table 5). As mentioned earlier, 
data on the effec tiveness of genotyping 
were not always derived from the 
literature 25,31,32, but in some instances 
based on assumed values 29,30. 
Discounting for costs and consequences 
(at an annual rate of 3%) was applied in 
the two studies that reported a lifetime 
horizon of analysis 25,32. This adjustment is 
not needed when the time horizon of the 
study is no more than 1 year. However, You 
et al. also reported using a discount rate of 
3%, while the reported time horizon was 
only 12 months 31. 
Owing to lack of detail, some items of 
the quality checklist were answered with 
some uncertainty. For example, it is likely 
that Leey et al. performed an incremental 
analysis, even though the results were not 
presented as such in the article 27. Higashi 
et al. did not contain all elements of a full 
economic evaluation, since the purpose 
of their analysis was to illustrate how the 
cost–effectiveness of genetic tests could be 
assessed 26. As a consequence, their article 
scored poorly on the checklist. Studies of 
high quality were the studies of Eckman 
et al. 25, You et al. 31 and Patrick et al. 32. 
Based on this quality assessment, there 
seems to be no clear relationship between 
the quality of the stud ies and the reported 
results. You et al. reported different results 
from Patrick et al. 32 and Eckman et al. 
25, and this might be owing to the fact 
that they used a 12-month time horizon 
instead of a lifetime horizon, but this may 
also be because of other reasons, such as 
differences in effectiveness estimates 31. 
One could argue that a 12-month time 
horizon could underesti mate the potential 
health gain from genotyping, since it 
would ignore the long-term impact of 
major clinical events that occur during the 
first year of anticoagulation. 
discussion 
There is considerable variation in the results 
of existing economic evaluations of genotype-
guided dosing of coumarin derivatives. Most 
studies indicate that a genotype-guided 
dos ing strategy leads to improved health 
outcome, but at higher cost than usual care. 
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However, a direct comparison of cost–
effectiveness among studies is hampered by 
variability in method ology (e.g., economic 
outcome measure, per spective and currency), 
clinical considerations (e.g., consideration of 
thromboembolic events and genotypes) and 
parameter estimation (e.g., cost of genotyping 
and source of evidence on effectiveness). 
A significant limitation of the 
analyses is the choice of measure of 
cost–effectiveness. This will influence the 
results; for instance, it is highly likely that 
the cost per life-year saved by genotype-
guided dosing will be higher than the 
cost per adverse event avoided. You et 
al. is the only study to report on all three 
outcome mea sures (cost per bleeding 
event averted, life-year gained and QALY 
gained) 31. Schalekamp et al. estimated 
the cost per bleeding event averted to be 
€4233 (US$5151), and compared this 
with a payer’s willingness to pay up to 
€20,000 (US$24,336) per QALY gained 29. 
However, as the denominators differ, and 
willingness to pay might not apply to other 
settings (e.g., USA is US$50,000–100,000 
per QALY gained 34), the results are not 
readily interpretable. 
A second important difference 
among the studies is the values of the 
input parameters used in the analyses. 
For instance, the base case values for 
genotyping costs vary by more than 
tenfold. However, this variation alone 
cannot explain the difference in cost–
effectiveness estimates across the studies. 
One critical factor that affected the results 
was the substantial uncertainty in the 
effectiveness of genotyping in reducing the 
risk of haemorrhage or thromboembolic 
events. In almost half of the studies, 
effectiveness was based on assumptions 
and not on clinical data. For the studies that 
considered clinical data, data were derived 
from only a few small clinical trials 25,31,32. 
The limitations of a lack of evi dence on the 
effectiveness of genotyping have also been 
reported by Hughes et al. 35. Without such 
information, no definitive conclusions can 
be made about the cost–effectiveness of 
this strategy. 
The effectiveness of genotyping, as 
well as the baseline rate of bleeding events, 
might differ between populations, based 
for example on age or racial ancestry 36. 
In our review, we found that some studies 
focused only on patients with a specific 
clinical indication (atrial fibrilla tion) 
25,27,32, while other studies included all 
types of indications 24,26,28-31. Schalekamp et 
al. took a different approach and exam ined 
the cost–effectiveness of genotyping 
only patients with an initial INR of 2.5 or 
higher on the fourth day of therapy. They 
concluded that genotyping this subgroup 
only seemed to be more cost effective 
than genotyping every patient 29. Another 
way to distinguish patient subgroups 
would be to consider the total dura tion 
of anticoagulation therapy. Maybe 
patients receiving anticoagulation for 
a shorter period of time (e.g., patients 
with venous thromboem bolism) would 
obtain more benefit from geno typing than 
other patients (e.g., patients with atrial 
fibrillation). That is, one could argue that 
the proportion of time spent trying to 
achieve a stable INR is much greater in 
patients with venous thromboembolism 
than it is in patients with atrial fibrillation, 
since the latter are usually treated with 
coumarin derivatives for a much longer 
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period. This might lead to the conclusion 
that the benefit of genotyping would 
be greater for patients with venous 
thromboembolism. However, the absolute 
amount of time spent trying to achieve a 
stable INR does not differ between these 
two groups. Since the absolute differences 
in time will determine the absolute 
differences in risk of clinical events, the 
total duration of anticoagulation therapy 
will not affect the effectiveness and cost–
effectiveness of a genotyping strategy. 
The studies assessed in this review used 
diff erent data inputs, different analytic 
decision models and different assumptions. 
It is there fore difficult to determine what 
exactly causes the differences in ICERs 
across the studies. The effectiveness 
results of the only study that did not focus 
on warfarin (but on acenocoumarol) fall 
within the range of results of the warfarin 
studies 29. The different cost–effectiveness 
results can also not be explained by differ-
ences between countries, since eight of the 
nine studies focused on the USA. 
The quality of the studies varied 
considerably. Some studies were poorly 
documented and diffi cult to appraise 27. A 
limitation of this review, therefore, is the 
fact that the quality of reporting might 
preclude judgment on the quality of 
the economic evaluation. The study by 
Higashi et al. scored poorly in our quality 
assessment, but the authors never presented 
it as a fully-fledged eco nomic evaluation 
in the first place 26. Instead, the study was 
included in their article as an illus tration 
of the concepts of an economic evaluation 
of pharmacogenetic testing. Even though 
their paper did not address all the elements 
of a full economic evaluation, we still 
found it useful to include it in this review. 
In fact, it described the very first economic 
evaluation on this subject and gave an 
initial indication of the cost–effectiveness 
of genotyping warfarin patients.
Together, the evidence to date does 
not allow for a conclusion to be drawn on 
whether or not genotype-guided dosing is 
cost effective. It is therefore not possible to 
confirm whether or not pharmacogenetic-
guided dosing should be applied in routine 
clinical practice. Although the US FDA 
has already changed the label of warfarin, 
promot ing the use of pharmacogenetic 
tests 102, many would recommend delaying 
any decision regard ing applying this 
strategy in clinical practice until more 
effectiveness data and reliable estimates of 
cost–effectiveness become available 35. 
The quality of economic evaluations 
in other therapeutic areas has tended to 
improve over time 37,38 as more evidence 
becomes available. The limitations 
identified in this review, and diff erences 
among the selected studies, can assist in the 
design of future economic evaluations. We 
propose the following recommendations. 
First, effectiveness data used for the 
economic evalu ation should be based on 
large RCTs, to elimi nate confounding 
factors and reduce bias and uncertainty 
around any estimates of effective ness. 
Second, the total cost associated with geno-
typing should be better established. These 
may be better approximated alongside a 
clinical trial. For example, reliable cost 
estimates for adverse events associated with 
warfarin use were calcu lated by Jorgensen 
et al., using a microcosting analysis as part 
of a prospective cohort study 39. Valid 
cost estimates will vary across different 
120
genotyping strategies and treatment 
settings (e.g., hospital, general practitioner 
or anticoagu lation clinic). Third, it is 
important to overcome the difficulties that 
arise when different studies use different 
outcome measures. The results of different 
economic evaluations are more read ily 
comparable if the results are reported 
using the same outcome measures. Future 
economic evaluations of a genotype-guided 
dosing strategy for coumarin derivatives 
should report either the cost per QALY 
gained and/or the cost per life-year gained 40. 
QALYs should be estimated by using utility 
scores based on a preference-based method 
(e.g., the EQ-5D™; EuroQol Group, 
Rotterdam, The Netherlands) 41. Additional 
recommendations for consideration in the 
design of economic evaluations in relation 
to venous thromboembolism prophylaxis, 
including the use of a lifetime time horizon 
to account for the thromboembolic 
death and bleeding events, have been 
highlighted by Wolowacz et al. 41. Other 
recommendations relate to choice of 
clini cal events, choice of comparator, model 
input (efficacy and safety data and utility 
weights), and reporting of results.
conclusion 
The results of published economic 
evaluations on the cost–effectiveness of 
genotype-guided dosing in treatment with 
coumarin derivatives are not sufficient to 
determine whether or not this strategy 
is cost effective. Before reliable cost–
effectiveness studies can be performed, 
more evidence about the effectiveness 
of genotyping is required, and the cost 
associated with a genotyping strategy 
should be defined and measured more 
precisely. 
future PersPective 
More information on effectiveness and 
costs of this strategy should be made 
available before any recommendations 
can be made about whether or not 
a genotype-guided dosing strategy 
should be implemented. Obviously, it is 
impossible to obtain perfect evidence, 
but it is not clear what level of evidence 
is enough to make a decision about the 
implementation of a pharmacogenetic 
test. Therefore, value of information 
(VOI) analyses should be performed to 
establish the cost–effectiveness of further 
research on the effi ciency of the strategy. 
If the costs of perform ing this research are 
greater than the benefits of the additional 
information, it would not be worthwhile 
to conduct this research 42. Future studies 
should concentrate on collecting more 
data on the input parameters that have 
the great est influence on the uncertainty 
regarding the cost–effectiveness of 
genotyping. These parameters include: 
the effectiveness of genotyping on the 
incidence of (recurrent) thromboembolic 
events; the effectiveness of genotyping 
on the incidence of bleeding events, and 
the costs asso ciated with genotyping. The 
costs of conducting such research should 
also be considered. 
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Randomised controlled trials to 
establish the effectiveness of genotype-
guided dosing in treat ment with coumarin 
derivatives are currently underway 21,22. 
Most of these studies will only investigate 
the effectiveness of genotyping before 
treatment with warfarin 22,103. The European 
Pharmacogenetics of Anticoagulation 
Therapy (EU-PACT) trial will investigate 
the effect of genotyping in treatment 
with warfarin as well as in treatment with 
acenocoumarol and phenprocoumon 21. 
The results of these trials will provide 
the necessary evidence about the 
effectiveness of a genotyping strategy to 
make it possible to conduct sufficiently 
valid and precise economic evaluations. 
This will be possible in 3–4 years from 
now, because the two largest tri als, the 
Clarification of Optimal Anticoagulation 
through Genetics (COAG) study 103 and 
the EU-PACT trial 21, are scheduled for 
completion in 2012 and 2013, respectively. 
The trials that are currently underway 
will investigate the effectiveness of 
genotyping and will be performed 
independent of any VOI anal yses being 
performed. However, when the results of 
these studies are available, or when new 
stud ies are being planned on the efficiency 
of this strategy, the VOI analyses can 
be very useful to establish the cost–
effectiveness of performing economic 
evaluations on this subject.
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suPPlement
search strategy
The following search strategy was used in all databases to find relevant articles. Search terms 
1 to 5 were used to identify studies of coumarin derivatives. Terms 6 to 9 were used to 
identify studies of genotype-guided dosing and terms 10 to 27 were used to find economic 
evaluations. Lastly, the results from these three categories were combined in steps 28 to 31.
search terms
1. coumari*
2. anticoag*
3. acenocoum*
4. phenproc*
5. warfarin*
6. pharmacogenet*
7. genetic*
8. screen*
9. genot*
10. economics
11. econom*
12. costs
13. costly
14. costing
15. price
16. prices
17. pricing
18. pharmacoeconomics
19. pharmacoecon*
20. budget*
21. expenditure* 
22. energy
23. 21 not 22
24. “value for money”
25. cost-eff*
26. cost-ben*
27. cost-util*
28. 1 or 2 or 3 or 4 or 5
29. 6 or 7 or 8 or 9
30. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 23 or 24 or 25 or 26 or 27
31. 28 and 29 and 30
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clinical and economic conseQuences of 
Pharmacogenetic-guided dosing 
of warfarin
talitha i. verhoef, tom schalekamp, william K. redekop, anthonius de boer, 
anke-hilse maitland-van der Zee 
Expert Rev. Pharmacoeconomics Outcomes Res. 10(4), 375–378 (2010)

abstract
Patients using warfarin for oral anticoagulant therapy need to be frequently monitored 
because of warfarin’s narrow therapeutic range and the large variation in dose 
requirements among patients. Patients receiving the wrong dose have an increased risk of 
bleeding or thromboembolic events. The required dose is influenced by environmental 
factors, such as gender, age, diet and concomitant medication, as well as genetic factors. 
Pharmacogenetic testing prior to warfarin initiation might improve dosing accuracy and, 
therefore, safety and efficacy of warfarin treatment. Meckley et al. studied the clinical 
consequences and costs of genotyping before warfarin treatment. The results of their 
study suggest that pharmacogenetic-guided dosing of patients initiating warfarin could 
improve health (quality-adjusted life-years) but at a high cost per quality-adjusted 
life-year gained. Owing to the inevitable assumptions that have to be made in all cost–
effectiveness models, great uncertainty remains regarding the cost–effectiveness of 
pharmacogenetic-guided warfarin dosing.
evaluation of: Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. 
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic 
testing. Pharmacoeconomics 28(1), 61–74 (2010).
introduction
Warfarin is a drug widely used for oral 
anti coagulation in patients with atrial 
fibrillation, venous thromboembolism or 
a prosthetic heart valve to reduce the risk 
of thromboembolic events 1. The optimal 
warfarin dose is assessed by measuring 
the international normalised ratio (INR), 
which should be kept within a narrow 
range, since the risk of thromboembolic 
events decreases with an increasing INR, 
while the risk of bleeding events increases. 
A large inter- and intra-patient variability in 
warfarin dose require ment makes frequent 
INR monitoring neces sary. The required 
dosage is influenced by several factors, 
such as gender, age, diet, concomitant 
medication and genetic factors. 
Polymorphisms in both the 
CYP2C9 gene, encoding for the main 
metabolizing enzyme, cytochrome P450 
2C9 (CYP2C9), and the VKORC1 gene, 
encoding the target enzyme vita min K 
epoxide reductase multiprotein complex 
1, explain approximately a third of the 
varia tion in warfarin dose requirement. 
Information regarding the genotype of a 
patient can therefore be used to predict 
the warfarin maintenance dose. Although 
the ability of genotype-guided dosing to 
improve the safety and efficacy of warfarin 
treatment has been investigated in a 
few small randomised controlled trials, 
there is still no clear evidence about the 
effectiveness of this dosing strategy 2.
The economic impact of genotyping 
patients prior to warfarin use is also not 
clear. Results from cost–effectiveness 
analyses of warfarin pharmacogenetics 
(using genetic information to determine 
the required dose) do not all point in the 
same direction 3-5. In one of these studies 
genotyping appeared to be the dominant 
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strat egy, meaning that genotyping was 
more effec tive and less costly than not 
genotyping 4. By contrast, other studies 
found that the gain in effectiveness 
was coupled with higher costs 3,5. In 
most studies the effect of genotyping 
was based directly on its observed or 
assumed impact on the risk of bleeding 
and thromboembolic events, although 
the studies performed to date have not 
been large enough to detect reductions 
of adverse events. Using the association 
between the level of INR with the risk 
of bleeding and thromboembolic events, 
Meckley et al. developed a policy model 
to evaluate the clinical and economic 
consequences of pharmacogenetic-guided 
warfarin dosing, based on the effect of 
genotyping on INR levels 1.
summary of methods & results 
In their study Meckley et al. developed 
a decision analytic Markov model 
to perform an economic evaluation 
comparing genotype-guided dosing with 
standard anticoagulation care using a 
life time horizon 1. The base-case scenario 
focused on 65-year-old patients with atrial 
fibrillation who were initiated on long-term 
treatment with warfarin. Patients were 
stratified by genotype into three different 
groups: the first group consisted of CYP2C9 
wild-type/VKORC1 wild-type patients, the 
second of CYP2C9 wild-type/VKORC1 
variant patients, and in the last group were 
the CYP2C9 variants. This last group was 
not stratified by VKORC1 genotype for 
group size reasons. All patients entered the 
Markov model in a healthy (‘well’) state 
and could move from this state to the states 
‘clot’, ‘bleed’, ‘sequelae’ or ‘death’ in monthly 
cycles. The probabilities to experience a 
major bleeding or thromboembolic event 
were based on the time spent within, above 
or below therapeutic INR range. The time 
patients spent within, above and below 
therapeutic INR range was based on data 
from the COUMAGEN trial 6. This trial 
provided data on the difference in time 
spent in therapeutic INR range between 
the genotype-guided dosing group and 
the standard dosing group, but the authors 
reanalysed the COUMAGEN data in order 
to obtain additional information regarding 
the time spent above or below this range. 
The differences in time spent within the 
differ ent INR ranges between the two 
dosing strategies were used in the model 
for the first month and reduced to zero in 
the sixth month of therapy. An increased 
bleeding risk of 2.26, independent of the 
effect of INR, was assumed from a meta-
analysis for the CYP2C9 variant patients, 
which was subjected to sensitivity analysis 7.
Utility (or quality-of-life) scores for the 
different health states were used to calculate 
the difference in quality-adjusted life-years 
(QALYs) between the standard and the 
genotype-guided dosing group. Genotyping 
itself was assumed to have no effect on the 
quality of life of the patient. The difference 
in costs between the two strategies was 
calculated and included only direct 
medical costs, since the authors applied 
a third party payer perspective. One-way 
sensitivity analyses were performed for 
all input parameters over prespecified 
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ranges and several scenario analyses were 
conducted. The chance that the incremental 
cost–effectiveness ratio (ICER) would 
fall below a certain willingness-to-pay 
threshold (e.g., US$50,000 per QALY 
gained) was calculated in a probabilistic 
sensitivity analysis using Monte Carlo 
simulations. Meckley et al. found that 
pharmacogenetics could reduce the time 
spent above therapeutic INR range in the 
CYP2C9 variant group by 15%, and the 
time spent below therapeutic range in the 
CYP2C9 wild-type/VKORC1 wild-type 
group by 8% 1. In the third group (CYP2C9 
wild-type/VKORC1 variants) there were 
no differences in time spent above or 
below therapeutic INR range between 
the two dosing strategies. In the base 
case analysis the incidence of bleedings 
was reduced by 0.17%, the incidence of 
thromboembolic events increased by 
0.03% and incidence of death reduced by 
0.13% in the pharmacogenetic-guided 
dosing group. These differences resulted in 
a QALY increase of 0.0027. As genotyping 
also led to an overall cost increase of 
US$162, the ICER was US$60,725 per 
QALY gained. When looking at the 
ICERs in the different genotype groups, 
pharmacogenetic-guided dosing was most 
cost effective in the group consisting of 
VKORC1 and CYP2C9 wild-type patients. 
In this group there was a decrease in the 
risk of bleedings, thromboembolic events 
and deaths. The ICER for this group was 
US$13,500 per QALY gained. For the 
patients with CYP2C9 variant alleles 
genotype-guided dosing was dominated by 
the standard dosing strategy, meaning that 
genotyping resulted in a decrease in QALYs 
and an increase in costs. This result arose 
because of an increase in the frequency of 
thromboembolic events in this group.
The uncertainty around the cost of a 
pharmacogenetic test, as investigated in 
the one-way sensitivity analysis, caused 
the largest part of the uncertainty around 
the cost–effectiveness ratio. In one of 
the scenario analyses, data from Caraco 
et al. were used instead of data from the 
COUMAGEN trial 8. In this scenario, the 
genotyping strategy was the dominant 
strategy. Genotyping was also the 
dominant strategy when it was assumed 
that genotyping reduced the bleeding 
risk in CYP2C9 variant patients further. 
The probabilistic sensitivity analysis 
revealed that there was a 15% chance that 
the pharmacogenetic-guided dosing was 
the dominant strategy. In addition, it was 
estimated that there was a 46% chance that 
the true ICER was below US$50,000 per 
QALY gained and a 67% chance that it was 
below US$100,000 per QALY gained.
discussion 
This study suggested that pharmacogenetic-
guided dosing of war farin could improve 
the health of patients initiating warfarin 
while also increasing healthcare costs 
compared with a standard dosing regimen. 
The probability that genotyping would 
cost less than US$50,000 per QALY 
gained was estimated to be almost 50%. 
However, owing to uncertainty regarding 
the values of several input parameters, 
Meckley et al. found that the possible 
impact of genotyping ranged from a 
131
8
Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin
possibility that genotype-guided dosing 
is the dominant strategy to a possibility 
that it is less effective and more costly than 
a standard dosing regimen 1. This wide 
range of possible realities is mainly due 
to uncertainty regarding the effectiveness 
of pharmacogenetic-guided dosing on 
the risk of serious adverse events or 
therapeutic failure of warfarin therapy. 
Patients with a variant genotype have 
a higher risk of bleed ings due to warfarin 
therapy, because of a lower dose require-
ment. A genotype-guided dosing strategy 
might reduce this risk when patients with 
a variant genotype receive a lower dose. It 
is, therefore, remarkable that genotyping 
appeared to be less cost effective in 
patients with a variant genotype. This was 
explained by the increase in the number 
of thromboembolic events in this group, 
which might indicate that the dosages for 
these patients were overadjusted.
Since the clinical trials performed 
to date provide no direct evi dence 
regarding the influence of genotyping 
on the incidence of adverse events or 
therapeutic failure, these authors used the 
time within, above and below therapeutic 
INR range as a surrogate for these clinical 
end points. This method has been used in 
two other studies investigating the cost–
effectiveness of pharmacogenetic-guided 
dosing of warfarin 5,9. In the study of 
Patrick et al., data from the COUMAGEN 
trial 6 together with data from Caraco 
et al. 8 were used to calculate the effect 
of genotyping on the time spent within 
therapeutic INR range 9. In a probabilistic 
sensitivity analysis Patrick et al. found a 
chance of 42% that genotyping would be 
cost effective given a willingness to pay of 
$50,000 per QALY 9, which is quite similar 
to the 46% in the study of Meckley et al. 
1. In the study of You et al. this chance 
was 38% 5 and the base case results were 
also less optimistic than in the Meckley 
et al. study 1, since they reported an ICER 
of $347,059 per QALY gained. In the 
study by You et al. lower baseline adverse 
event rates were used and the effect of 
genotyping was not stratified by genotype 
as in the current study. In the probabilistic 
sensitivity analysis by Meckley et al. the 
costs of the genetic test are also varied 1. It 
would have been more useful to vary this 
parameter in a scenario analysis, because 
at the moment of decision-making the 
prices will be known already. 
The development of this model using 
INR as a surrogate end point for bleedings 
and thromboembolic events seems very 
useful, as there is not enough evidence about 
the effect of genotyping on the adverse 
event rate. However, the uncertainty around 
the results of this study are still too large to 
allow any recommendations regarding the 
implementation of pharmacogenetics in 
treatment with warfarin. This uncertainty 
is mainly caused by the fact that there 
is not sufficient evidence regarding the 
effect of genotyping on INR ranges either, 
because this has only been investigated in 
a few small clinical trials. For some input 
parameters, such as the effect of genotyping 
on INR after the first month of therapy, 
the authors needed to make assumptions, 
because there is no evidence yet available 
on these parameters. Therefore, it is 
necessary to delay any recommendations 
regarding genotyping until more data from 
large clinical trials become available.
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exPert commentary & five-year view 
Pharmacogenetic-guided dosing of 
warfarin and other coumarin derivatives 
seems to be a promising new method 
to improve the safety and efficacy of 
oral anticoagulant therapy. Currently, 
the response to warfarin treatment is 
evaluated by INR measure ment after the 
first few days of therapy. The prescribed 
dose can then be adapted to the patient’s 
needs, so the patient will receive a more 
individualised dose after this first INR 
measure ment. However, in the first few 
days of therapy, no informa tion on the 
patient’s response is available, so all 
patients receive the same loading dose. 
If patients were to be genotyped before 
they started taking warfarin, the loading 
dose for the first few days could already 
be personalised. However, this would 
only be possible if the genotype results 
are available before warfarin initiation. 
Therefore, it is desirable to have a fast, 
reproducible and accurate method to 
genotype; for this purpose, point-of-care 
testing might be useful.
Meckley et al. have shown that 
pharmacogenetic-guided dosing could 
improve health at higher healthcare costs 
compared with standard care, but there 
is not enough information available yet 
on the effectiveness of this genotype-
guided dosing method 1. Moreover, as the 
study of You et al. 5 demonstrates, a low 
adverse event rate with warfarin therapy 
will make genotyping less cost effective. 
As a consequence, the cost–effectiveness 
of pharmaco genetic-guided warfarin 
dosing will differ between countries and 
will be particularly favorable in settings 
where warfarin therapy is complicated 
by a relatively high rate of bleedings and 
thrombo embolic events. The upcoming 
use of direct thrombin inhibitors might 
also reduce the value of genotype-guided 
warfarin dosing in the future to some extent.
It is not yet fully known how to use 
the genetic information to adjust the 
prescribed warfarin dose. In the study 
of Meckley et al. it seemed that patients 
with a variant genotype were under dosed 
in the pharmacogenetic-guided dosing 
strategy 1. Dosing algorithms, such as 
the dosing algorithm developed by the 
International Warfarin Pharmacogenetics 
Consortium 10, there fore need to be 
developed and tested widely to find the 
optimal way of adjusting the dose of 
warfarin or other coumarin deriva tives 
according to the genetic information. It 
is also not yet clear whether the genetic 
information has any value for determining 
the right dose after the first few days of 
therapy, when the dose is also adjusted 
according to the INR values of the patients.
Within a few years, more data on this 
subject will become available, as several 
large clinical trials investigating the 
effective ness of pharmacogenetic-guided 
dosing algorithms in treatment with 
warfarin and other coumarin derivatives 
are now under way 11,101. Since the primary 
outcome of these studies is time within 
therapeutic INR range, a model like the 
one presented in this study of Meckley 
et al. 1 would be very useful to assess not 
only the effectiveness but also the cost–
effectiveness of a pharmacogenetic-guided 
dosing strategy.
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abstract
Objectives: To investigate the cost–effectiveness of pharmacogenetic-guided 
phenprocoumon dosing versus standard anticoagulation care in Dutch patients with 
atrial fibrillation.
Methods: Using a decision-analytic Markov model, cost–effectiveness of pharmacogenetic-
guided therapy versus standard care was estimated.
Results: Compared with standard care, the pharmacogenetic-guided dosing strategy 
increased quality-adjusted life-years (QALYs) only very slightly and increased costs by 
€15. The incremental cost–effectiveness ratio was €2658 per QALY gained. In sensitivity 
analyses, the cost of genotyping had the largest influence on the cost–effectiveness ratio. 
In a probabilistic sensitivity analysis, the incremental costs of genotype-guided dosing 
were less than €20,000 per QALY gained in 75.6% of the simulations. 
Conclusions: Pharmacogenetic-guided dosing of phenprocoumon has the potential to 
increase health slightly and may be able to achieve this in a cost-effective way. Owing 
to the many uncertainties it is too early to conclude whether or not patients starting 
phenprocoumon should be genotyped.
introduction
Coumarin derivatives are widely used 
anticoagulants, prescribed to treat 
and prevent thromboembolic events, 
in patients with, for example, atrial 
fibrillation 1,2. Warfarin is the most commonly 
used coumarin anticoagulant, but in several 
European countries phenprocoumon 
or acenocoumarol are more frequently 
used 3. Warfarin, acenocoumarol and 
phenprocoumon have a similar mechanism 
of action, but phenprocoumon has a 
longer elimination half- life (110–130 
h vs. 24–58 h for warfarin and 2–7 h for 
acenocoumarol) 4. Treatment with coumarin 
derivatives is challenging owing to a narrow 
therapeutic range and large variability in 
dose–response among users, which can result 
in under- or over-anticoagulation 5. Under-
anticoagulation is associated with treatment 
failure, an increased risk of thromboembolic 
events; over-anticoagulation is associated 
with an increased risk of bleeding 6. Major 
bleeding events, such as intracranial 
haemorrhage or gastrointestinal bleeds can 
be life-threatening and are costly to manage 
7. The anticoagulant effect of coumarins 
should therefore be monitored frequently 
by measuring the prothrombin time, 
commonly expressed as the International 
Normalised Ratio (INR; ratio of patient 
prothrombin time to a control sample). 
The target INR range for atrial fibrillation 
is normally 2.0–3.0. In some countries a 
slightly different range is used, such as in The 
Netherlands, where a therapeutic INR range 
of 2.0–3.5 is used 8.
The variability in dose requirements 
can be explained by several factors 
such as age, sex, height, weight, 
concomitant medication, diet and 
genetic factors 4. Polymorphisms in the 
CYP2C9 and VKORC1 genes together 
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explain approximately one-third 
of the variation in coumarin dose 
requirements 9,10. The CYP2C9 gene 
codes for the main metabolizing enzyme 
of coumarin anticoagulant, CYP2C9, and 
the VKORC1 gene codes for the target 
enzyme, VKORC1. Information about a 
patient’s genotype could thus be used to 
guide the coumarin dose before treatment 
initiation, thereby increasing the safety 
and effectiveness of the treatment 11,12. 
Some small clinical trials have already 
investigated the effectiveness of this 
pharmacogenetic-guided dosing 13-16 and 
larger trials are underway 17-19.
In addition to effectiveness, the cost–
effectiveness of genotyping should be 
considered before implementation in 
clinical practice. Several authors have 
investigated this for warfarin and the 
most recent study was published in 
2010 by Meckley et al. 20. These authors 
studied the cost–effectiveness of warfarin 
pharmacogenetic-guided dosing using the 
INR as a validated surrogate measure for 
the risk of bleeding and thromboembolic 
events. The cost–effectiveness of genotype-
guided dosing of acenocoumarol in 
The Netherlands has been studied by 
Schalekamp et al. 21. However, to our 
knowledge, no studies have examined the 
cost–effectiveness of genotyping patients 
initiating phenprocoumon. The aim of 
this study was to investigate the cost–
effectiveness of pharmacogenetic-guided 
phenprocoumon dosing versus standard 
anticoagulation care in Dutch patients 
with atrial fibrillation. This indication is the 
most important indication for coumarin 
anticoagulants and these patients 
frequently need lifelong treatment.
materials & methods
model structure
A decision-analytic Markov model was 
developed by Meckley et al. to analyse the 
cost–effectiveness of pharmacogenetic-
guided dosing for warfarin 20. This model 
was used as a basis for the analyses in 
our study and adapted in several ways, as 
discussed in the next section. The model 
was developed using Tree- Age software 
(TreeAge Pro 2012). The model was used 
to compare the incidence of adverse events, 
quality-adjusted life-years (QALYs), and 
direct medical costs of pharmacogenetic-
guided phenprocoumon therapy (PGx) 
versus standard phenprocoumon 
therapy over a lifetime horizon. In The 
Netherlands, standard phenprocoumon 
therapy is managed by anticoagulation 
clinics. After the treatment is initiated 
with a standard loading dose, the INR is 
measured and the dose can be adapted by 
specialised physicians afterwards.
Data from the pre-EU-PACT study 
were used to populate the decision-
analytic Markov model 12. In this study, 
patient-level data regarding age, INR 
values, therapy indication, and CYP2C9 
and VKORC1 genotype of 624 patients 
receiving standard phenprocoumon 
therapy were collected. The base-case 
analysis consisted of a hypothetical cohort 
of patients with atrial fibrillation, aged 71.5 
years (mean age at start of therapy for atrial 
fibrillation in the pre-EU-PACT study 12) 
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initiating phenprocoumon therapy. Figure 
1 shows the decision tree with the two 
strategies, PGx versus standard care. 
Patients were first stratified by VKORC1 
genotype, because this gene has the largest 
influence on INR variation 12. Patients in 
each of the VKORC1 genotype groups 
were then further stratified by CYP2C9 
genotype. The CYP2C9 wild-type group 
consisted of *1*1 patients, and carriers of 
at least one *2 or *3 allele were classified as 
variant carriers.
The decision-analytic Markov model 
consisted of six Markov states: atrial 
fibrillation with no adverse event, no 
adverse event plus stop therapy, major 
bleeding event (bleed), thromboembolic 
event, sequelae and death. All patients 
entered the model in the ‘healthy with atrial 
fibrillation’ state and could move to other 
states at monthly intervals (Figure 2). Major 
bleeds were classified as an intracranial 
haemorrhage (ICH) or a gastrointestinal 
(GI) bleed, since the majority (89%) of 
extracranial haemorrhages are GI bleeds 22. 
A total of 16% of the major bleeds in The 
Netherlands were ICH 101 and we assumed 
that the other (extracranial) bleeds were 
GI bleeds. Patients with a GI bleed were 
assumed to recover after 1 month, while 
patients with an ICH had a 44% chance of 
dying 101 and 50% chance of recovery with 
sequelae 22. The remaining patients (6%), 
who experienced an ICH and subsequently 
New phenprocoumon patient
Pharmacogenetic-
guided dosing
Standard care
VKORC1 GG
VKORC1 AG
VKORC1 AA
VKORC1 AA
CYP2C9 wild-type
VKORC1 AG
VKORC1 GG
CYP2C9 variant
CYP2C9 wild-type
CYP2C9 variant
figure 1. Model structure of the decision tree used to analyse the cost–effectiveness of pharmacogenetic-
guided dosing versus standard care. Patients initiating treatment with phenprocoumon are classified 
according to treatment arm (pharmacogenetic- guided dosing or standard care) and stratified by 
genotype. The two arms are equal up to the Markov node. At this point, different chances of developing 
adverse events are defined. M: Markov nodes.
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fully recovered, were assumed to stop 
phenprocoumon therapy as a result. A 
total of 60% of the thromboembolic events 
were classified as ischaemic stroke and the 
remainder (40%) as transient ischaemic 
attack (TIA). Stroke and TIA represent the 
main therapeutic effect of phenprocoumon. 
In order to prevent the model from 
being too complicated, we decided not 
to include other cardiovascular events, 
such as myocardial infarction or angina 
pectoris, and invasive interventions, such 
as coronary bypass surgery or percutaneous 
coronary interventions, but focus on the 
main therapeutic effect only. We assumed 
that 11% of the patients with a stroke 
died within 1 month 101, 47% recovered 
with sequelae 20 and the remainder fully 
recovered within 1 month. All patients with 
a TIA were assumed to be fully recovered 
the next month. Age-specific mortality 
rates were taken into account for all 
patients. Input parameters of the model are 
shown in Table 1. Utilities and disutilities 
of the different health states and the cost 
parameters are shown in Table 2.
clinical input
An INR measure such as time in therapeutic 
range is commonly used as the primary 
outcome in clinical trials investigating 
the effect of genotyping because of the 
relatively low rate of adverse events 13,16,17,20. 
The percentage time in different INR 
ranges was therefore used to determine 
the probability of an event for each of 
the genotype subgroups. The average 
percentage time spent in the four different 
INR ranges, <2.0; 2.0–3.5; >3.5–5.0 and 
>5.0 was determined for each genotype 
subgroup from data of the pre-EU-PACT 
study, which was assumed to reflect the 
standard phenprocoumon treatment in 
The Netherlands. The percentage time in 
figure 2. Markov model health states. All patients enter the model in the ‘healthy + AF’ state and can 
move to other states at monthly intervals. AF: Atrial fibrillation; TE: Thromboembolic event.
Healthy   
+ AF
Bleed
Dead
Stop
therapy
TE
Sequelae
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different INR ranges was calculated using 
the method of Rosendaal et al. 23 with 
Predictive Analytics Software Statistics 
(PASW Statistics) software, version 18. 
Figure 3 depicts the percentage time spent 
in the different INR ranges during the 
first and sixth month of phenprocoumon 
treatment in the different VKORC1 (GG, 
GA and AA) and CYP2C9 (wild-type or 
variant carrier) genotypes. It was assumed 
that this percentage is stable from month 
12 of anticoagulation therapy. The risks of 
adverse events associated with each of the 
four INR ranges were derived from the 
meta-analysis by Oake et al. 24. In this study 
the risk of bleeding or thromboembolic 
events was investigated for four INR ranges 
(<2.0; 2.0–3.0; >3.0–5.0 and >5) where the 
target range was 2.0–3.0. We assumed that 
the risk of an adverse event associated with 
an INR in this target range was similar to 
the risk with an INR in the 2.0–3.5 target 
range used in The Netherlands.
The increased risk of thromboembolic 
events at INR levels >5 is different from 
what would be expected. According to Oake 
et al., this reflects a curvilinear association 
between INR levels and thromboembolic 
event risk, which is found in several studies 
in their meta-analysis 24. This association 
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would be attributable to patients at high 
risk for overanticoagulation who also 
have an increased risk of thromboembolic 
events, such as patients with thrombophilic 
syndromes.
The effects of pharmacogenetic-guided 
dosing were projected with the surrogate 
end point of percentage time spent in 
the different INR ranges. Meckley et 
al. 20 used data from the COUMAGEN 
trial 13 to model the effect of genotyping. 
This enabled them to obtain patient-
level data on INR time within, below 
and above the therapeutic range. In a 
more recent study of Anderson et al., the 
CoumaGen-II trial 16, data of 504 patients 
on a pharmacogenetic-guided warfarin 
dosing regimen were compared with data 
of parallel controls on standard warfarin 
dosing. In this CoumaGen-II trial, patients 
in the pharmacogenetic guidance group 
spent 10.5% more time within therapeutic 
INR range than the control patients in the 
first month (68.9 vs. 58.4%, respectively) 
and 12.6% more in the first 3-month period 
(71.2 vs. 58.6%, respectively). Patients on 
a genetic-guided dose had 10.3% fewer 
out-of-range INRs in the first month, if 
table 2. Utility and cost parameters used in the model
Parameter base case range source
Utilities
Atrial fibrillation 0.81 0.7784 to 0.8430 Meckley et al. (2010) 20
Phenprocoumon use -0.013 -0.005 to -0.021 Meckley et al. (2010) 20
GI bleed -0.06 -0.02 to -0.10 Meckley et al. (2010) 20
ICH -0.1385 -0.1182 to -0.1600 Meckley et al. (2010) 20
TIA -0.1032 -0.0881 to -0.1189 Meckley et al. (2010) 20
Stroke -0.1385 -0.1182 to -0.1600 Meckley et al. (2010) 20
Sequelae -0.374 -0.160 to -0.588 Meckley et al. (2010) 20
Costs (€)
Genotyping 40 20 to 160† Howard et al. (2011) 25
Phenprocoumon tablets per month 1.72 1.38 to 2.10‡ Medicijnkosten.nl 103
INR measurement + visit to anticoagulant clinic 11.74 9 to 14‡ Schalekamp et al. (2006) 21
GI bleed 12,093 9670 to 14,510‡ Schalekamp et al. (2006) 21
ICH 19,132 15,300 to 22,960‡ Schalekamp et al. (2006) 21
TIA 1305 1044 to 1566‡ DRGs 104
Stroke 10,000 8000 to 12,000‡ Struijs et al (2006) 26
Sequelae - first month 9000 7200 to 10,800‡ Verhoef et al. (2012) 27
Sequalae - subsequent months 450 360 to 540‡ Verhoef et al. (2012) 27
Discount rate costs (%) 4 0%to 8 CVZ
†Half the estimated price of a point of care test compared to the current price in a Dutch laboratory. ‡±20%.
CVZ: Dutch Health Care Insurance Board; DRG: Diagnosis-related group; GI: Gastrointestinal; ICH: 
Intracranial haemorrhage; INR: International Normalised Ratio; TIA: Transient ischaemic attack.
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compared with control patients (31.2 vs. 
41.5%, respectively) and 12% fewer up to 
the end of the third month (30.3 vs. 42.3%, 
respectively). This difference was mainly 
driven by a reduction in subtherapeutic 
INRs. In our model, we used these data 
to calculate the percentage time in the 
different INR ranges in the PGx arm. We 
assumed that genotyping would lead to 
a 12.6% increase in time within range in 
the first month and that approximately 
three-quarters of this change (9%) would 
be attributed to a decrease in time below 
range. This assumption was made because 
in the CoumaGen-II trial INR values 
<1.5 were reduced by genotyping, while 
there was no significant difference in INR 
values >4 16. The remaining a quarter was 
assumed to be attributed to a decrease in 
time above range; 2.7% decrease in time 
between 3.5 and 5 and 0.9% decrease in 
time above 5. This effect of genotyping 
in the first month of therapy was linearly 
interpolated to zero in the sixth month. 
Effects were discounted at an annual rate of 
1.5% in accordance with Dutch guidelines 
for pharmacoeconomic analyses 102.
utilities, disutilities & cost data
In our model, we used the same estimates 
for quality of life (utilities) used by Meckley 
et al. 20. We assumed that the disutility 
of using phenprocoumon therapy is the 
same as for using warfarin. Because the 
hypothetical cohort of patients included 
in this model all had atrial fibrillation, 
the utility of atrial fibrillation (0.81) was 
applied to all patients and a disutility 
of 0.013 for phenprocoumon use was 
applied. Disutilities were also ascribed in 
case of an adverse event.
Costs were determined from a 
healthcare sector perspective for the 
year 2011 in Euros (€) and discounted 
at 4% per year in accordance with Dutch 
guidelines. While these guidelines 
recommend using a societal perspective, 
we used a healthcare sector perspective 
since most of the cost differences were 
expected to be found in this sector. The 
costs of a point of care genotyping test 
were estimated to be less than US$50 per 
test with an instrument of approximately 
US$15,000 25 and the base-case estimate 
for the costs of genotyping was €40. In 
The Netherlands, the INR is monitored 
on average 20.3-times per year 101. We 
therefore calculated a frequency of 1.7 
measurements per month, until death 
or an adverse event and assumed that six 
measurements would take place in the 
first month. Patients who experienced an 
adverse event were assumed to have an 
additional INR measurement that month. 
If patients recovered and continued using 
phenprocoumon, they were assumed to 
have one INR measurement a month until 
another adverse event or death. Costs of an 
individual anticoagulation visit including 
an INR measurement were derived from 
Schalekamp et al., who performed a 
previous Dutch cost–effectiveness analysis 
of genotyping versus standard care in 
acenocoumarol 21.
Assuming an average dose of one tablet 
per day, the costs of phenprocoumon 
tablets were estimated at €1.72 per 
month 103. Costs of GI bleeds and ICH 
were derived from Schalekamp et al. 21 
and stroke costs from Struijs et al. 26. 
Dutch diagnosis-related groups from three 
different hospitals were used to estimate 
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the costs of a TIA 104. Since the total costs 
the first year after stroke were estimated at 
€24,500 and the costs of subsequent years 
at €5500, we assumed that sequelae would 
cost €9000 once and €450 per month after 
a stroke or ICH 27. All costs were expressed 
in € for the year 2011 and corrected for 
inflation whenever necessary.
analyses
Base-case estimates of the costs and 
QALYs of the PGx strategy and standard 
care were determined followed by one-way 
sensitivity analyses to evaluate the impact 
of the values of different input parameters 
on the results. The parameters were 
varied over their 95% CIs or decreased 
and increased by 20% if a confidence 
interval was not available. The effect of 
genotyping (as found in CoumaGen-II) 
was decreased and increased by 50%. The 
costs of genotyping were varied from €20 
(i.e., half the estimated price of a point of 
care test) to €160 (the current price of 
genotyping for CYP2C9 and VKORC1 in 
a Dutch laboratory) and the discount rate 
was varied from 0 to 3% for effects and 
from 0 to 8% for costs.
We also conducted the following 
scenario analyses:
 • A best-case scenario where the costs 
of genotyping are €20 and the effect 
of genotyping is 50% larger than in the 
base-case analysis;
 • A worst-case scenario where the costs 
of genotyping are €160 and the effect 
of genotyping is 50% smaller than in 
the base case analysis;
 • The impact of genotype-guided dosing 
on INR control lasts only 1 month 
after treatment initiation;
 • The impact of genotype-guided dosing 
on INR control lasts up to 1 year after 
treatment initiation;
The effectiveness of a pharmacogenetic-
guided dosing regimen is based on the 
COUMAGEN trial, as in the study of 
Meckley et al. In the study of Meckley et 
al. the effectiveness is defined separately 
for VKORC1/ CYP2C9 wild-type 
patients, VKORC1 variant carriers/ 
CYP2C9 wild-type patients and CYP2C9 
variant carriers. The last group, CYP2C9 
variant carriers, was not stratified by 
VKORC1 genotype. We also modelled the 
effectiveness of genotyping for these three 
groups, but in contrast with Meckley et al. 
we applied different risks of adverse events 
for INR 3.5–5 and INR >5 instead of one 
risk of INR >3.
A probabilistic sensitivity analysis 
using 10,000 Monte Carlo simulations 
was performed to examine the combined 
impact of uncertainties about the values of 
multiple input parameters on the estimated 
cost–effectiveness of genotyping. This also 
enabled us to calculate the chance that 
genotyping would be cost effective at a 
certain threshold or willingness-to-pay. 
Dirichlet distributions were used for the 
probabilities with more than two possible 
results (e.g., genotype, outcome of adverse 
events). β distributions were used for all 
other probabilities and utilities, and γ 
distributions for the costs. The costs of 
genotyping were varied using a triangular 
distribution. All parameters were varied in 
this probabilistic sensitivity analysis.
148
results
base case
Figure 4 shows the cumulative risk of 
haemorrhage and thromboembolism 
during the first year for the PGx strategy 
and for standard care. The difference 
between the two strategies increases 
during the first months, but is stable 
afterwards.
Table 3 shows the results of the cost–
effectiveness analyses for all patients and 
per genotype group. Compared with 
standard care, the pharmacogenetic-guided 
dosing strategy increased the QALYs 
very slightly, by 0.0057 (2 days in full 
health), and increased costs by €15.15. 
The incremental cost–effectiveness ratio 
figure 4. Cumulative risk of adverse events in the first 12 months of treatment. (a) Bleeding event; (b) 
thromboembolism. PGx: Pharmacogenetic-guided dosing; TE: Thromboembolic event.
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(ICER) was €2658 per QALY gained. 
Life expectancy in the pharmacogenetic-
guided arm was 11.592 years versus 11.585 
years in the standard care arm (difference 
of 0.007 years or 2.5 days). The costs per 
life-years saved were therefore €2225. 
For patients on pharmacogenetic-guided 
phenprocoumon therapy, the incidence of 
bleeds in the first year was estimated to be 
0.16% lower than for patients on standard 
phenprocoumon treatment. The incidence 
of thromboembolic events was 0.08% lower 
and the number of deaths was 0.02% lower.
sensitivity analysis
Figure 5 shows a tornado diagram, 
summarizing the results of the one-way 
sensitivity analysis of the 10 parameters 
with the largest influence on the cost–
effectiveness ratio. The cost of genotyping 
had the largest influence on the cost–
effectiveness ratio. The ICER varied from 
-€850 (less costly and more effective) to 
€23,850 when the costs of genotyping 
were varied from €20 to €160, respectively.
The scenario analyses confirmed that 
changing some key assumptions of the 
model had a large influence on the ICER 
(Table 4). In the best-case scenario, 
genotyping was more effective and less 
costly than standard care. In the worst-case 
scenario, however, the costs per QALY 
gained increased to almost €53,000. The 
duration of the effect of genotyping, as 
well as the source of effectiveness data 
(COUMAGEN or CoumaGen-II), 
also had a large impact on the cost–
effectiveness.
In the probabilistic sensitivity analysis, 
pharmacogenetic-guided dosing was 
more effective and more costly in 95% 
of the simulations (Figure 6) and was 
the dominant strategy (less costly, more 
effective) in 4.7%. These analyses also 
showed that there is a 75.6% chance that 
genotyping is cost effective at a willingness 
to pay threshold of €20,000 per QALY 
gained (Figure 7). Figure 7 also shows the 
probability that genotyping would be cost 
effective over a range of likely thresholds.
table 3. Results of the cost-effectiveness analysis – base case
strategy
first year incidence per 100 patients, n (95% ci) total (95% ci)
bleeds tes deaths Qalys costs (€)
icer
(€/Qaly 
gained)
PGx 2.19 
(1.90-2.48)
3.07 
(2.74-3.40)
2.57 
(2.14-3.00)
9.1823
(9.11-9.25)
7949.16
(7885-8014)
Standard 2.35
(2.06-2.64)
3.15
(2.80-3.50)
2.59
(2.16-3.02)
9.1766
(9.10-9.25)
7934.01
(7870-7998)
∆ -0.16
(-0.75-0.43)
-0.08 
(-0.77-0.61)
-0.02
(-0.88-0.84)
0.0057
(-0.14-0.15)
15.15
(-113-144)
2658
ICER: Incremental cost–effectiveness ratio; PGx: Pharmacogenetic-guided dosing; QALY: Quality-adjusted 
life-year; TE: Thromboembolic event.
150
figure 5. Tornado diagram showing the ten parameters with the largest influence on the cost–effectiveness 
ratio of pharmacogenetic-guided dosing versus standard care. The range of the incremental cost–effectiveness 
ratio in the one-way sensitivity analysis over the range of the parameter (in parentheses) is represented by 
the horizontal bars. A wide bar indicates that this parameter introduces a large degree of uncertainty. INR: 
International Normalised Ratio; TE: Thromboembolic event; QALY: Quality-adjusted life-year.
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table 4. Results of the scenario analyses
scenario Qaly cost (€) icer (€/Qaly gained)
Base case 0.0057 15.15 2658
Best case, cost of genotyping €20/ 50% more effective 0.0085 -17.29 PGx dominates
Worst case, cost of genotyping €160/ 50% less effective 0.0028 147.58 52,707
Impact of genotype-guided dosing on INR control lasts 1 month 0.0019 31.64 16,652
Impact of genotype-guided dosing on INR control lasts 1 year 0.0112 -9.20 PGx dominates
Effectiveness of genotype-guided dosing from 
COUMAGEN (as in Meckley et al. (20))
0.0014 25.54 18,242
ICER: Incremental cost–effectiveness ratio; PGx: Pharmacogenetic-guided dosing; QALY: Quality- adjusted 
life-year.
discussion
Our results show that pharmacogenetic-
guided dosing of phenprocoumon has the 
potential to decrease the risk of bleeding 
and thromboembolic events and thereby 
increase health slightly. More importantly, 
genotyping may be able to achieve this in 
a cost-effective way. Based on the base-case 
analysis, genotyping costs approximately 
€2700 per QALY gained. There is, however, 
large uncertainty regarding some important 
assumptions in the model, specifically 
the effectiveness of a pharmacogenetic-
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guided dosing regimen and the costs of 
the genetic test. Our model was based 
on existing work developed earlier to 
investigate the cost–effectiveness of 
warfarin pharmacogenomics testing 20. 
Some changes were necessary to adapt it to 
the Dutch setting of anticoagulation clinics.
Schalekamp et al. studied the cost–
effectiveness of CYP2C9 genotyping in 
acenocoumarol users in The Netherlands 
and estimated the costs at €4233 per 
bleeding event avoided in 2006 21. In the 
current study, we not only looked at the 
potential decrease in the bleeding rate 
amongst genotyped patients, but also at 
the rate of thromboembolic events. If both 
the risk of bleeding and thromboembolic 
events could be decreased, this would lead 
to a more favourable cost–effectiveness 
ratio for genotype- guided dosing. 
Another addition in our model compared 
with Schalekamp and coworkers is that we 
also looked at VKORC1 genotype instead 
of only at CYP2C9 genotype. Lastly, we 
performed a cost–utility analyses (i.e., 
costs per QALY gained) while Schalekamp 
et al. looked at cost per bleeding event 
avoided. Decision makers often require 
a cost–utility analysis. Since the Dutch 
guidelines do not express a threshold or 
willingness to pay, we examined cost–
effectiveness of genotyping at various 
thresholds and used a threshold of 
€20,000 in the analysis because of its use 
in previous reimbursement decisions 32.
In a cost–effectiveness study on 
warfarin pharmacogenetics by Patrick et al. 
it was shown that age had the largest effect 
on the ICER in the one-way sensitivity 
analysis 29. In our study, a large effect of 
age was also seen, but the largest effect was 
seen for the costs of genotyping. This also 
figure 6. Scatter plot reflecting the uncertainty in the differences in costs and effectiveness between 
genotyping and standard care (based on probabilistic sensitivity analysis). QALY: Quality-adjusted life-year.
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had a large effect in the study of Patrick et 
al., although this effect was smaller than 
the effect of age. These differences cannot 
simply be explained by differences in the 
ranges in age and genotype costs that were 
studied and may likely be due to differences 
in how age was linked to health outcomes. 
In two other cost–effectiveness studies on 
warfarin pharmacogenetics, by You et al. 
and by Eckman et al., cost of genotyping 
also played a very large role in the variation 
of ICER in one-way sensitivity analysis 30,31.
This study is also the first cost–
effectiveness study on coumarin 
pharmacogenetics using an existing model. 
Partly owing to the differences in model 
characteristics, results of previous analyses 
were difficult to compare. In this study we 
adapted the previously published model of 
Meckley et al. 20. The estimated ICER in the 
study of Meckley et al. was considerably 
higher than in our study (US$60,750), 
which indicates that genotyping might 
have a bigger chance of being cost effective 
in The Netherlands than in the USA. This 
difference is probably mainly due to the 
higher costs of genotyping (US$175) in 
the USA, but is also related to the smaller 
effect estimate used in the study of Meckley 
et al. The effect estimate in the study of 
Meckley et al. was derived from the first 
COUMAGEN 13 trial instead of the more 
recent CoumaGen-II trial 16 used in our 
study. Genotyping had a smaller effect in 
the first trial than in the more recent trial. 
We have used data from the CoumaGen-II 
trial, as this was the most recent data and 
the largest trial performed at this moment.
A major limitation of our study is the 
lack of reliable data on the effectiveness 
of genotyping phenprocoumon patients 
from appropriately powered clinical trials. 
Some large ongoing clinical trials are 
investigating the impact of genotyping 
warfarin patients 18,19. In the EU- PACT 
trial, phenprocoumon and acenocoumarol 
are also being investigated 17. The results 
of these trials can be used to investigate 
figure 7. Cost–effectiveness acceptability curve. This curve, generated from the Monte Carlo simulations, 
represents the probability that pharmacogenetic-guided dosing would be cost effective compared with 
standard care at different thresholds of willingness-to-pay. QALY: Quality-adjusted life-year.
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the cost–effectiveness further. Another 
uncertainty in the model is the cost of a 
genotyping test. It is estimated a novel point 
of care test would cost less than US$50 
to genotype a patient for CYP2C9 and 
VKORC1, but the price will also depend 
on how often this test will be used 25. If 
pharmacogenetic testing becomes standard 
practice in treatment with phenprocoumon 
(or warfarin or acenocoumarol) the price of 
the test will probably decrease.
Another possible limitation of this study 
is the use of a surrogate end point (INR) to 
estimate the effectiveness of genotyping 
instead of using the risk of bleeding and 
thrombosis directly. However, time in INR 
range is the primary outcome in two of 
the large trials 17,18, and this model could 
therefore also be used when these data 
become available. We did not use outcomes 
as acute coronary syndrome or angina 
pectoris or invasive interventions such as 
coronary bypass surgery or percutaneous 
coronary interventions. The consequence 
of this is not clear. To our knowledge, 
there is no data on whether genotype-
guided dosing will change the risk on the 
occurrence of these events.
It is possible that some parameters that 
are varied in the probabilistic sensitivity 
analysis are correlated (e.g., age and 
bleeding risk). However, we did not include 
multivariate distributions, because this data 
was not available. We therefore assumed 
independence of these variables, which could 
have inflated the second order uncertainty.
A strength of this study is the fact that 
we were able to use an existing model and 
adapt it to the desired setting and improve 
it to reflect the clinical situation more 
precisely, which makes it easier to compare 
the different studies.
conclusion
Compared with standard care, 
pharmacogenetic-guided dosing has the 
potential to increase health and may be able 
to achieve this in a cost-effective way. It is, 
however, too early to conclude whether 
or not patients starting phenprocoumon 
should be genotyped, because of significant 
uncertainties regarding some important 
assumptions in the model. The main factors 
for this uncertainty are the effectiveness of 
a pharmacogenetic-guided dosing regimen 
and the costs of the genetic test.
future PersPective
Recently, new oral anticoagulants (direct 
thrombin inhibitors and factor Xa inhibitors) 
have been developed for stroke prevention in 
patients with atrial fibrillation and these are 
thought be good alternatives for coumarin 
derivatives 33,34. These drugs have some 
advantages over coumarin anticoagulants, 
such as not requiring frequent monitoring 
(which is often considered burdensome 
for the patient). On the other hand, no 
appropriate antidote is available yet and 
bleedings tend to be more serious. Moreover, 
these new drugs are more expensive than 
coumarin derivatives, so it is also important 
to study their cost–effectiveness 35,36. In the 
RE-LY trial the investigators found that the 
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benefit of dabigatran compared with warfarin 
was related to the quality of care of the 
warfarin treatment 37. An important question 
to be answered in the coming years is whether 
it would be better to improve the current 
standard therapy with coumarin derivatives 
by use of pharmacogenetics or to use an 
entirely new drug. Both the effectiveness 
and the cost–effectiveness of these options 
should be investigated. Possibly, both 
options (the new oral anticoagulants and 
pharmacogenetic-guided dosing of coumarin 
anticoagulants) could be used in the future. 
In some situations, the costs will play a more 
important role and decision-makers will try 
to find a cost-saving solution. In countries 
where the quality of coumarin treatment is 
currently low, genotyping could possibly be a 
cost-saving option.
Currently, several large trials are 
investigating the clinical effectiveness 
of genotype-guided dosing of coumarin 
derivatives 17-19. When more information 
on this subject becomes available in the 
coming years, the model used in this study 
could be adapted and used to assess the 
cost–effectiveness of pharmacogenetics 
using phenprocoumon, acenocoumarol 
or warfarin to treat patients with atrial 
fibrillation versus standard care. A value of 
information analysis can be performed to 
determine whether or not it is worthwhile 
to collect extra information to reduce 
uncertainty about the cost–effectiveness 
of a new treatment. As new information 
about the effectiveness of genotyping is 
expected in the very near future, we did not 
think it useful to perform such a value of 
information analysis at this time. However, 
it would be worthwhile to perform such 
an analysis after all information from the 
trials has been analysed.
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abstract
Genotyping patients for CYP2C9 and VKORC1 polymorphisms can improve the accuracy 
of dosing during the initiation of anticoagulation with vitamin K antagonists (coumarin 
derivatives). The anticipated degree of improvement in the safety of anticoagulation with 
coumarin derivatives through genotyping may vary depending on the quality of patient care, 
which varies both with and among countries. The management and the cost of anticoagulant 
care can therefore influence the cost–effectiveness of genotyping within any given country. 
In this article, we provide an overview of the cost–effectiveness of pharmacogenetics-guided 
dosing of coumarin derivatives. We describe the organization of anticoagulant care in the UK, 
Sweden, The Netherlands, Greece, Germany and Austria, where a genotype-guided dosing 
algorithm is currently being investigated as part of the EU-PACT trial. We also explore the 
costs of anticoagulant care for the treatment of atrial fibrillation in these countries.
introduction
Coumarin derivatives are commonly 
prescribed for the treatment and 
prevention of thrombo embolic events 1. 
Anticoagulation therapy with coumarin 
derivatives requires frequent monitoring 
of the International Normalised Ratio 
(INR), an indicator of the clotting 
tendency of blood, to maintain within a 
narrow therapeutic range. For patients 
with atrial fibrillation, the INR target range 
is normally 2.0–3.0, with some exceptions 
such as 2.5–3.5 in The Netherlands 2. 
Wide inter- and intra-patient variability 
in dose requirement exists, which makes 
it difficult to predict the right dose. INR 
values below the therapeutic range lead 
to loss of efficacy and an increased risk of 
thromboembolic events, while INR values 
above the therapeutic range lead to toxicity 
with an increased risk of bleeding events. 
The latter can be minor or major and life-
threatening or fatal, such as intracranial 
haemorrhage (ICH) 3. The variation in 
dose requirements can be explained by 
several factors, including age, weight, 
height, vitamin K intake and concomitant 
medication; however, genetic factors also 
explain a substantial proportion of this 
variability 4. Genotyping the CYP2C9 and 
VKORC1 genes may help to predict the 
required coumarin dose prior to treatment 
of the patients 5. CYP2C9 encodes the 
main metabolizing enzyme of coumarin 
anticoagulants, CYP2C9, and VKORC1 
encodes the pharmacodynamic target 
enzyme for coumarin anticoagulants, 
VKORC1. By prescribing a dose that is 
based on genotype and clinical factors, 
it is anticipated that patients will both 
reach a therapeutic INR quicker and 
maintain within range for longer. This 
could decrease the risk of adverse events, 
including stroke and bleed ing; however, 
supporting evidence from appro priately 
powered clinical trials are hitherto 
unavailable. 
For the implementation of 
pharmacogenetic testing in practice, further 
evidence of the clinical effectiveness and 
cost–effectiveness is necessary. Currently, 
two major clinical trials are ongoing to 
investigate the former 6,7, and an economic 
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analysis is planned to estimate the 
incremental cost–effectiveness of the new 
dosing strategy compared with standard 
care (i.e., a nongenotype-guided dosing 
regimen). Several cost–effectiveness 
analyses of genotyping have previously been 
performed, but with limited conclusions 
about their economic value, principally 
because of the uncertainty in the clinical 
evidence 8-16. Furthermore, most of the 
cost–effectiveness studies were conducted 
in the USA, where anticoagulation services 
are organised differently from European 
countries. However, even among European 
countries, diff erent models of care apply. In 
some countries, treatment is managed by 
specialised physicians in anticoagulation 
clinics, while in others, this is being 
performed by hospital specialists (includ-
ing anticoagulation pharmacists or nurses) 
or by the general practitioners (GPs). These 
diff erences contribute to variation in the 
quality 17-21 and costs of care, and will impact 
on the cost–effectiveness of genotyping.
The aim of this article is to describe 
the cur rent standards of coumarin 
anticoagulant therapy and its associated 
costs, relating to the manage ment of atrial 
fibrillation in different European countries. 
First, we provide a brief overview of the 
results of the cost–effectiveness analyses 
of pharmacogenetic-guided dosing of 
coumarin derivatives performed to date. 
Next, we describe the organization of 
anticoagulant care in the UK, Sweden, 
The Netherlands, Greece, Germany and 
Austria; countries in which a genotype-
guided dosing algorithm is currently 
being investigated as part of the EU-PACT 
trial. Finally, we summarise the costs of 
anticoagulant therapy for each country.
method
We reviewed the literature for economic 
evalu ations of pharmacogenetic testing in 
relation to anticoagulation with coumarin 
derivatives. Relevant articles were sourced 
from our previ ous related review 22, and 
from an electronic search of PubMed, 
following the same search strategy. In 
our previous review, nine articles were 
selected. More details about this selec tion 
and the quality assessment can be found 
elsewhere 22. During our PubMed search, 
we found one additional article describing 
the cost–effectiveness of genotype-guided 
warfarin dos ing 16. We also conducted 
literature searches for details of current 
anticoagulant care systems in the sample 
countries, as well as the associ ated costs. 
Additional information, sourced from 
governmental organizations or from 
interviews with experts, supplemented 
our reviews. 
We examined the following characteristics 
of each system: the setting of anticoagulant 
care (i.e., hospital, GP or specialised clinic), 
most frequently used coumarin derivative, 
popula tion, mean annual frequency of 
INR monitor ing, mean percentage time in 
therapeutic INR range, major bleeding rate, 
stroke rate and the number of self-managing 
patients. We also col lected information about 
costs of the coumarin anticoagulant and 
INR measurements, and that of managing a 
gastrointestinal (GI) bleed, ICH, stroke and 
transient ischaemic attack (TIA).
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overview of available cost–
effectiveness analyses
CYP2C9 genotyping 
In 2003, Higashi and Veenstra made an 
approxi mation of the cost–effectiveness of 
genotyping warfarin users for CYP2C9 in 
the USA to illus trate the concepts of cost–
effectiveness analyses of pharmacogenetic 
testing 8. In their study the authors estimated 
the costs of a genotype-guided dosing 
strategy to be US$5940 per bleed ing event 
avoided. Because this analysis was only used 
for didactic purposes, it was incom plete and 
a comparator was not mentioned. However, 
1 year later You et al. performed the first full 
economic evaluation, which resulted in a 
cost–effectiveness ratio of US$5778 per 
bleeding averted, compared with standard 
care 9. The comparator in all following 
studies was standard anticoagulation care. 
McWilliam et al. estimated the cost per 
bleeding averted at US$13,500 in 2008 11. 
Schalekamp et al. reported the first (and 
only) cost–effectiveness analysis focused 
on the use of acenocoumarol in The 
Netherlands instead of the use of warfarin 
in the US in 2006 15. The authors found that 
the cost per bleeding event avoided was 
US$5151. This cost–effectiveness ratio was 
sensitive to diff erent parameters, including 
the bleeding rate, prevalence of a CYP2C9 
polymorphism and the cost of genotyping.
CYP2C9 & VKORC1 genotyping
Some cost–effectiveness analyses have 
also included genotyping for VKORC1 
10,12-14, which was first reported to have an 
effect on the required coumarin dose in 
2005 23. These studies also include a measure 
of utility and were therefore able to present 
their estimates of cost–effectiveness as 
cost per quality-adjusted life-year (QALY) 
gained, which ranged from US$171,000–
347,000. The willingness to pay in the USA 
is US$50,000–100,000 per QALY gained 24. 
One important limitation of the 
studies per formed before 2010 is that the 
effectiveness of genotyping was based 
mainly on assumptions and not on robust, 
appropriately powered, clinical trial 
evidence. Meckley et al. used time below, 
within and above therapeutic INR range 
as a surrogate to estimate and compare the 
risk of different adverse events in both the 
genotyped group and the standard care 
group 16. They concluded that genotyping 
was more effective than standard care, but 
at a cost of US$60,750 per QALY gained. 
The authors also performed a probabilistic 
sensitivity analysis and showed that the 
chance that genotyping would be cost-
effective at a threshold of US$50,000 per 
QALY gained was 46%. 
The results of the different cost–
effective ness studies published in the 
past vary widely. The primary cause of 
this variation relates to the uncertainty 
around the effectiveness of geno typing. 
This uncertainty is caused by the small 
number of randomised controlled 
trials, and the heterogeneity of patient 
populations, trial design, definitions of 
outcomes and reporting of results among 
these randomised controlled trials. 
Another factor is the estimation of costs; 
for example, the cost of genotyping varied 
from US$67–575. However, since the 
costs of a phar macogenetic test are steadily 
decreasing, there is a greater likelihood 
that genotyping will be cost-effective 
provided that it leads to marginal health 
benefits compared with standard care. 
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Differences among studies may also be 
explained by the wide range in the scope 
of the analysis (e.g., produc tivity costs and 
time horizon), which can, for example, 
influence the estimated overall costs of 
major bleeding and stroke.
management of anticoagulant 
treatment in different countries 
Anticoagulant treatment is organised 
differently among different countries. 
In this section, we describe the main 
characteristics of the organi zation of 
treatment with coumarin derivatives in 
selected European countries. The principal 
findings are summarised in Table 1.
UK 
Approximately 950,000 patients are 
using war farin in the UK (prevalence is 
approximately 1.6%) 17,25. Anticoagulation 
therapy services are delivered in a number 
of different settings including full-service 
provision in secondary or primary care, 
shared provision between primary and 
secondary care and domiciliary provision. 
An estimated 20,000 (2%) patients self-
monitor their INR Heneghan C, Pers. Comm.. Most 
patients are initiated on warfarin in hospital 
and man aged long term by GPs 17,101. 
The frequency of INR measurements is 
usually between eight and 12 per year 26. 
However, there is consider able variation in 
published reports. In a study by Jones et al., 
the mean time between consecutive INR 
measurements was 15.7 days, implying an 
average of 23 INR measurements per year 27; 
and Jorgensen et al. reported a median of 
16 (range 1–57) INR measurements over 
a 6-month period 28. The percentage time 
spent within therapeutic INR range in 
routine UK practice is, on average, 63.1% 29. 
This compares with estimates of 60–68% 
from other studies of rou tine care 27,30,31, 
and 72% in the UK centres that recruited 
patients for the RE-LY trial 21. 
Based on a UK General Practice 
Research Database review of patients 
with atrial fibrilla tion, Rietbrock et al. 
determined an ischaemic stroke rate of 3.2 
events per 100 patient-years 32. The risk of 
major bleeds was estimated by NICE at 
2.4% per year in its costing report on atrial 
fibrillation 102. This was based on the study 
by Fitzmaurice et al., which suggested that 
the annual rate is 2.4–8.1% 33, Abdelhafiz 
and Wheeldon who calculated a rate 
of 2% 34 and Carroll and Majeed who 
suggested a rate of 2.3% per year 35.
Sweden 
In Sweden approximately 150,000 
patients are using warfarin (prevalence is 
approximately 1.6%) 36,37. The treatment 
is managed by anticoagulation centres 
in a hospital setting or in primary care 37. 
The proportion of patients monitored in 
primary healthcare units is depen dent on 
local tradition and differs from region to 
region. A large difference between regions 
can be seen in the study of Wallvik et al., 
where the proportion of warfarin users 
monitored by the GP ranged from only 
10% up to 80% 38. In Stockholm most 
patients are treated by the GP 39. In many 
primary healthcare clin ics the GP works 
alone, but often their GP is also assisted 
by a nurse. The patient can either come to 
the clinic for INR measurement or a blood 
sample for INR measurement can be 
taken at the patient’s home 40. In the study 
of Wieloch et al., the INR is measured 
on average 13.6-times per year 37. This 
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is in line with the frequency of INR 
measurements in the study of Davidson 
et al. for patients treated in primary care 
(13.7) 41. In a hospital clinic, the INR 
was measured 16.9-times per year. In the 
first year, five extra measurements were 
assumed. Björholt et al. showed that 
when patients were initiated on warfarin, 
the INR was measured 12.4-times in the 
first 3 months and 17.1-times in months 
4–12 42. In this study, the frequency of 
INR measurements in the second year 
was 16.2. The average percentage time 
spent within the target INR range was 
found to be 76.2% and this per centage was 
somewhat higher in primary care centres 
(80.3%) than in hospital-based centres 
(75.7%) 37. The exact number of patients 
on self-management is unknown, as well 
as the per centage time in range for this 
treatment strategy. The number of self-
testing patients has been esti mated at 
1500 Svensson P, Pers. Comm.. 
Lind et al. calculated an incidence of 
a bleed ing event of 3.3 per 100 patient-
years 43. In an earlier study by these 
authors, the incidence of a GI bleed and an 
ICH was 1.3 and 0.6 per 100 patient-years, 
respectively 44. Similar rates were observed 
in the study of Asberg et al. (GI bleed: 
1.18 per 100 patient-years; ICH: 0.89 per 
100 patient-years) 45, Friberg et al. (ICH: 
0.6 per 100 patient-years) 46 and Wallvik 
et al. (GI bleed: 1.4 per 100 patient-years; 
ICH: 0.7 per 100 patient-years) 38. Lind et 
al. also studied the occurrence of stroke 
and showed a rate of 2.8 strokes per 100 
patient-years 43. In a study by Åsberg et al., 
ischaemic stroke occurred 3.5-times per 
100 patient-years in patients who were 
treated with warfarin after a first stroke 47.
The Netherlands
In The Netherlands, 398,000 patients 
were treated with a coumarin derivative 
in 2010 (prevalence is approximately 
2.4%) 103. The most frequently used 
coumarin anticoagulant is acenocoumarol 
(81%), while the remaining patients are 
given phenprocoumon 103. All coumarin 
users are referred to a specialised 
anticoagulation clinic to monitor their 
treatment. Patients either go to the clinic 
for INR measurement (60%) or are visited 
at home (40%) by a nurse from the clinic. 
The anticoagulant dose and interval 
between monitoring visits is determined 
by specialised physicians 2,48,103. The target 
INR in The Netherlands is higher than 
in other European countries. The target 
range for atrial fibrillation for example, is 
2.5–3.5 49. The median frequency of INR 
measurements per patient per year was 
20.3 in 2010 and the median percentage 
time in target INR range was 78.5% for 
patients on long-term acenocoumarol or 
phenprocoumon treatment (6 months 
to lifelong). For patients on short-
term treatment (2–6 months) with 
acenocoumarol or phenprocoumon or 
in the initiation phase (0–2 months), 
this percentage was 74.3 and 62.6%, 
respectively 103. Torn et al. demonstrated 
that the percentage time in range between 
different age groups varies from 61% in 
patients older than 80 years to 68% in 
patients aged between 60 and 70 years 50. 
In a study of Gadisseur et al. the percentage 
time in range for patients treated in a 
specialised anticoagulation clinic was 
63.5% 51. This study also investigated the 
quality of patient self-management and 
found that patients on self-management 
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table 1. Summary characteristics (point estimates) of anticoagulant care in different countries
united Kingdom sweden The netherlands greece germany austria
Setting GP (hospital initiates) 17,101 GP/Hospital 37 Specialised anticoagulation 
clinics 2,48
Private sector 53 GP /Hospital Stingl J, Pers. Comm. GP (hospital 
 initiates) Haschke-Becher E, Pers. Comm.
Most frequently used coumarin anticoagulant Warfarin 17,25 Warfarin 37 Acenocoumarol 103 Acenocoumarol 54 Phenprocoumon 57 Phenprocoumon Haschke-Becher E, Pers. Comm.
Population, n (% prevalence) 950,000 (1.6) 17 150,000 (1.6) 36 398,000 (2.4) 103 20,000 (0.2) 53 750,000 (0.9) 56 60,000 (0.7) 104
Frequency of INR monitoring 10 26 13.6 37 20.3 103 12 53,55 1458 12  65
Time in target INR range (%) 63.1 29 76.2 37 78.5 103 UNK 56 59 66 61
Annual major bleeding rate 0.024 102 0.033 43 0.014 103 0.028 53 0.027 (gastrointestinal  
bleed) 59
UNK
Annual stroke rate 0.032 32 0.028 43 0.001 103 0.053 53 0.022 59 UNK
Frequency of self-management (%) 20,000 (2.1) Heneghan C, Pers. Comm. 1500 (1) Svensson P, Pers. Comm 25,000 (6) 103 20 (<0.1) 53 130,000 (17) 62 3500 (6) 105
GP: General practitioner; INR: International Normalised Ratio; UNK: Not known.
had a slightly higher percentage time in 
range (68%). According to the Federation 
of Dutch Thrombosis Services (FNT), 
25,000 patients were self-managing in 
2010, with a median percentage time 
in range of 80% 103. In both the report 
of the FNT and the study of Gadisseur 
et al. the percentage time in range for 
phenprocoumon was higher (4–12%) 
than for acenocoumarol 51,103.
The FNT also keeps a record of 
bleeding or thromboembolic events during 
coumarin use. In 2010, the incidence of 
major bleeding was 1.4 per 100 patient-
years. There were 0.2 ICHs and 0.4 GI 
bleeds per 100 patient-years. Ischaemic 
strokes occurred 0.1-times per 100 patient-
years 103. The frequency of these events was 
low in comparison with earlier studies by 
Torn et al. and Visser et al. 2,52. In the study 
of Torn et al., the rate of major bleeding 
and thromboembolic events was 2.9 and 
1.4 per 100 patient-years, respectively 2. 
Visser et al. demonstrated an incidence 
of four major bleeding events per 100 
patients-years (2.1 GI; 0.76 ICH) 52.
Greece
It is estimated that in Greece only 20,000 
patients are on chronic anticoagulant therapy 
(prevalence is approximately 0.2%) 53. The 
number of acenocoumarol users is currently 
probably higher than 20,000; however, no 
official number is available Manolopoulos VG, Pers. 
Comm). Acenocoumarol is the most frequently 
used coumarin anticoagulant here, followed 
by warfarin 54. In Greece, healthcare is orga-
nised by either the private sector or the public 
sec tor, and it is estimated that approximately 
60% of the acenocoumarol users are 
treated in the pri vate healthcare sector 53. 
Approximately 30% of the patients are treated 
in insurance funds’ healthcare facilities and 
10% in specialised oral anticoagulant therapy 
hospital clinics. On aver age, patients visit the 
physician’s office once per month for INR 
measurement 53,55. Geitona et al. studied the 
costs of anticoagulant treatment in patients 
monitored with the traditional method and 
with self-monitoring 53. In this study, a panel 
estimated the probability of complica tions. 
For the traditional method, the incidence 
of haemorrhagic complications was 2.8% 
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and the incidence of thromboembolic 
episodes was 5.3%. The risk of 
complications was lower in special ised oral 
anticoagulation clinics (2.5% haemorrhagic 
complications and 0.9% thromboembolic 
episodes) and for self-monitoring (1.5% 
haemorrhagic complications and 0.9% 
thromboembolic episodes). Less than 0.1% 
of the acenocoumarol users perform self-
monitoring 53.
Germany 
Approximately 750,000 patients use 
a cou marin derivative in Germany 
(prevalence is approximately 0.9%) 56. 
The majority of these patients are treated 
with phenprocoumon 57. In most cases, 
the therapy is managed by the GP who 
checks the INR on average 14-times per 
year Stingl J. Pers. Comm.,58. In a study on adher-
ence to anticoagulation guidelines in 
patients with atrial fibrillation, McBride et 
al. reported that patients spent 56% of the 
time in the thera peutic INR range 59. Voller 
et al. studied the quality of patient self-
management and found that these patients 
spent 67.8% of the time in the therapeutic 
INR range versus 58.5% in patients who 
were managed by the GP 60. In a study by 
Siebenhofer et al. self-management was 
com pared with routine care in Germany 
and Austria. In the self-management group, 
the percentage time within target range was 
73, versus 66% in the routine-care group 61. 
Approximately 130,000–160,000 coumarin 
users are self-man aging 62,63. McBride et al. 
also investigated the complications that 
occurred during a 9-month observation 
period. During this period, 1.7% of the 
patients suffered a stroke, 0.3% a TIA 
and 19% of the patients had a bleeding 
event, which were mostly gum and nasal 
bleeds (2% were a GI bleed) 59. Jobski et al. 
estimated an incidence of hospitalizations 
for bleeding of 2.79 per 100 patient-years 64. 
The annual incidence of events shown in 
Table 1 are based on conver sions of these 
figures to a 1-year period.
Austria 
Phenprocoumon is the most frequently 
used coumarin anticoagulant in Austria 
and treatment is normally initiated in the 
hospital and monitoring is done by the 
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GP Haschke-Becher E, Pers. Comm.. More than 60,000 
patients are on long-term phenprocoumon 
treatment in Austria (prevalence is 
approximately 0.7%) 104. Currently, routine 
care in Austria involves monthly INR moni-
toring 65. Approximately 3500 patients are 
undertaking self-management 105. In a study 
of Austria and Germany, Siebenhofer et 
al. found that the percentage time within 
the target INR range of 2.0–3.0 in routine 
care was 66 and 74% for patients doing 
self-management 61. Data on percentage 
time within the INR target range and 
risks of complications such as bleed ing or 
stroke rate were not available for Austria 
specifically.
cost of anticoagulant treatment 
As can be expected, the costs associated 
with anticoagulant treatment and 
complications diff er among European 
countries. In the section that follows, 
we describe the main cost param eters 
associated with coumarin use in the sample 
countries. The costs of the coumarin 
antico agulant, INR measurements and 
management of major bleedings (i.e., GI 
bleeds and ICH), strokes and TIAs are 
summarised per country in Table 2. All 
costs in this table are expressed in euros 
for the year 2011.
UK
The total cost of anticoagulation services 
in England, based on more than 2.4 million 
epi sodes, was GB£51 million in 2010/11 
(€63 mil lion) – equivalent to GB£20.97 
(€26.00) per unit of activity 106. In its 
appraisals of newer oral anticoagulants, 
NICE considered a cost of GB£241.54 
(€299.50) per patient per annum to be a 
realistic estimate for INR monitoring 107,108. 
However, there is considerable varia tion in 
published estimates 109. According to Ali et 
al. the total costs of monitoring, including 
INR measurement, travel, time off work, 
nurse visits and postage, were GB£117.60 
(€145.82) per year in 2011 66; based on a 
large prospective cohort study 28, Pink et 
al. estimated an annual cost of GB£198.39 
(€246 in 2011) 67. Warfarin tablets cost 
approximately GB£41 (€52 in 2011) per 
year 67. According to Pink et al. a major 
bleed costs GB£1685 (€2129 in 2011) to 
manage 67. Jowett et al. calculated the costs 
of a GI bleed to be GB£1051 (€1303 in 
2011) and an ICH GB£2059/€2746 68. 
Kansal et al. reported that the costs of a GI 
bleed were higher, at GB£1594 (€2009 in 
2011); and the cost of ICH varied from 
GB£3059 (€3855 in 2011) to GB£24,234 
(€30,537 in 2011) depending on the 
severity 69. Jowett et al. reported that the 
acute costs for an ischaemic stroke vary 
from GB£1746 to GB£2574 (mean costs 
were €2880 in 2011), depending on the 
severity 68. After the acute phase, the costs 
are estimated at GB£13.37 (€17.83 in 
2011) per day. Hemingway et al. estimated 
the total costs for the first year after a stroke 
to be GB£9845 (€12,208 in 2011) followed 
by GB£2572 (€3506 in 2011) in each 
subsequent year 70. Jowett et al. estimated 
the costs of a TIA at GB£756 (€1008 in 
2011) 68, compared with GB£1064 (€1341 
in 2011) by Kansal et al. 69.
Sweden 
Costs of INR monitoring were estimated 
at €22 per measurement in Sweden 111. 
In two other studies, the costs of an INR 
measurement were calculated for hospital 
clinics and primary care separately. In these 
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studies the costs were approximately €21 
if the patient was managed by a hospital 
clinic and €62 if managed by the GP 36,41. 
Warfarin tablets have been estimated to 
cost approximately €66 (€67 in 2011) per 
patient per year 41. Costs of a complicated 
GI bleed, very complicated GI bleed and 
uncompli cated GI bleed were €3986, 
€5939 and €2686, respectively, according 
to a comprehensive price list used for 
reimbursements 110. In a Swedish study, 
in-hospital costs for stroke were €11,503 
and total costs 1 year after stroke were 
€18,503 111. From the second year after 
stroke, costs were €5332 111. In Swedish 
studies the costs of stroke are often used as 
an estimate for the costs of an ICH 112. The 
costs of a TIA were €2561 110.
The Netherlands 
Schalekamp et al. reported that the 
costs for INR measurement were on 
average €10.23 (€11.74 in 2011). INR 
measurement in the anticoagulant clinic 
was slightly cheaper than when the blood 
sample was taken at home (€11.05 vs 
12.43, respectively) 15. Acenocoumarol 
tablets cost on average €30.37 per year and 
phenprocoumon tablets cost €20.68 per 
year 113. A GI bleed was estimated to cost 
€11,900 (€12,093 in 2011) by calculation 
of the weighted mean of duodenum and 
stomach bleeds without perforation 15,71. 
Hospitalization costs for a subarachnoid 
haemorrhage were estimated to be €15,584 
in 2001 (€19,132 in 2011) and the total 
costs for the first year after this bleed were 
estimated at €24,435 (€29,999 in 2011) 72. 
These costs are comparable with the costs 
estimated for a bleed in the CNS including 
the costs for a nursing home of €28,419 in 
2004 (€32,614 in 2011) 73. According to 
Struijs et al., hospital costs for a stroke were 
€7971 (€10,000 in 2011) 74. Total costs for 
the first year were €19,523 (€24,493 in 
2011) and the costs for every subsequent 
year after stroke €4427 (€5554 in 2011). 
The costs of a TIA in Dutch diagnosis-
related groups of three different hospitals 
were on average €1305 in 2011 114.
Greece 
Geitona et al. investigated the costs of 
differ ent monitoring methods for oral 
anticoagula tion 53. In this study private 
market prices as well as shadow prices 
were used, because of the discrepancies 
between nominal and actual prices in the 
public healthcare sector in Greece. The 
market price of an INR measurement 
was €20 (€22 in 2011) and the shadow 
price was €15 (€16.85 in 2011). The 
price of a medi cal visit for anticoagulation 
monitoring was €30 (€33 in 2011; shadow 
price €20–€22.50 in 2011). In a study of 
Daskalopoulos et al. in 2005, the costs 
of an INR measurement were €20.63 
(€23.17 in 2011 55), which is simi lar to 
the market price used by Geitona et al. 
53. In the study by Daskalopoulos et al., 
the costs of acenocoumarol tablets were 
€11.52 for 6 months, or €23.04 (€25.88 
in 2011) per year. A GI bleed without 
severe comorbid medical conditions or 
devastating complications costs €375 and 
with severe comorbid medical con ditions 
or devastating complications it costs 
€934 115. An ischaemic stroke and ICH cost 
between €1625 and €2475 115. In a study 
by Gioldasis et al., costs of a stroke were 
€3215 (€3384 in 2011) and of an ICH 
€5305 (€5586 in 2011) 75. Maniadakis et 
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al. estimated the costs for hospitalization 
for stroke to be €842 (€887 in 2011) and 
total costs of the first year after stroke to 
be €12,115 (€12,756 in 2011) 76. A TIA 
costs between €495 and €1118 115. Table 2 
shows the average price of adverse events 
with and without severe comorbid medical 
conditions or devastating complications.
Germany 
In Germany, the cost of diagnostics for 
an INR measurement was €4.60 in 2004 
(€5.28 in 2011) 58 and the cost of oral 
anticoagulation was €14.76 per month 
in 2009 (€15 in 2011) 77. According to 
McBride et al. the cost of hospital admission 
for a GI bleed was €1742.50 and the cost of 
other bleeds were €1802.14 in 2004 (€2000 
and 2068, respectively in 2011) 58. Costs of 
an ICH were €8920 (€10,951 in 2011) in 
the study of Weimar et al. 78. Total direct 
costs of a stroke were €9394 (€10,551 in 
2011) in the study of Brüggenjürgen et 
al. 79. These authors showed that the costs 
of a stroke were higher in patients with 
atrial fibril lation specifically (€11,799 in 
2005 and €13,252 in 2011). Reinhold et al. 
showed the cost for acute hospitalization 
(€3804) and rehabilitation clinic (€7532) 
separately 77. In this study, the costs of 
a TIA were €2022.50 (€2061 in 2011). 
Kolominsky-Rabas et al. estimated the 
yearly costs for stroke after the first year to 
be €5479 (€6288 in 2011) 80.
Austria 
Data on costs of phenprocoumon tablets, 
INR monitoring and bleeding were not 
available for Austria specifically. Wancata 
et al. estimated that the costs of a stroke in 
Austria were €20,784 in 2004 (€23,852 in 
2011) 81. Acute costs for stroke were €4404 
(€5589 in 2011), in a study by Levy et al. 82.
discussion 
Anticoagulant treatment with coumarin 
deriva tives is challenging because 
of the narrow thera peutic window 
and the associated risk of bleed ing or 
thromboembolic events when the dose is 
either too high or too low. Consequently, 
INR is monitored frequently, as is 
evidenced by our analysis of six European 
countries. Our review also highlights 
the many differences in organiza tion of 
anticoagulant care. The setting in which 
the INR monitoring and coumarin dosing 
takes place varies from a specialised 
anticoagulation clinic to the GP and 
hospital settings. The fre quency of INR 
monitoring varies from 10- to 20-times per 
year. A marked difference in the prevalence 
of coumarin use among the different 
countries can be seen. In the UK, Sweden 
and The Netherlands the prevalence 
is approximately 2%, while in Greece, 
Germany and Austria the prevalence seems 
to be lower than 1%. A pos sible explanation 
for this could be that physicians prescribe 
coumarin anticoagulants less frequently 
in these coun tries, because of different 
guidelines or because they are hesitant to 
prescribe the drug due to pos sible bleeding 
complications. Unfortunately there is no 
literature describing this. 
Another possible reason for the 
difference found could be that the 
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reporting of coumarin use is less well 
organised and the true prevalence of 
coumarin use is actu ally higher than that 
found in the literature. The apparent large 
difference between 0.2 and 2.4% could 
also be caused by differences in methods 
of assessment across these studies and the 
year these studies were conducted. 
The quality of anticoagulation, in terms 
of percentage time spent in the target INR 
range, and rate of complications also varies 
between countries. In The Netherlands 
the percentage time in target range is 
highest (78.5%) and the estimated rates of 
bleeding and stroke are the lowest (1.4 and 
0.1%, respectively). The reason for this 
might be that in The Netherlands cou marin 
therapy is managed by specialised antico-
agulation clinics. However, differences in 
study designs and populations may have 
important confounding effects. The costs 
associated with coumarin therapy and the 
management of these complications also 
differ appreciably. 
Differences in the management and 
quality of anticoagulant care could influence 
the effective ness and cost–effectiveness 
of pre-treatment geno typing. The greatest 
health benefit (and highest probability of 
being cost-effective) would be expected 
in countries where anticoagulant care is 
less well organised or the quality is low; 
whereas the least health benefit would be 
achieved where anticoagulation care is 
already of a high stan dard. Nevertheless, 
genotyping might still be a cost-effective 
(or cost-saving) strategy in coun-
tries where anticoagulant care is well 
organised if a consequence is that less INR 
measurements are required when patients 
reach a stable dose earlier with genotyping. 
If possible, country-specific data on the 
effectiveness of genotyping should be used 
as well as country-specific costs in a cost–
effectiveness analysis. 
This article is the first to systematically 
describe the differences in organization 
and costs of anticoagulant care in 
different European countries. However, 
more information was avail able for 
some countries than for others. In The 
Netherlands, for example, the FNT analyses 
and publishes the percentage time in target 
range and the occurrence of complications 
for most anticoagulation clinics every year 
and thereby pro vides reliable and current 
information on routine practice. For 
some other countries, we had to rely on 
information from clinical trials, which may 
not be generalizable to routine practice. The 
data on costs were similarly derived from 
different sources, and will vary according to 
perspective, year of analysis and the items 
included in the calculations of overall costs.
conclusion 
Many differences exist between 
European coun tries in the organization 
of anticoagulation ser vices, and the costs 
of anticoagulant therapy with coumarin 
derivatives. Because of these differences, 
it is likely that the cost–effective ness 
of pharmacogenetic-guided dosing of 
cou marin derivatives will vary considerably 
among countries. Consequently, 
appropriate methods are necessary to deal 
with these differences. These methods 
should include appropriate use of country-
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specific information about current care and 
its costs. In addition, a good understanding 
of how pharmacogenetic-guided dosing 
would be integrated into care is essential 
in estimating its cost–effectiveness in a 
particular country.
future PersPective 
Currently, several large trials are ongoing to 
investigate the effectiveness of pharmacoge-
netic-guided coumarin dosing 6,7. The 
COAG trial investigates genotyping in 
different centres in the USA (NCT00839657 
116) and the EU-PACT trial in different 
European countries (NCT01119261, 
NCT01119274, NCT01119300 117–119). 
The results of the EU-PACT trial could be 
used together with the country-specific 
infor mation in the present study to analyse 
the cost–effectiveness of this treatment 
strategy in differ ent countries. This could 
help decision makers to decide whether to 
implement pharmacogenetics in coumarin 
therapy or not. 
Pharmacogenetics is not the only 
development in the area of anticoagulant 
therapy. Recently, new drugs (e.g., 
direct thrombin inhibitors and factor 
Xa inhibitors) have been developed for 
anticoagulant treatment and these might be 
good alternatives for warfarin 83,84. One of 
the advantages of these drugs is the fact that 
they do not require frequent monitoring 
(which is often considered burdensome for 
the patient), while the lack of a biomarker 
to monitor the extent of anticoagulation 
can also be seen as a disadvan tage. Other 
disadvantages include an anticipated 
decrease in therapy adherence, interactions 
with other drugs and the fact that no antidote 
yet exists. Another issue is the costs of these 
new drugs, which are more expensive than 
coumarin derivatives. With the current 
climate of increasing healthcare expenses 
and the need to cut costs, the budget impact 
and cost–effectiveness of imple menting 
these new drugs should be investigated. 
The data in this article provide information 
for future analyses of the cost–effectiveness 
of geno typing versus standard care, but 
can also be used to inform future analyses 
of the cost–effectiveness of the new oral 
anticoagulants. Shah et al. dem onstrated 
that the cost–effectiveness of dabiga-
tran, a direct thrombin inhibitor, versus 
warfarin was dependent of the time spent 
in target INR range with warfarin 85. With 
a high percent age time in range, dabigatran 
appeared to be less cost effective than when 
this percentage was low. You et al. also found 
that dabigatran would be less cost-effective 
with better INR control in warfarin users, in 
a cost–effectiveness analysis of dabigatran 
versus pharmacogenetic-guided war farin 
dosing 86. Pink et al. also concluded that 
dabigatran will only be cost-effective for 
patients with an increased risk of stroke and 
for patients on coumarin anticoagulants 
with a low percentage time in the INR 
target range 67. When genotyping improves 
the time spent in the target range, this could 
be a more cost-effective option than using 
the new drugs. This should be investigated 
in future cost–effectiveness analyses. 
Currently, there is not enough evidence 
about the effect of genotyping or the effect 
of the new oral anticoagulants to make any 
recommendations regarding this.
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abstract
Objectives: To investigate the cost-effectiveness of apixaban, rivaroxaban and dabigatran, 
compared to coumarin derivatives for stroke prevention in patients with atrial fibrillation 
in a country with specialised anticoagulation clinics (The Netherlands) and in a country 
without these clinics (the United Kingdom).
Methods: A decision-analytic Markov model was used to analyse the cost-effectiveness of 
apixaban, rivaroxaban and dabigatran compared to acenocoumarol in The Netherlands 
and warfarin in the United Kingdom over a lifetime horizon.
Results: In the Netherlands, the use of apixaban, rivaroxaban or dabigatran increased 
health by 0.36, 0.17 and 0.37 quality-adjusted life-years (QALYs), but also increased 
costs by €4,762, €5,621 and €5,812, respectively. The incremental cost-effectiveness 
ratios (ICERs) were €13,170, €32,845 and €15,816 per QALY gained. In the United 
Kingdom, health was increased by 0.45, 0.30 and 0.46 QALYs and the incremental costs 
were similar for all three new oral anticoagulants (€5,189 to €5,274). The ICERs varied 
from €11,400 to €16,970 per QALY gained. In The Netherlands, apixaban had the highest 
chance (61%) to be cost-effective at a threshold of €20,000 and in the United Kingdom 
this chance was 72% for both dabigatran and apixaban. The quality of care reflected in 
time in therapeutic range had an important influence on the ICER.
Conclusions: Apixaban, rivaroxaban and dabigatran are cost-effective alternatives to 
warfarin in the United Kingdom, while in The Netherlands, only apixaban and dabigatran 
could be considered cost-effective. The cost-effectiveness of the new oral anticoagulants 
is largely dependent on the setting and quality of local anticoagulant care facilities.
introduction
Patients with atrial fibrillation (AF) 
are at increased risk of stroke and other 
thromboembolic events. Therefore an 
anticoagulant is often indicated to decrease 
this risk 1. Vitamin K antagonists (or 
coumarin derivatives) have been used for 
many years as oral anticoagulants for stroke 
and systemic embolism (SE) prevention in 
patients with AF. These drugs have a small 
therapeutic window and a large inter-
individual and intra-individual variability 
in dose response. Frequent monitoring 
of the anticoagulant effect (expressed as 
International normalised ratio, INR) is 
therefore required 2. Recently, new oral 
anticoagulants have become available for 
the prevention of stroke and SE in patients 
with AF. These drugs do not require 
such monitoring and have been shown in 
randomised controlled trials to be non-
inferior or even superior to warfarin in the 
prevention of stroke and SE 3-6.
Dabigatran is a direct thrombin 
inhibitor and at a dose of 150 mg this 
anticoagulant is associated with a lower 
rate of stroke and SE and a similar 
bleeding rate if compared to warfarin 3,4. 
Apixaban is a factor Xa inhibitor and was 
shown to be superior to warfarin in the 
prevention of stroke and SE as well as 
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bleeding 5. Another factor Xa inhibitor, 
rivaroxaban, was non-inferior to warfarin 
for the prevention of stroke and SE and 
fewer intracranial or fatal bleeding events 
occurred in patients using this drug 6. All 
three new oral anticoagulant drugs are 
considered useful alternatives to coumarin 
derivatives 3-6. However, since the costs of 
these new drugs are considerably higher 
than the costs of coumarin anticoagulants, 
it is important to investigate their cost-
effectiveness carefully.
The cost-effectiveness of dabigatran 
has been investigated in several studies 
and it was shown to be cost-effective 7-9. 
When the quality of the warfarin treatment 
is higher (a higher percentage of time is 
spent in the therapeutic INR range), the 
chance that dabigatran is cost-effective is 
lower. Because the quality of the treatment 
with coumarin derivatives varies across 
different countries and different healthcare 
settings, the cost-effectiveness of the new 
oral anticoagulants needs to be investigated 
in different settings 10. In the Netherlands, 
treatment with coumarin derivatives is 
monitored and guided by specialised 
anticoagulation clinics. The percentage 
time patients spent in the therapeutic INR 
range in this country is 76-79% for patients 
using short or long-term (2 months to 
lifetime) acenocoumarol, which is the most 
frequently used coumarin anticoagulant 
in The Netherlands 11. In the United 
Kingdom, warfarin is most frequently 
used and many warfarin users are treated 
by general practitioners 12. The percentage 
time spent in the therapeutic INR range is 
lower than in the Netherlands; one estimate 
was approximately 63% 13. The aim of this 
study is therefore to investigate the cost-
effectiveness of apixaban, rivaroxaban 
and dabigatran, compared to coumarin 
derivatives in a country with specialised 
anticoagulation clinics (The Netherlands) 
and in a country where the treatment of 
many patients with coumarin anticoagulants 
occurs in a primary care setting rather than 
a specialised anticoagulation clinic (the 
United Kingdom).
methods
model structure
A decision-analytic Markov model was 
used to analyse the cost-effectiveness of the 
three new oral anticoagulants (apixaban, 
rivaroxaban and dabigatran) compared to 
coumarin derivatives (acenocoumarol in 
The Netherlands and warfarin in the United 
Kingdom). The model was developed 
using TreeAge software (TreeAge Pro 
2012). The base-case analysis consisted of 
a hypothetical cohort of patients with AF, 
aged 70 years, initiating oral anticoagulant 
therapy.
Figure 1 shows the decision tree with 
the four treatment options. The decision-
analytic Markov model consisted of nine 
health states: Healthy with AF, ischaemic 
stroke (IS), transient ischaemic attack 
(TIA), myocardial infarction (MI), systemic 
embolism (SE), intracranial haemorrhage 
(ICH), extra cranial haemorrhage (ECH), 
disability and death. All patients entered 
the model in the ‘healthy with AF’ state 
and could move to one of the other states at 
monthly intervals. Patients with an IS had 
a 37% chance of dying and 32% chance of 
184
disability 5,6. The chance that an ICH would 
be disabling was 50% and that it would be 
fatal was 44% 11,14. MI and ECH were fatal in 
16% and 7% of the cases, respectively 11,15,16. 
We assumed a similar percentage of fatal 
cases (7%) in SE as in ECH and a mortality 
rate of 5.6% in patients in the disability 
state 17. Age-specific mortality rates were 
taken into account for all patients. Input 
parameters of the model for both The 
Netherlands and the United Kingdom are 
shown in Table 1. 
clinical event rates
Annual rates of clinical events of the new 
oral anticoagulants were derived from 
three large randomised controlled trials. 
Data from the ARISTOTLE trial were 
used for event rates of a apixaban at a 
dose of 5 mg twice daily 5, data from the 
ROCKET-AF trial for rivaroxaban 20 mg 
once daily 6 and from the RE-LY trial for 
dabigatran 150 mg twice daily 3,4. To adjust 
for differences in baseline risks between 
the three trials the indirect comparison 
method by Bucher et al. was used 18. Event 
rates for rivaroxaban and dabigatran were 
calculated by multiplying the relative 
treatment effects by the event rates of the 
warfarin arm in the apixaban trial.
To correct for differences in quality of 
coumarin anticoagulant care, the rates of 
figure 1. Schematic representation of the decision tree and Markov model. Patients initiating oral anticoagulant 
therapy can be treated by one of the four drugs with different chances of developing adverse events. 
Patient with atrial fibrillation
Dabigatran
No event
Ischaemic stroke
Transient ischaemic attack
Myocardial infarction
Systemic embolism
Intracranial haemorrhage
Extra cranial haemorrhage
Death
Coumarin derivative
Apixaban
Rivaroxaban
Recover
Disability
Fatal
Recover
Fatal
Recover
Fatal
Recover
Disability
Fatal
Recover
Fatal
Recover
Any or no event
Disability
Survive
Fatal
No event
No event
No event
No event
No event
Disability
Disability
Disability
Dead
Dead
Dead
Dead
Dead
Dead
Dead
No event
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clinical events were based on the time spent 
in the therapeutic INR range. The risks of 
thromboembolic and haemorrhagic events 
associated with different INR ranges were 
derived from a meta-analysis by Oake et 
al. 19. The proportion of thromboembolic 
events that were stroke, MI or SE and the 
proportion of haemorrhagic events that 
were intracranial or extracranial were 
derived from the warfarin arms of the 
three trials of the new oral anticoagulants 
(weighted average) 3-6. As in previous cost-
effectiveness studies, we assumed that 28% 
of ischaemic strokes were TIA 8,20. In our 
model we used a percentage time spent in 
the target range of 76% for the Netherlands 
and 63% for the United Kingdom after the 
initiation period (2 months) 11,13. In the 
first month of treatment this percentage 
was 50% (own data, not published 21). 
During the first 2 months 75% of the 
out-of-range INRs were subtherapeutic 
(INR<2) and after the initiation period 
out-of-range INRs were more often 
table 1. Model input parameters for both the Netherlands and the United Kingdom
Parameter base case range source
Age at start of treatment 70 60 to 80 Assumption
Outcome of events (if occurring) %
Fatal stroke 37 0.30 to 0.44 5,6
Disabling stroke 32 0.26 to 0.38 5,6
Fatal transient ischaemic attack 0 - Assumption
Fatal systemic embolism 7 0.056 to 0.084 Assumption
Fatal myocardial infarction 16 0.13 to 0.19 15,16
Fatal intracranial haemorrhage 44 0.35 to 0.53 11
Disabling intracranial haemorrhage 50 0.40 to 0.60 14
Fatal extracranial haemorrhage 7 0.056 to 0.084 11
Monthly mortality rate disability state 5.6 0.04 to 0.07 17
QALYs and decrements
Atrial fibrillation 0.81 0.67819 to 0.91373 22
Use of vitamin K antagonist -0.013 -0.002 to -0.033 22
Use of new oral anticoagulant -0.006 -0.004 to -0.007 20
Use of aspirin -0.002 -0.000 to 0.006 20
Stroke -0.1385 -0.11843 to -0.15998 22
Transient ischaemic attack -0.10322 -0.09912 to -0.11894 22
Systemic embolism -0.1199 -0.10224 to -0.13880 22
Myocardial infarction -0.1247 -0.10645 to -0.14356 22
Intracranial haemorrhage -0.1814 -0.15500 to -0.20885 22
Extracranial haemorrhage -0.06 -0.02 to -0.10 17
Disability -0.374 -0.160 to -0.588 17
186
supratherapeutic (70% INR>3) (own data, 
not published 21). Patients on either one of 
the new oral anticoagulants or on coumarin 
therapy were assumed to switch to aspirin 
after an ICH 1. The annual rates of clinical 
events of the different treatment options are 
shown in Table S1 (Supplement).
Quality of life and costs
The baseline quality of life in our model was 
0.81 for patients with AF 22. A decrement 
of 0.013 was applied for acenocoumarol 
or warfarin use and a decrement of 0.006 
for apixaban, rivaroxaban or dabigatran 
use. Decrements were also ascribed 
when patients experienced an adverse 
event. Table 1 shows QALY values and 
decrements for the different health states.
The frequency of INR measurements 
has been estimated at 20.4 per year in 
the Netherlands and 10 per year in the 
United Kingdom 11,23 . We assumed 4 extra 
measurements in the first month and 1 extra 
measurement after an adverse event. Costs 
of an INR measurement were derived from 
the Dutch healthcare authority tariff and 
from a report of the National Institute for 
Health and Care Excellence (NICE) 24,25. 
Monthly drug costs were estimated using 
data from the Dutch healthcare insurance 
board and the NICE report 25,26. Costs of the 
drugs and adverse events are shown in Table 
2. Costs were determined from a healthcare 
sector perspective for the year 2012 in 
Euros (€). While the Dutch guidelines 
recommend using a societal perspective, we 
used a healthcare sector perspective since 
most of the cost differences were expected 
to be found in this sector. Effects were 
discounted at an annual rate of 1.5% for 
The Netherlands and 3.5% for the United 
Kingdom and costs at an annual rate of 
4% and 3.5% respectively, according to 
the national guidelines 27,28. Because of the 
different guidelines regarding discount rates 
in the two countries, we also performed the 
analysis without discounting.
base case and sensitivity analyses
Base-case estimates of the costs and 
QALYs of apixaban, rivaroxaban, 
dabigatran and the coumarin derivative 
were determined. Also several sensitivity 
analysis were performed. First, one-way 
sensitivity analyses were conducted to 
examine the impact of model parameters 
and assumptions on the results. The 
parameters were varied over their 95% 
confidence intervals or decreased and 
increased by 20% if a confidence interval 
was not available. Second, we performed 
a probabilistic sensitivity analysis using 
10,000 Monte Carlo simulations to 
evaluate the combined impact of multiple 
model parameters on the estimated cost-
effectiveness of the new oral anticoagulants. 
Dirichlet distributions were used to vary 
the probabilities of different outcomes 
of stroke and ICH (more than 2 possible 
results). Beta distributions were used 
for all other probabilities and QALYs, 
and gamma distributions for the costs. 
A uniform distribution was used to vary 
the frequency of INR measurements and 
a normal distribution for the percentage 
time spent in the therapeutic INR range.
In the United Kingdom, NICE 
expressed a willingness to pay threshold of 
£20,000-30,000 per QALY gained 29. The 
Dutch guidelines do not express such a 
threshold because it depends on different 
factors, but €20,000 was often used in 
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previous reimbursement decisions 30. We 
therefore studied the chance that the new 
oral anticoagulants would be cost-effective 
at thresholds of €20,000 and €36,000 
(approximately £30,000), but also varied 
this threshold over a wider range in a cost-
effectiveness acceptability curve.
results
base case
Figure 2 shows the first-year incidence of 
the clinical events per 100 patient-years 
for acenocoumarol in The Netherlands, 
warfarin in the United Kingdom and 
apixaban, rivaroxaban or dabigatran 
in both countries. All three new oral 
anticoagulants had a lower stroke rate 
than acenocoumarol and warfarin. ECHs 
were more frequent in rivaroxaban 
and dabigatran, but less frequent in 
apixaban than in either of the coumarin 
anticoagulants.
Table 3 shows the results of the cost-
effectiveness analyses of the new oral 
anticoagulants compared to a coumarin 
derivative in The Netherlands and the 
United Kingdom. In the Netherlands, 
the use of apixaban increased costs 
by €4,762, the use of rivaroxaban by 
€5,621 and dabigatran by €5,812. QALYs 
were increased by 0.36, 0.17 and 0.37, 
respectively. The incremental cost-
effectiveness ratio (ICER) was €13,170 
per QALY gained for apixaban, €32,845 
per QALY gained for rivaroxaban and 
€15,816 per QALY gained for dabigatran. 
In the United Kingdom the incremental 
costs were similar for all three new oral 
anticoagulants (€5,189 to €5,274). 
Apixaban use increased QALYs by 0.45, 
rivaroxaban by 0.31 and dabigatran by 
0.46. The ICER of apixaban (€11,655 per 
QALY gained) and dabigatran (€11,400 
per QALY gained) were somewhat lower 
than that of rivaroxaban (€16,970 per 
QALY gained). The costs per life year 
gained of apixaban, rivaroxaban and 
0,00%
0,50%
1,00%
1,50%
2,00%
2,50%
IS MI SE TIA ECH ICH
Acenocoumarol
Warfarin
Apixaban
Rivaroxaban
Dabigatran
figure 2. First year incidence of clinical events per 100 patient-years. IS=ischaemic stroke, TIA=transient 
ischaemic attack, SE=systemic embolism, MI=myocardial infarction, ICH=intracranial haemorrhage, 
ECH=extra cranial haemorrhage. Acenocoumarol as used in the Netherlands and warfarin as used in 
the United Kingdom.
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dabigatran were €14,353, €54,420 and 
€17,284, respectively in The Netherlands 
and €11,544, €18,471 and €11,324 in the 
United Kingdom.
sensitivity analyses
Figures S1 to S6 (Supplement) show the 
tornado diagrams summarizing the results 
of the one way sensitivity analysis. These 
diagrams depict the 10 parameters with 
the largest influence on the ICER. In the 
Netherlands, the percentage time in range 
(varied from 66-86%) had the largest 
impact on the cost-effectiveness results 
for all three new oral anticoagulants. This 
parameter had a smaller impact in the 
United Kingdom (varied from 53-73%), 
where the risk of ICH at an INR of 3-5 
(varied from 0.39-5.18) had the largest 
impact for apixaban and dabigatran and 
the second largest impact for rivaroxaban. 
The probability of ICH (varied from 0.33-
0.85) had the largest impact on the cost-
effectiveness results of rivaroxaban.
In the probabilistic sensitivity 
analysis, the new oral anticoagulants 
were more costly and more effective 
than coumarin anticoagulants in the 
majority of the simulations (figure 3). 
In The Netherlands, apixaban had the 
highest chance to be cost-effective at a 
willingness to pay threshold of €20,000 
or €36,000 per QALY gained (61% 
and 76%, respectively). The ICER was 
below these thresholds in 55% and 74% 
of the simulations for dabigatran and 
in 34% and 48% of the simulations for 
rivaroxaban, respectively. In the United 
Kingdom, apixaban and dabigatran had 
similar chances to be cost-effective at a 
willingness to pay threshold of €20,000 
or €36,000 per QALY gained (for both 
drugs 72% and 88%, respectively). These 
chances were lower for rivaroxaban (52% 
and 70%, respectively). Figure 4 shows 
table 3. Results of the cost-effectiveness analysis – base case
treatment total costs (€) total Qalys
compared to coumarin anticoagulant
∆ costs (€) ∆ Qalys
icer (€/Qaly 
gained) 
The Netherlands
Acenocoumarol 9,676 (13,428) 9.629 (10.968) Reference therapy
Apixaban 14,438 (20,160) 9.991 (11.403) 4,762 (6,732) 0.362 (0.435) 13,170 (15,474)
Rivaroxaban 15,328 (21,332) 9.802 (11.171) 5,652 (7,904) 0.172 (0.203) 32,845 (38,939)
Dabigatran 15,488 (21,628) 9.997 (11.410) 5,812 (8,200) 0.367 (0.443) 15,816 (18,531)
The United Kingdom
Warfarin 7,845 (10,436) 8.042 (10.706) Reference therapy
Apixaban 13,119 (17,638) 8.494 (11.403) 5,274 (7,201) 0.453 (0.696) 11,655 (10,341)
Rivaroxaban 13,035 (17,475) 8.347 (11.171) 5,190 (7,039) 0.306 (0.464) 16,970 (15,162)
Dabigatran 13,054 (17,549) 8.498 (11.410) 5,208 (7,113) 0.457 (0.704) 11,400 (10,106)
Results using the country specific discount rates are shown. In grey, also the non-discounted results are shown.
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figure 3. Scatter plots reflecting the uncertainty in the differences in costs and effectiveness between 
the new oral anticoagulants and coumarin anticoagulants (based on probabilistic sensitivity analysis)
the probability that any of the different 
oral anticoagulants would be the most 
cost-effective option in The Netherlands 
or in the United Kingdom over a range 
of likely thresholds. In The Netherlands, 
apixaban is the most cost-effective option 
when the willingness to pay is €20,000 per 
QALY gained or higher. Dabigatran has a 
lower chance to be the most cost-effective 
at this threshold, but is close to apixaban 
at higher thresholds. Rivaroxaban does 
not have a high chance of being the most 
cost-effective option. The results for the 
United Kingdom show that dabigatran 
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has a relatively high chance of being the 
most cost-effective when the willingness 
to pay exceeds €20,000 (or 16,317 
pounds), closely followed by apixaban.
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figure 4. Cost-effectiveness acceptability curve for The Netherlands and the United Kingdom. 
discussion
Our results confirm that apixaban, 
rivaroxaban and dabigatran are all cost-
effective alternatives to warfarin in the 
United Kingdom. In The Netherlands, 
however, the incremental costs per QALY 
gained for these new oral anticoagulants 
are higher and rivaroxaban could not be 
considered cost-effective at a willingness 
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to pay of €20,000 per QALY gained. The 
percentage time spent in the therapeutic 
INR range had an important effect on 
the cost-effectiveness ratio. These results 
indicate that the cost-effectiveness of 
the new oral anticoagulants is largely 
dependent on the setting and quality of 
local anticoagulant care facilities.
To our knowledge this is the first study 
comparing the cost-effectiveness of the 
new oral anticoagulants in two different 
countries with different healthcare 
settings. Moreover, the cost-effectiveness 
of these new drugs in the Dutch setting 
has not been published before. For the 
United Kingdom, Pink et al. showed 
a base case ICER for dabigatran of 
£23,082 (approximately €28,000) and 
a 60% chance that this drug would be 
cost-effective at a threshold of £30,000 9. 
Alternatively, the base case ICER in a study 
by Kansal et al. was £4,831 (approximately 
€5,900) 31. This difference is probably 
caused by differences in cost and quality 
of life estimates. For example, higher 
long-term costs of stroke and higher 
warfarin monitoring costs were used in 
the study by Kansal et al.. In our study, the 
ICER of dabigatran in the United Kingdom 
was somewhere in between at €11,400 per 
QALY gained.  Also, this is one of the first 
studies investigating the cost-effectiveness 
of the three new oral anticoagulants 
together. Harrington et al., studied their 
cost-effectiveness in the setting of the 
United States and found that the ICER 
of all three new oral anticoagulants was 
below their willingness to pay threshold 32. 
One thing that Harrington et al. did 
not do is adjust the clinical event rates 
for differences in baseline risks between 
the three trials. Although we adjusted 
the clinical event rates from the three 
trials for differences in baseline risks, 
uncertainty remains about the comparison 
between the three different new oral 
anticoagulants. Because the three drugs 
have not been studied in a head-to-head 
trial, it was not possible to investigate the 
cost-effectiveness of these drugs using 
information from a direct comparison. 
Another limitation is that the follow-up in 
the three trials was approximately 2 years. 
We extrapolated this data to a lifetime 
horizon, assuming the event rates would 
remain stable after 2 years. Lastly, because 
no official cost-effectiveness threshold 
exists in The Netherlands, it is difficult 
to state whether or not a new therapy 
will be considered as cost-effective. This 
threshold is influenced by several factors, 
for example life expectancy 30.
Our results indicate that country or 
healthcare setting specific analyses are 
important to study the cost-effectiveness 
of new oral anticoagulant compared 
to coumarin derivatives. Because of 
differences in costs of the drugs or 
differences in the treatment costs of clinical 
events, the cost-effectiveness of drugs 
can differ between countries. But more 
important in this case is the difference 
in healthcare setting and quality of the 
treatment with coumarin derivatives. In 
the Dutch setting of anticoagulant clinics, 
with a high percentage time spent in the 
therapeutic INR range, the new drugs 
are less cost-effective than in the English 
setting where patients are treated by the 
general practitioner and spend less time 
in the therapeutic INR range. A strength 
of this study is that we compared the 
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new oral anticoagulants with coumarin 
derivatives in two different countries 
using the same model. Because the 
analyses are performed in the same way, 
the results are easier to compare than in 
two different studies. Although different 
coumarin anticoagulants were used in the 
two countries, we believe this would not 
cause differences in our results because of 
the similarity between different coumarin 
anticoagulants.
In the United Kingdom apixaban, 
rivaroxaban and dabigatran all appear to 
be cost-effective alternatives to warfarin, 
increasing health at acceptable costs. 
Although all three new oral anticoagulants 
also lead to improved health in The 
Netherlands, the incremental costs of 
rivaroxaban are higher than what may 
be regarded as acceptable. Dabigatran 
and apixaban do seem to be the cost-
effective options in The Netherlands. 
In both countries the use of new oral 
anticoagulants will impact the healthcare 
budget. Whether it is better to spend the 
budget on new oral anticoagulants or on 
improving the quality of current care with 
coumarin derivatives (by for example 
personalised dosing) is an interesting 
question for debate.
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figure s1. Tornado diagram of apixaban vs. acenocoumarol in The Netherlands.
figure s2. Tornado diagram of rivaroxaban vs. acenocoumarol in The Netherlands.
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figure s3. Tornado diagram of dabigatran vs. acenocoumarol in The Netherlands.
figure s4. Tornado diagram of apixaban vs. warfarin in the United Kingdom.
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figure s5. Tornado diagram of rivaroxaban vs. warfarin in the United Kingdom.
figure s6. Tornado diagram of dabigatran vs. warfarin in the United Kingdom.
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Cost-effectiveness of new oral anticoagulants

general discussion

introduction
Coumarin derivatives are widely used 
oral anticoagulants. In Europe, warfarin, 
phenprocoumon and acenocoumarol are 
frequently used. In 2009, approximately 
385.000 patients were treated with 
acenocoumarol or phenprocoumon in The 
Netherlands and this number increased 
to approximately 430.000 in 2011 1. The 
most common indication for coumarin 
anticoagulant therapy is atrial fibrillation, 
followed by venous thromboembolism. 
Due to the ageing of the population, the 
number of patients with atrial fibrillation is 
expected to increase further in the coming 
years 2. Patients with atrial fibrillation have 
an increased risk of stroke and systemic 
embolism. Coumarin anticoagulant 
treatment can reduce this risk by 60% 3. 
However, while reducing the risk of stroke 
and other thromboembolic events, 
treatment with coumarin derivatives 
increases the risk of bleeding. To balance 
the risk of thromboembolic events and the 
risk of bleeding, frequent monitoring of 
the anticoagulant effect is required, which 
is done by measuring the International 
Normalised Ratio (INR). The optimal 
balance between effectiveness and safety 
is seen when the INR is between 2 and 
3 4. Because of the large variability in 
dose requirement among patients and 
interactions with, for example, food and 
other drugs, keeping the INR within this 
therapeutic range is difficult 5. This causes a 
risk of thromboembolic and bleeding events 
and coumarin derivatives are therefore often 
associated with drug-related hospitalisation 
or visits to the emergency department 6,7.
One of the factors explaining the 
variation in dose requirement among 
patients is genetic variation. Single 
nucleotide polymorphisms (SNPs) in 
two genes (CYP2C9 and VKORC1) can 
explain approximately one-third of the 
dose variation 8-11. The CYP2C9 gene 
codes for the main metabolizing enzyme 
of coumarin derivatives, CYP2C9, and 
the VKORC1 gene codes for the target 
enzyme of coumarin derivatives, VKORC1. 
Information on these two genes, together 
with other patient characteristics such as age, 
height, weight,  race, and use of concomitant 
medication can be used to predict the 
coumarin dose and with this information 
approximately 50% of dose variation can 
be explained 12,13. It is expected that using 
a genotype-guided dosing algorithm using 
information on CYP2C9 and VKORC1 
genotype can improve anticoagulation 
control and thereby decrease the risk 
of thromboembolic or bleeding events. 
Whether this really improves the efficacy 
and safety of coumarin therapy is currently 
being investigated in clinical trials in the 
United States and Europe 14,15.
Another development in anticoagulation 
is the use of new oral anticoagulants (direct 
thrombin inhibitors and factor Xa inhibitors). 
In a meta-analysis of three large randomised 
trials, the efficacy and safety of dabigatran, 
apixaban and rivaroxaban was investigated 
compared to warfarin in patients with atrial 
fibrillation 16. Compared to warfarin the 
new oral anticoagulants reduced the risk 
of ischaemic stroke, haemorrhagic stroke 
and intracranial bleeding. The results were 
inconclusive for gastrointestinal bleeding 
and major bleeding. For the treatment of 
acute venous thromboembolism, the new 
oral anticoagulants had a similar risk of 
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recurrence compared to coumarin derivatives 
in a different meta-analysis 17. An advantage 
of these new oral anticoagulants is that the 
effect does not need to be monitored, which 
is the case with coumarin derivatives. For the 
treatment of acute venous thromboembolism, 
no initial treatment with a low molecular 
weight heparin is required. Patients can find 
it burdensome to visit the clinic often for 
monitoring of the coumarin treatment. For 
these patients, using a new oral anticoagulant 
might be an attractive option. The new oral 
anticoagulants are therefore an interesting 
alternative to coumarin derivatives.
As is the case for many new 
developments in health, improving 
anticoagulant therapy by genotype-guided 
dosing or new oral anticoagulants is likely 
to increase costs. Implementation of 
genotype-guided coumarin dosing or the 
use of new oral anticoagulants does not 
only depend on the benefit-risk ratio, but 
also on the support of other stakeholders, 
such as health insurance companies. Health 
care expenditures are increasing and budget 
allocation decisions should be made. 
Informing the decision makers about the 
additional costs that need to be incurred to 
gain health (preferably expressed in Quality 
Adjusted Life Years, QALYs) will help to 
select the best options for reimbursement. 
It is therefore important to analyse the cost 
per QALY gained (cost-effectiveness or 
cost-utility) of these new treatment options. 
In this chapter we will discuss the 
results of this thesis in which the subjects 
described above are addressed. We will 
first describe the main findings and their 
relevance. Secondly, we will discuss 
strengths and limitations of this thesis and 
lastly we will consider the implications of 
the results.
main findings and relevance
improving coumarin anticoagulant 
therapy
In the first part of this thesis different ways 
to improve coumarin anticoagulation 
control are addressed. A genotype-guided 
algorithm might help to predict the required 
coumarin dose and prescribe a personalised 
dose to a patient commencing coumarin 
therapy (chapter 2). However, after a few 
days of treatment, the anticoagulant effect 
will be checked by measuring the INR 
and the dose will be amended accordingly. 
After reaching a stable dose, the algorithm 
used to predict the dose will not be used 
anymore. We hypothesised that knowledge 
of the patient’s genotype would still be 
useful after reaching a stable dose when 
this information can be used to determine 
how much the dose should be decreased 
or increased when the INR is above 
or below the target range respectively. 
Whether there are differences in over 
or underanticoagulation between the 
different genotypes after the initiation 
phase was still unknown.  We found that 
during the first 3 months of therapy, 
acenocoumarol users carrying a VKORC1 
variant allele (T-allele) had a higher 
risk of overdosing, while carriers of the 
common allele (C-allele) had a higher 
risk of underdosing (chapter 3). Patients 
with a VKORC1 TT genotype had a higher 
chance of a supratherapeutic INR up to 
the sixth month of therapy. For CYP2C9 
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there were no differences in occurrence of 
out-of-range INRs between the different 
genotypes after the first month. This 
suggests that after a stable dose is found 
and a stable INR is reached, genotype 
information does not predict over or 
underanticoagulation. These results were 
also seen in phenprocoumon users, where 
INR control was not significantly different 
between the VKORC1 and CYP2C9 
genotypes after the first month (chapter 
4). The value of genotype information 
after the first month of coumarin treatment 
therefore seems very limited.
One possible way to improve the 
prediction of the required coumarin dose 
would be to add more parameters to the 
dosing algorithm. The algorithm developed 
by van Schie et al. 18, and used in the European 
Pharmacogenetics of Anticoagulant Therapy 
(EU-PACT) study, included information 
on VKORC1 and CYP2C9 genotype, age, 
gender, height, weight and amiodarone use. 
Omeprazole and esomeprazole use also 
affect the phenprocoumon maintenance 
dose (chapter 5). On average, patients 
using omeprazole required a 0.49 mg lower 
dose and patients using esomeprazole a 
0.39 mg lower dose per day compared to 
non-users. When the use of omeprazole or 
esomeprazole was included in the genotype-
guided algorithm, 56.7% of dose variation 
could be explained. However, this was only 
0.8% more than the original algorithm. 
Other additional factors also appear to have a 
limited value for dose prediction. Statins, for 
example, only affected acenocoumarol dose 
and not phenprocoumon dose 19. Additional 
genetic factors, such as CYP4F2, CYP3A4 
and GATA-4, were not clinically relevant to 
include in a dosing algorithm 20,21.
Instead of predicting the dose more 
accurately, the effectiveness of coumarin 
anticoagulant therapy could be improved 
by increasing the adherence to these 
drugs. The attitude patients have towards 
their treatment is associated with the risk 
of non-adherence 22,23. The beliefs about 
medicines questionnaire can be used to 
study the attitude of patients towards the 
anticoagulant therapy (chapter 6). On 
average, coumarin users had a positive 
attitude towards the therapy as they 
scored higher on the necessity scale than 
on the concerns scale. But patients with 
atrial fibrillation scored lower on the 
necessity scale than patients with venous 
thromboembolism and had a lower 
necessity-concerns differential, indicating 
a less positive attitude. Patients with atrial 
fibrillation therefore have a higher chance 
of non-adherence. 
country specific cost-effectiveness 
analyses
In the second part of this thesis the issues 
around the cost-effectiveness of options 
to improve anticoagulant therapy were 
addressed. Several studies on the cost-
effectiveness of genotype-guided dosing of 
coumarin anticoagulants had been published 
by the end of 2009 (chapter 7).  The results 
of these analyses varied considerably. Two 
factors causing large uncertainty were the 
effectiveness of genotyping and the costs 
of genetic testing. As the costs of genetic 
testing are expected to decrease if it is 
used on a larger scale, the genetic test for 
VKORC1 and CYP2C9 genotypes will 
probably not cost more than US$50 24. 
The uncertainty around the effectiveness 
is therefore currently the most important 
207
12
General discussion
issue. No sufficiently powered clinical trials 
have been published yet, but the results are 
expected soon. As the primary outcome of 
these trials is the percentage time spent in 
the therapeutic INR range instead of the 
incidence of bleeding or thromboembolic 
events, this measure will also be used in 
models to study the cost-effectiveness. This 
measure was also used in a cost-effectiveness 
study on genotype-guided dosing of 
warfarin in the United States (chapter 
8) 25. Because almost all of the previously 
published cost-effectiveness studies focused 
on the United States and on warfarin, 
almost no information was available for the 
European situation. We therefore used and 
adapted the model described in chapter 8 to 
study the cost-effectiveness of genotyping 
for phenprocoumon in The Netherlands 
(chapter 9). Although more recent data 
was used to model the effectiveness, the 
uncertainty was still large.
Because anticoagulation services are 
organized differently in the United States 
than in Europe, it is important to study 
the cost-effectiveness of genotyping in 
Europe. But even in Europe, differences 
exist in the healthcare systems (chapter 
10). In some countries, anticoagulant care 
is managed by specialized anticoagulation 
clinics, while in other countries this is 
done by the general practitioner (GP) 
or in the hospital. These differences can 
lead to differences in the quality and costs 
of care and therefore impact the cost-
effectiveness of genotype-guided dosing. 
In a country where the anticoagulant 
care is less well organized and the quality 
of anticoagulant care is relatively low, 
more health benefit can be expected from 
genotyping than from a country with 
better organized care. The probability that 
this new treatment option would be cost-
effective will also be higher in this case. 
Next to the effectiveness of genotyping, 
the costs of, for example, medical events 
can differ between countries. The results 
of chapter 10 and 11 underline the 
importance of addressing these country 
specific issues when studying the cost-
effectiveness of new treatment options for 
anticoagulant therapy.
An alternative to improving the 
coumarin anticoagulant therapy by 
genotype-guided dosing is to use new 
oral anticoagulants. The cost-effectiveness 
of dabigatran, apixaban and rivaroxaban 
compared with coumarin anticoagulants 
varies between countries (chapter 11). 
In the United Kingdom, all three new 
oral anticoagulants could be considered 
cost-effective. In The Netherlands the 
cost-effectiveness ratios of all new oral 
anticoagulants were higher than in the 
United Kingdom and the cost-effectiveness 
ratio of rivaroxaban  was even higher 
than the willingness to pay threshold of 
€20,000. This difference seems to be mainly 
driven by the differences in time spent in 
the therapeutic INR range. These results 
confirm that the cost-effectiveness is largely 
dependent on the setting and quality of local 
anticoagulant care facilities and underlines 
the importance of country specific analyses. 
Because the comparison between two 
countries can be hampered by variability 
in methodology, clinical considerations 
and parameter estimates when the cost-
effectiveness is studied with two different 
models, an analysis of different countries 
using the same model with only differences 
in country specific parameters is preferred.
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strengths and limitations
observational data and trial data
For most studies described in this thesis 
observational data has been used. An 
observational study was performed (pre-
EU-PACT) mainly to collect data for the 
development of the dosing algorithms 
to be used in the EU-PACT trial. This 
pre-EU-PACT study provided us with 
a large observational dataset with more 
than one thousand Dutch acenocoumarol 
and phenprocoumon users. This data has 
been used to study the impact of genetic 
variation and concomitant medication on 
the anticoagulant effect. A limitation of 
this study was that the data were collected 
retrospectively. Because we included 
patients who attended the clinic during 
one week in 2009, very unstable patients 
might be underrepresented because they 
stopped treatment before the moment of 
data collection. Although the data could 
be considered a good representation 
of the Dutch clinical situation, it is 
less comparable with other European 
countries, because of differences in 
treatment setting and target INR range. 
In The Netherlands, the treatment of 
all patients is managed by specialized 
anticoagulation clinics and the quality 
of care is high 1,2. Next to this, the target 
INR range is 2.0-3.5 instead of 2.0-3.0 as in 
most other countries. The percentage time 
within the therapeutic range of patients 
in the pre-EU-PACT dataset is therefore 
higher than in other European countries. 
If compared to randomised trials, the risk 
of bias, such as selection and information bias 
and confounding is higher in observational 
studies. However, in our observational data, 
the population was very representative for 
the population of coumarin users, because 
of the few exclusion criteria and because 
the patients were treated according to every 
day practice. All patients requiring coumarin 
anticoagulant therapy in the low intensity 
category (INR 2.0-3.5) could be included 
in the study when they were not pregnant, 
breastfeeding or living in a nursing home. 
In the EU-PACT trial, more strict inclusion 
and exclusion criteria were applied. Patients 
should have either atrial fibrillation or 
venous thromboembolism and should never 
have been treated with coumarin derivatives 
before. The treatment should be for at least 
12 weeks. If the genotype was already known, 
patients were excluded. Also pregnant or 
breastfeeding women were excluded, as 
well as patients with cognitive impairment. 
The lower risk of bias and confounding is an 
advantage of the trial data.
The EU-PACT trial was carried out in 
six European countries to investigate the 
effectiveness of pre-treatment genotyping 
for CYP2C9 and VKORC1 polymorphisms. 
The results are not available yet. In the 
United States, other trials have also been 
performed on pharmacogenetic warfarin 
dosing 26,27. A strength of the EU-PACT 
study is that different coumarin derivatives 
were included in this study. The study 
was performed on warfarin in the United 
Kingdom and Sweden, on acenocoumarol 
in Greece and The Netherlands and on 
phenprocoumon in The Netherlands, 
Germany and Austria. The primary 
outcome is the percentage time spent with 
an INR between 2 and 3. Participants in 
The Netherlands were therefore also treated 
with this target INR range and therefore it 
will be possible to compare all countries. 
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Patients in the intervention arm of the trial 
all received a loading and maintenance 
dose based on a genotype-guided 
algorithm. Patients in the control arm in the 
acenocoumarol and phenprocoumon trials 
received a loading dose based on a clinical 
algorithm including the same variables as 
the genotype-guided algorithm, except 
the genetic information. In the warfarin 
trial however, patients in the control arm 
received a standard loading dose instead 
of a dose based on a clinical algorithm. A 
larger difference between the genotype-
guided dosing algorithm and standard care 
is expected than between the genotype-
guided algorithm and a clinical algorithm 
because a clinical algorithm might already 
perform better than the standard dosing 
regimen. Therefore a greater benefit of the 
genotype-guided dosing algorithm might 
be expected in the warfarin trial. 
Next to the percentage time in 
INR range, the EU-PACT study will 
investigate for example the number of 
INR measurements, quality of life and the 
utility of a point-of-care genotype test. 
This point-of-care test makes it possible 
to determine the CYP2C9 and VKORC1 
genotype within 100 minutes and has not 
been used in clinical practice before. We 
validated this method using 156 samples 
from the UK, Sweden and The Netherlands 
and all genotypes were in concordance 
with results obtained by other methods. 
It is a simple test which can be performed 
by for example anticoagulation clinic staff 
without laboratory training 24. 
cost-effectiveness uncertainties
Many uncertainties exist in the studies 
on the cost-effectiveness of genotype-
guided dosing of coumarin derivatives. 
As mentioned before, the effectiveness of 
this strategy is a major contributor to this 
uncertainty.  Because we are still waiting 
for the results from large randomised 
trials, the studies in this thesis cannot 
provide a conclusion about whether or not 
genotyping should be implemented. For 
the cost-effectiveness analyses in this thesis, 
many assumptions were made. For example, 
because of the lack of information about 
the difference in effect of genotyping on 
anticoagulation control between different 
genotypes, we assumed a similar effect 
among all genotypes. In reality, genotyping 
will probably have the highest impact in 
patients requiring a very high or very low 
dose and less impact in a patient requiring 
an average dose. The cost-effectiveness 
will therefore depend on the prevalence of 
the sensitive or resistant genotypes, which 
varies between different populations 28. 
We also assumed that genotyping would 
have a beneficial effect during the first 
six months of therapy, which is in reality 
probably not more than 3 months, when 
taking into account the results from 
chapter 3 and 4. Next to this, we assumed 
a similar effectiveness of genotype-guided 
phenprocoumon dosing as for genotype-
guided warfarin dosing, because only data 
from trials on genotype-guided warfarin 
dosing were available. No clinical study on 
genotype-guided phenprocoumon dosing 
has been published yet.
In the cost-effectiveness study on the 
pharmacogenetics of phenprocoumon 
we used the percentage time spent in 
the therapeutic INR range as a surrogate 
endpoint for bleeding and thromboembolic 
events. We also used this surrogate endpoint 
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in the study on the new oral anticoagulants, 
but for the coumarin anticoagulant arm 
only. The time spent in different INR 
ranges can be linked to different risks of 
bleeding or thromboembolic events 4. A 
more direct method using the incidence 
of adverse events instead of the surrogate 
INR might lead to less uncertainty, but 
the clinical trials published or currently 
underway are not powered to detect 
differences in these events. It is therefore 
necessary to use the INR as a surrogate 
endpoint in the model. An advantage of 
this endpoint is the possibility to vary the 
percentage time spent in the therapeutic 
INR range to reflect the differences in 
quality of care among different countries 
or settings. This proved especially useful in 
our study on the cost-effectiveness of new 
oral anticoagulants in The Netherlands and 
the United Kingdom. In these countries, 
anticoagulant care is managed differently 
and a different quality of coumarin 
anticoagulant treatment is seen, which 
could be reflected by a different percentage 
time in therapeutic INR range in the cost-
effectiveness models. An assumption in this 
study was that the results from the clinical 
trials on new oral anticoagulants, with an 
average follow up time of approximately 2 
years, could be extrapolated to the lifetime 
horizon of the model. 
Due to the many assumptions in our 
cost-effectiveness analysis, it was necessary 
to perform several sensitivity analyses. All 
parameters were varied over a plausible 
range to determine their impact on the 
cost-effectiveness result. In this way, 
factors causing the largest uncertainty 
could be identified. Also, the chance 
that the new treatment option would be 
cost-effective given a certain threshold 
could be determined by varying multiple 
parameters simultaneously in a probabilistic 
sensitivity analysis. In The Netherlands, 
pharmacogenetic-guided dosing had a 
76% chance of being cost-effectiveness at 
a willingness-to-pay threshold of €20.000 
provided that the percentage time in INR 
range would increase by at least 6% if patients 
received a dose based on their genotype. 
The chance that the new oral anticoagulants 
would be cost-effective was higher in the UK 
than in The Netherlands.
imPlications
use of new oral anticoagulants
The results of this thesis show that there 
are different ways to improve anticoagulant 
therapy for patients with, for example, atrial 
fibrillation. It is plausible that the new oral 
anticoagulants will be used more widely, 
but that coumarin derivatives will also still 
be used, with or without pharmacogenetic-
guided dosing. The choice between the 
different options will depend on the situation 
and the patient. The new oral anticoagulants 
are more effective in the prevention of stroke 
and can be administered as a fixed dose 
and patients do not need to be monitored. 
However, there are also some disadvantages 
to these new drugs. Dabigatran and 
apixaban have to be taken twice daily, 
instead of once daily, which is the case for 
coumarin derivatives or rivaroxaban. This 
could have a negative effect on the patient 
adherence, together with the fact that the 
treatment is not monitored. No biomarker 
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is currently available for monitoring. 
Another disadvantage is that patients with 
renal insufficiency have an increased risk of 
bleeding when using dabigatran, because 
of the prolonged half-live 29. If a bleeding 
occurs or when emergency surgery is 
performed, no specific antidote is available 
yet. The use of Prothrombin Complex 
Concentrate may be considered, but there 
is currently limited evidence supporting 
this 30. In the RE-LY trial, an increased 
risk of myocardial infarction was seen in 
the group of patients on dabigatran 31, 
although this difference was not statistically 
significant in a re-analysis of the data after 
identification of additional events 32. In a 
recent meta-analysis including dabigatran, 
apixaban, rivaroxaban, betrixaban and 
edoxaban for atrial fibriallation, venous 
thromboembolism, orthopaedic surgery or 
acute coronary syndrome, the new drugs 
were associated with an increased risk of 
gastrointestinal bleeds 33.
Although the new oral anticoagulants 
are considered to be effective and safe at 
a fixed dose, personalised dosing of these 
drugs might also be useful in the future. 
For example, it is recommended that 
patients older than 80 years receive a lower 
dabigatran dose than younger patients 
(110 mg twice daily instead of 150 mg 
twice daily) 34. Although there is not much 
evidence on the pharmacogenetics of the 
new oral anticoagulants yet, this might also 
play a role. A first genome wide association 
study identified 2 loci (CES1 and ABCB1) 
associated with the pharmacokinetics of 
dabigatran 35.  The authors stated that the 
possibility exists that genotyping could 
be used to tailor the dabigatran dose to 
improve the efficacy and safety of this drug.
Personalised treatment with 
coumarin derivatives
While the new oral anticoagulants will be 
used more widely, in some cases coumarin 
derivatives might still be preferred over the 
new oral anticoagulants. Physicians have 
more experience with coumarin derivatives 
and therefore might prefer to describe these 
‘old’ drugs. Other physicians might prefer 
the new drugs, but prescribe coumarin 
derivatives to specific patients. This could 
be the case for patients with, for example, 
hepatic or renal impairment, patients with 
a higher risk for non-adherence or patients 
who prefer using coumarin anticoagulants 
instead of the new drugs because of the 
disadvantages of the new drugs. For these 
patients, personalised dosing of coumarin 
derivatives by using a pharmacogenetic-
guided algorithm could be a good treatment 
option. Currently, more evidence on the 
benefit of genotyping is collected, which is 
expected in the near future.
If pharmacogenetic-guided dosing is 
proven to increase the effectiveness and 
safety of coumarin anticoagulant therapy, 
several issues should be addressed before it 
can be used on a large scale. First, someone 
will need to perform the genetic test. This 
can be the GP, a specialised physician, a 
nurse or the pharmacist, depending on 
the organisation of care in the relevant 
country.  With the novel point-of-care 
test described earlier in this chapter it is 
not necessary to send a blood sample to 
a laboratory, which saves time. The point-
of-care test is a very easy method which 
can also be performed by a nurse without 
laboratory training. However, if many 
patients will be genotyped it might be more 
efficient to genotype multiple samples 
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at the same time in a clinical chemistry 
laboratory.  After performing the test, the 
results should be documented and made 
available to other involved persons, such 
as the physician and the pharmacist. The 
physician determining the starting dose 
should know how to interpret the results 
and how to calculate the required dose. 
All these issues require involvement of 
different stakeholders.
How pharmacogenetic-guided dosing 
can be implemented and how the workflow 
should be designed depends on the current 
organisation of care in the relevant country. 
In countries where anticoagulant clinics 
are involved, the role of these clinics will 
change considerably when coumarin 
derivatives will be used less frequently 
because of the increasing use of the new 
oral anticoagulants. The role of these clinics 
could then, for example, be concentrated 
more on patient education or advice to 
clinicians and pharmacists. This could 
include the more complicated issues with 
the new oral anticoagulants, such as reversal 
therapy, advice on pharmacogenetic issues 
with coumarin derivatives or maybe also on 
pharmacogenetic issues with the new oral 
anticoagulants, because pharmacogenetics 
might also play a role in the prescription of 
these new drugs 35.
economic considerations
Because the quality of care and associated 
costs vary among different countries, 
the decision about which treatment 
option should be used can be different 
between countries. In some situations 
improving the quality of current care 
might be more attractive than using the 
new oral anticoagulants. This can be 
achieved in several ways, for example by 
setting up specialised anticoagulation 
clinics, using personalised medicine 
and pharmacogenetic-guided dosing 
or providing extra patient education to 
improve adherence. Because these options 
can also lead to increased costs, it is 
important to assess the cost-effectiveness 
of these options also. Cost-effectiveness 
studies are important to inform decision 
makers about the economic consequences 
of the different treatment options. The 
budget impact of the different options will 
also have to be considered, especially in an 
economic situation where further increases 
in healthcare costs are not feasible.
future
More information on the effectiveness and 
cost-effectiveness of pharmacogenetics with 
coumarin derivatives can be expected in the 
near future. We expect to provide the results 
on the effectiveness of genotyping from the 
EU-PACT trial in the coming months and 
we will also use this data to assess the cost-
effectiveness. For the different European 
countries there will be data on patient 
characteristics, such as the prevalence of 
variant genotypes, the number of INR 
measurements required in the intervention 
and control arm, baseline quality of life 
and of course the percentage time in range 
during the first 3 months of therapy for 
both the intervention and control arm. 
Much information from this thesis has been 
collected to be used in our cost-effectiveness 
analysis with the EU-PACT data. Many 
country specific parameters from chapter 
10 will be used for the country specific cost-
effectiveness analyses. These parameters 
include the characteristics of standard care, 
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such as prevalence of coumarin anticoagulant 
use, frequency of INR measurements and 
setting, and country specific costs. Other 
information on, for example, disutility 
values of adverse events or outcome of 
events (fatal, disabilities etc.) will be derived 
from literature, as well as country specific 
guidelines on discount rates, perspective 
etc. The model with a link between data 
on percentage time in INR range and risk 
of adverse events described in chapter 9 of 
this thesis will serve as a basis for the model 
to investigate the cost-effectiveness using 
EU-PACT data. Cost-effectiveness analyses 
in different countries are possible when this 
model is combined with country specific 
parameters. This will make it possible to 
make reliable comparisons in the impact of 
pharmacogenetic-guided coumarin dosing 
between the different countries and to see in 
which countries it might be particularly cost-
effective.
After the new oral anticoagulants 
have been used for several years and 
pharmacogenetic-guided dosing of coumarin 
anticoagulants has been implemented as 
well, it will be important to re-evaluate 
the effectiveness and cost-effectiveness of 
these treatment options in clinical practice, 
because they might differ from what is seen 
in clinical trials. This would be an interesting 
topic for future research.
Adherence issues would also be useful 
to investigate in the future. Little is known 
about the adherence to the new oral 
anticoagulants. When the adherence to 
the new oral anticoagulants is in reality 
lower than in the clinical trials, the benefit 
of these drugs might be lower. The beliefs 
about medication questionnaire could be 
used to look at the patient’s attitude towards 
the new drugs and other methods, such as 
pill counts, could be used to assess therapy 
adherence. Another subject for future 
research might be to investigate how to 
improve adherence to anticoagulant drugs.
A final issue to consider in the future 
is the relationship between the explained 
variation in dose requirement and the 
possibility to maximise the effectiveness 
and safety of the treatment. With 
the current pharmacogenetic-guided 
algorithms, approximately 50% of the 
variation in dose requirement can be 
explained. It is unknown whether the risk 
of adverse events would further decrease if 
a larger percentage of the variation could 
be explained. Some patients require a 
very high or low dose, which cannot be 
explained by the CYP2C9 and VKORC1 
polymorphisms or the other factors 
included in the algorithms. It is interesting 
to look at other factors explaining these 
discordant phenotypes. An analysis to 
identify novel variants in candidate genes 
determining sensitivity or resistance to 
anticoagulation is planned.
conclusion
Personalised dosing of coumarin 
derivatives could be used to improve the 
therapy with coumarin derivatives in 
patients with atrial fibrillation, venous 
thromboembolism or other indications. 
Pharmacogenetic-guided algorithms can 
be used to predict the required coumarin 
dose before treatment initiation. However, 
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the impact of this strategy to improve 
anticoagulation control (and thereby 
increase the effectiveness and safety) 
seems to be limited to the first months of 
the treatment. New oral anticoagulants can 
also be used as alternatives to coumarin 
derivatives, because these drugs have been 
shown to be non-inferior or even superior 
to warfarin. For all treatment options, it is 
important to assess the cost-effectiveness 
in a country specific manner as quality of 
care and associated costs impact the cost-
effectiveness considerably.
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addendum

summary
Coumarin derivatives such as 
acenocoumarol, phenprocoumon and 
warfarin are frequently used for the 
prevention of stroke and systemic embolism 
in patients with atrial fibrillation or for the 
treatment of venous thromboembolism. 
These oral anticoagulants have a narrow 
therapeutic range and a large variability 
in dose requirement among patients. 
The anticoagulant effect is monitored by 
regular measurement of the International 
Normalised Ratio (INR). An INR below 
2 is related to therapy failure and thereby 
leads to an increased risk of stroke or 
systemic embolism, while an INR above 
3.5 leads to an increased risk of bleeding. 
Personalised dosing using genetic 
information is expected to help physicians 
to prescribe the required dose from the 
start of the therapy and thereby increase 
the efficacy and safety of the treatment. 
In the European Pharmacogenetics of 
Anticoagulant Therapy (EU-PACT) 
trial, we tested a dosing algorithm based 
on age, sex, height, weight, concomitant 
amiodarone use and CYP2C9 and VKORC1 
genotypes. It is important to assess the cost-
effectiveness of pharmacogenetic-guided 
coumarin dosing, because this information 
is used by payers such as health insurers 
to make decisions about reimbursement. 
In this thesis we describe the clinical and 
economic issues of personalised treatment 
with oral anticoagulant drugs. 
In chapter 1 we provide a general 
introduction and describe the aims of 
this thesis. Our aim was to study genetic 
and other determinants that explain 
the variability in response to coumarin 
derivatives. We also aimed to study the 
economic consequences of different 
options (personalised medicine or using 
new oral anticoagulant drugs) to improve 
anticoagulant therapy. More background 
information is provided in chapter 2. 
Currently, patients initiating coumarin 
anticoagulant therapy receive a standard 
loading dose for the first few days. The dose 
is adjusted when the INR is measured after 
a few days. When patients have reached a 
stable INR in the therapeutic range and 
a stable dose, INR measurements will 
be repeated every 4-6 weeks. The stable 
dose can vary up to 10-fold between 
patients. Polymorphisms in the CYP2C9 
gene, coding for the main metabolising 
enzyme of coumarin anticoagulants, and 
the VKORC1 gene, coding for the target 
enzyme of coumarin anticoagulants, 
together explain approximately one-third 
of the variation in dose requirement. Many 
genotype-guided dosing algorithms for 
warfarin have been developed in different 
populations. In contrast, fewer algorithms 
have been published for acenocoumarol 
and phenprocoumon. With these 
algorithms, more than 50% of dose 
variation can be explained. Several clinical 
studies have been published describing 
the effect of pharmacogenetic-guided 
dosing on anticoagulation control, but 
no convincing evidence about the clinical 
significance exists yet. Currently ongoing 
large randomised trials such as EU-PACT 
are expected to provide this evidence 
and this information can then also be 
used to assess the cost-effectiveness of 
pharmacogenetic-guided dosing.
Different determinants of variation 
in response to coumarin anticoagulants 
221
&
Summary
are studied in Part i of this thesis. We 
described the association between 
polymorphisms in CYP2C9 and VKORC1 
and over- and under-anticoagulation in 
different time periods after treatment 
initiation in chapter 3. VKORC1 
genotype had the largest influence on 
over- or under-anticoagulation. Among 
wild-type patients, 73% of the patients 
had a subtherapeutic INR and 30% a 
supratherapeutic INR  in the first month, 
compared to 45% with a subtherapeutic 
INR and 74% with a supratherapeutic 
INR among patients carrying two variant 
alleles. After the first month, the differences 
were much smaller and no difference was 
seen after the sixth month. In chapter 
4 we performed similar analysis for 
phenprocoumon and found no differences 
in risk of over- or under-anticoagulation 
between the genotypes after the first 
month. Pharmacogenetic information 
could therefore be used to prevent 
subtherapeutic or supratherapeutic INRs 
in the first month, but not after the first 
month for phenprocoumon or after 3-6 
months for acenocoumarol.
Concomitant medication use can 
also influence the required coumarin 
dose. In chapter 5 we investigated the 
interaction between the proton pump 
inhibitors omeprazole and esomeprazole 
and phenprocoumon. On average, patients 
using omeprazole or esomeprazole 
required a dose that was 0.49 or 0.39 mg 
per day lower than non-users respectively. 
When these proton pump inhibitors 
were included in a genotype-guided 
dosing algorithm, 56.7% of the dose 
variation could be explained, which is only 
marginally higher than an algorithm not 
including proton pump inhibitors. Next to 
prescribing the correct dose to a patient, 
it is important that a patient is compliant 
with this dose. Therapy adherence is 
associated with the beliefs that patients 
have about their medicines. We described 
the beliefs that patients included in the 
EU-PACT trial have about acenocoumarol 
and phenprocoumon in chapter 6. On 
average, coumarin users had a positive 
attitude towards their treatment. The 
beliefs score about the necessity of the 
treatment was higher than the beliefs score 
about the concerns (for example about side 
effects). This was not different from users 
of other cardiovascular drugs. However, 
patients with atrial fibrillation did have a 
lower score on the necessity beliefs than 
patients with venous thromboembolisms. 
Because of this less positive attitude, the 
risk of non-adherence is higher in patients 
with atrial fibrillation than in patients with 
venous thromboembolism.
In Part ii of this thesis we described 
studies on the cost-effectiveness of 
pharmacogenetic-guided dosing of 
coumarin derivatives, as well as the cost-
effectiveness of the new oral anticoagulants 
dabigatran, apixaban and rivaroxaban. We 
provide an overview of cost-effectiveness 
studies on pharmacogenetic-guided dosing 
of coumarin derivatives published up to the 
end of 2009 in chapter 7. All studies focused 
on genotype-guided dosing of warfarin 
in the United States, except one study on 
acenocoumarol in The Netherlands. The 
results of these studies varied considerably. 
In most studies genotyping led to improved 
health outcomes, but the costs were also 
higher than for standard care, with an 
incremental cost-effectiveness ratio up to 
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almost 350,000 US$ per Quality-Adjusted 
Life-Year (QALY) gained. The wide 
variation in results made it impossible to 
conclude whether or not pharmacogenetic-
guided dosing is a cost-effective strategy. 
More evidence on the effectiveness of 
genotyping on anticoagulation control was 
required and the costs of the genetic test 
needed to be defined more precisely.
In chapter 8 we evaluated a study by 
Meckley et al. on the benefits, risks and 
costs of pharmacogenetic-guided dosing 
of warfarin, published in 2010. In this 
study, the probabilities to experience a 
haemorrhagic or thromboembolic event 
were based on the time spent in different 
INR ranges. The percentage time spent in 
these ranges was derived from a clinical 
trial (CoumaGen) published in 2007. The 
incremental cost-effectiveness ratio of 
genotype-guided dosing versus standard 
care was US$60,000 per QALY gained, 
but the sensitivity analyses showed large 
uncertainty because the effectiveness 
of genotyping in clinical practice is still 
unclear.  The model was adapted to study 
the cost-effectiveness of pharmacogenetic-
guided phenprocoumon dosing in The 
Netherlands in chapter 9. In 2012, the 
results of the CoumaGenII trial were 
published, which showed a larger effect 
of genotyping than the CoumaGen trial 
published in 2007. We used data on the 
percentage time spent in the different 
INR ranges from this trial and assumed 
that genotyping one patient using a 
point-of-care genetic test would cost €40. 
Pharmacogenetic-guided dosing increased 
the QALYs only by 0.0057 (2 days in full 
health), but the incremental costs were 
also low (€15). The incremental cost-
effectiveness ratio was €2658. Because 
there was still a large uncertainty regarding 
the effectiveness, this study could not 
provide enough evidence to conclude 
whether or not pharmacogenetic-guided 
dosing should be implemented.
The management and costs of 
anticoagulant care can influence the cost-
effectiveness of pharmacogenetic-guided 
coumarin dosing. We described the 
organization and costs of anticoagulant 
care for the treatment of atrial fibrillation 
in 6 European countries in chapter 10. 
The setting in which the management of 
the treatment took place varied from a 
specialised anticoagulation clinic to the 
general practitioner and hospital settings. 
The percentage time spent in the target 
range, which is a measure for quality of 
anticoagulation, also varied considerably 
between the countries. The highest 
percentage time within range was seen in 
The Netherlands, which uses a system of 
specialised anticoagulation clinics. Because 
of these differences and the differences in 
costs associated with coumarin therapy 
and management of complications, it 
is likely that the cost-effectiveness of 
pharmacogenetic-guided dosing will also 
vary appreciably among countries. It is 
therefore important to perform country 
specific cost-effectiveness analyses. In 
chapter 11 we conducted country specific 
cost-effectiveness analyses on the new oral 
anticoagulants (NOACs) versus coumarin 
derivatives in The Netherlands and in the 
United Kingdom. In The Netherlands, 
acenocoumarol is most frequently used 
and treatment is monitored and guided by 
specialised anticoagulation clinics with a 
percentage time spent in the therapeutic 
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range of 76-79%. In The United Kingdom, 
warfarin is most frequently used and 
many patients are treated by a general 
practitioner with a percentage time spent 
in the therapeutic range of approximately 
63%. Because of these differences, the 
incremental cost-effectiveness ratios of the 
NOACs were higher in The Netherlands 
than in the United Kingdom, although 
dabigatran and apixaban could be 
considered cost-effective in both countries. 
The incremental cost-effectiveness ratio of 
rivaroxaban versus acenocoumarol in The 
Netherlands was almost €33,000 per QALY 
gained and this drug was therefore not 
considered as cost-effective in this country.
In chapter 12 we discuss the findings 
described in this thesis and their relevance, 
including the strengths and limitations of 
the studies, implications for clinical practise 
and future research. Pharmacogenetic-
guided dosing of coumarin derivatives 
could be used to improve the therapy for 
patients with atrial fibrillation or venous 
thromboembolism. NOACs were also 
shown to be promising alternatives to 
coumarin derivatives. The results of the 
cost-effectiveness studies in this thesis 
underline the importance of country 
specific cost-effectiveness analysis when 
looking at the economic consequences of 
improving oral anticoagulant therapy.
224
samenvatting
Acenocoumarol, fenprocoumon en 
warfarine zijn veel gebruikte orale 
antistollingsmiddelen voor het voorkomen 
van stolsels en bijvoorbeeld een herseninfarct 
bij patiënten met atrium fibrilleren of voor 
de behandeling van veneuze trombose. 
Deze antistollingsmiddelen behoren 
tot de groep van cumarinederivaten en 
hebben een kleine therapeutische breedte. 
Ook bestaat er een grote variabiliteit in 
de benodigde dosering onder patiënten. 
Het antistollingseffect wordt regelmatig 
gecontroleerd door het meten van de INR 
(International Normalised ratio). Wanneer 
een patiënt een INR lager dan 2 heeft, is er 
sprake van onderbehandeling en bestaat er 
een verhoogde kans op een herseninfarct 
of het ontstaan van een stolsel elders in de 
bloedsomloop. Bij een INR hoger dan 3,5 
wordt het risico op een bloeding groter. Het 
berekenen van een persoonlijke dosering 
kan artsen helpen om gelijk vanaf het begin 
van de behandeling de juiste hoeveelheid 
antistollingsmiddel voor te schrijven. Er 
wordt verwacht dat hierdoor de effectiviteit 
en veiligheid van de behandeling 
verbeterd kunnen worden. In het 
EU-PACT (European Pharmacogenetics 
of Anticoagulant Therapy) onderzoek 
hebben wij een doseer algoritme op basis 
van leeftijd, geslacht, lengte, gewicht, 
amiodaron gebruik en CYP2C9 en VKORC1 
genotype getest. Het is belangrijk om de 
kosteneffectiviteit van doseren op basis van 
het genotype te onderzoeken, omdat deze 
informatie gebruikt wordt om bijvoorbeeld 
te bepalen of de genetische test vergoed zou 
moeten worden door de zorgverzekeraar. 
In dit proefschrift beschrijven we de 
klinische en economische gevolgen van een 
geïndividualiseerde behandeling met orale 
antistollingsmiddelen. 
In hoofdstuk 1 geven we een algemene 
introductie op het onderwerp en beschrijven 
we het doel van het proefschrift. Het 
doel was om zowel genetische als andere 
factoren te onderzoeken die van invloed 
zijn op de variabiliteit in de reactie op 
cumarinederivaten. Daarnaast hebben we 
de kosteneffectiviteit van verschillende 
opties voor het verbeteren van de 
antistollingsbehandeling (gepersonaliseerd 
doseren of nieuwe orale antistollingsmiddelen 
zoals dabigatran, apixaban of rivaroxaban) 
bestudeerd. Meer achtergrond informatie 
wordt gegeven in hoofdstuk 2. De 
standaard antistollingszorg houdt op dit 
moment in dat patiënten die starten met 
een cumarinederivaat eerst een standaard 
oplaaddosering voorgeschreven krijgen. Na 
een paar dagen wordt de INR gemeten en 
de dosering aangepast. Ook wanneer de INR 
binnen het therapeutisch gebied ligt en de 
patiënt een stabiele dosering heeft, wordt de 
INR nog ongeveer elke 4-6 weken gemeten. 
De stabiele dosering kan wel tot een factor 
10 verschillen tussen patiënten. Ongeveer 
één derde van deze variatie kan worden 
verklaard door genetische verschillen in 
twee genen. Het CYP2C9 gen codeert voor 
het belangrijkste enzym in het metabolisme 
van cumarinederivaten. Het VKORC1 gen 
codeert voor het aangrijpingspunt van deze 
antistollingsmiddelen. In de literatuur zijn 
al vele doseeralgoritmes voor warfarine 
op basis van deze genetische informatie in 
verschillende populaties beschreven. Voor 
acenocoumarol en fenprocoumon zijn ook 
een aantal algoritmes ontwikkeld, hoewel 
dit er minder zijn dan voor warfarine. 
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Met behulp van deze algoritmes kan meer 
dan 50% van de variabiliteit in benodigde 
dosering worden verklaard. Het effect van 
deze doseeralgoritmes op de effectiviteit en 
veiligheid van de antistollingsbehandeling is 
al in een aantal klinische studies onderzocht, 
maar er bestaat nog geen overtuigend 
bewijs over de klinische relevantie van de 
genetische test. Op dit moment zijn er nog 
een aantal grote studies gaande, waaronder 
EU-PACT, die meer bewijs zullen leveren. 
Deze informatie kan ook gebruikt worden 
om de kosteneffectiviteit van dosering op 
basis van het genotype te bepalen.
In deel i van dit proefschrift zijn 
verschillende factoren bestudeerd die 
invloed kunnen hebben op de variatie in 
reactie op de antistollingsmiddelen. De 
associatie tussen genetische verschillen in 
CYP2C9 en VKORC1 en INR uitschieters 
in verschillende perioden na het starten 
van de behandeling is beschreven in 
hoofdstuk 3. VKORC1 genotype was 
het sterkst geassocieerd met het wel of 
niet hebben van INR uitschieters. Van 
de wild-type patiënten had 73% een INR 
lager dan 2 en 30% een INR hoger dan 3,5 
in de eerste maand. Onder de patiënten 
met twee variant allelen had daarentegen 
maar 30% een INR lager dan 2 en wel 74% 
een INR hoger dan 3,5. Deze verschillen 
waren veel kleiner na de eerste maand 
en niet meer aanwezig vanaf de zesde 
maand. In hoofdstuk 4 hebben we deze 
analyses herhaald voor fenprocoumon. Bij 
fenprocoumon waren er geen verschillen 
in het risico op een te hoge of te lage INR 
tussen de genotypen na de eerste maand 
van de behandeling. Farmacogenetica 
kan gebruikt worden om het risico op 
onder- of overdosering te verkleinen, maar 
dit is beperkt tot de eerste maand voor 
fenprocoumon en tot de eerste drie tot zes 
maanden voor acenocoumarol.
Gelijktijdig gebruik van andere 
geneesmiddelen heeft ook invloed op 
de benodigde dosering. In hoofdstuk 
5 hebben we de interactie tussen de 
protonpompremmers omeprazol en 
esomeprazol en fenprocoumon onderzocht. 
Gebruikers van omeprazol of esomeprazol 
hadden gemiddeld respectievelijk een 0,49 
en 0,39 mg/dag lagere dosering nodig 
in vergelijking met patiënten die deze 
middelen niet gebruikten. Door het gebruik 
van protonpompremmers op te nemen in 
een doseeralgoritme waarbij ook gebruik 
gemaakt wordt van de genetische informatie, 
kon 56,7% van de variatie verklaard 
worden. Met hetzelfde doseeralgoritme 
zonder protonpompremmers, kon 55,9% 
verklaard worden. Naast het voorschrijven 
van de juiste dosering is het ook belangrijk 
dat de patiënt zich aan de voorgeschreven 
dosering houdt. Therapietrouw is 
geassocieerd met de opvattingen die 
patiënten kunnen hebben over hun 
geneesmiddelen. In hoofdstuk 6 hebben 
we de opvattingen over fenprocoumon en 
acenocoumarol beschreven van patiënten 
uit de EU-PACT studie. Over het algemeen 
hadden cumarine gebruikers een positieve 
houding ten opzichte van hun behandeling. 
De score over de noodzaak van het 
gebruik van het antistollingsmiddel was 
hoger dan de score over de zorgen over 
bijvoorbeeld bijwerkingen. Dit was ook het 
geval bij gebruikers van andere middelen 
voor hart- en vaatziekten. Patiënten die 
een cumarinederivaat gebruikten voor 
atriumfibrilleren scoorden wel lager op de 
noodzaak opvattingen dan patiënten die 
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het voor veneuze trombose gebruikten. 
Door deze minder positieve houding ten 
opzichte van de antistollingsbehandeling, 
is het risico op therapie-ontrouw hoger 
bij patiënten met atriumfibrilleren dan bij 
patiënten met veneuze trombose. 
In deel ii van dit proefschrift hebben 
we studies naar de kosteneffectiviteit van 
doseren op basis van het genotype en van de 
nieuwe antistollingsmiddelen dabigatran, 
apixaban en rivaroxaban beschreven. We 
geven een overzicht van alle tot eind 2009 
gepubliceerde kosteneffectiviteitsstudies 
naar genotyperen voor de start van de 
cumarine behandeling in hoofdstuk 7. Al 
deze studies, behalve één, keken naar het 
bepalen van de warfarine dosering op basis 
van het genotype in de Verenigde Staten. 
Er was één studie naar de acenocoumarol 
dosering in Nederland. De resultaten van 
de studies lagen ver uiteen. In de meeste 
studies leverde het doseren op basis van 
het genotype wel een gezondheidswinst 
op, maar ook de kosten waren hoger dan 
voor de huidige standaard zorg. De kosten 
per voor kwaliteit van leven gecorrigeerd 
levensjaar (QALY) was in één studie zelfs 
$350.000. Omdat de resultaten zo ver 
uiteen lagen, was het niet mogelijk om te 
concluderen of het vooraf genetisch testen 
kosteneffectief is of niet. Er is meer bewijs 
nodig over de effectiviteit en veiligheid 
van genetische doseeralgoritmen bij de 
cumarine behandeling en ook de kosten 
van de genetische test moeten preciezer 
worden vastgesteld.
In hoofdstuk 8 hebben we een onderzoek 
van Meckley en collega’s beoordeeld. Dit 
onderzoek naar de gezondheidswinst en de 
kosteneffectiviteit van genotyperen voor de 
warfarine behandeling is gepubliceerd in 
2010. De kans op bloedingen of trombose 
was gebaseerd op het percentage tijd binnen 
verschillende INR grenswaarden. Voor 
deze percentages maakten de onderzoekers 
gebruik van gegevens uit een klinische 
studie (CoumaGen) gepubliceerd in 2007. 
Ten opzichte van standaard zorg waren de 
extra kosten per gewonnen QALY in deze 
studie $60.000, maar er bleek nog een grote 
onzekerheid te zijn in de sensitiviteitsanalyse, 
met name over het effect van genotyperen in 
de klinische praktijk. Het model van Meckley 
en collega’s hebben wij in hoofdstuk 
9 aangepast om de kosteneffectiviteit 
van genotyperen bij de fenprocoumon 
behandeling in Nederland te onderzoeken. In 
2012 zijn de resultaten van de CoumaGenII 
trial gepubliceerd. In dit onderzoek werd een 
groter effect van genotyperen gezien dan in 
de CoumaGen trial van 2007. Wij hebben 
gebruik gemaakt van het percentage tijd in 
het INR streefgebied uit de nieuwste studie. 
Daarnaast hebben we aangenomen dat de 
patiënten konden worden gegenotypeerd 
met een point-of-care test voor €40 per 
patiënt. Door patiënten voor de start met 
fenprocoumon te genotyperen kon er een 
geringe gezondheidswinst van 0,0057 
QALYs behaald worden (2 dagen in volledige 
gezondheid) bij een kleine toename in 
kosten (€15). De kosteneffectiviteitsratio 
was €2658 per gewonnen QALY. Vanwege 
de nog steeds bestaande onzekerheid over 
de effectiviteit van genotyperen, konden 
we met deze studie nog niet genoeg bewijs 
leveren om te concluderen of doseren op 
basis van het genotype zou moeten worden 
geïmplementeerd.
De organisatie en de kosten van de 
antistollingszorg kunnen de kosteneffectiviteit 
van doseren op basis van het genotype 
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beïnvloeden. In hoofdstuk 10 hebben we 
de organisatie van de antistollingszorg en 
de gerelateerde kosten voor de behandeling 
van atriumfibrilleren in zes Europese landen 
beschreven. In sommige landen wordt de 
behandeling met cumarinederivaten begeleid 
door gespecialiseerde trombosediensten, 
terwijl dit in andere landen gedaan wordt 
door de huisarts of een arts in het ziekenhuis. 
Het percentage tijd binnen de INR 
streefwaarden (een maat voor de kwaliteit van 
de antistollingsbehandeling) verschilt ook 
tussen de landen. In Nederland, waar patiënten 
worden behandeld in trombosediensten, 
was dit percentage het hoogst. Door deze 
verschillen en door verschillen in de kosten 
gerelateerd aan de cumarine behandeling 
of de behandeling van complicaties, zal 
ook de kosteneffectiviteit van genotyperen 
in de verschillende landen uiteenlopen. 
Daarom is het belangrijk om land-specifieke 
kosteneffectiviteitsanalyses uit te voeren. In 
hoofdstuk 11 hebben wij een land-specifieke 
kosteneffectiviteitsanalyse uitgevoerd 
waarin we de nieuwe antistollingsmiddelen 
dabigatran, apixaban en rivaroxaban 
vergeleken met de cumarinederivaten in 
Engeland en in Nederland. In Nederland 
is acenocoumarol het meest gebruikte 
cumarinederivaat en is het percentage tijd in 
het INR streefgebied in de trombosediensten 
76-79%. In Engeland wordt warfarine het 
meest gebruikt en de meeste patiënten 
worden door de huisarts behandeld. Het 
percentage tijd binnen het INR streefgebied 
is daar ongeveer 63%. Door deze verschillen 
waren de kosten per gewonnen QALY bij 
de nieuwe antistollingsmiddelen lager in 
Engeland dan in Nederland. In beide landen 
kon de behandeling met dabigatran en 
apixaban gezien worden als kosteneffectief. 
In Nederland waren de extra kosten van 
rivaroxaban bijna €33.000 per gewonnen 
QALY en daarom kon dit middel als niet 
kosteneffectief worden beschouwd in dit 
land. 
In hoofdstuk 12 bespreken we de 
resultaten van dit proefschrift en de 
relevantie ervan. Daarbij beschrijven we 
ook de plus- en minpunten van de studies, 
de implicaties voor de klinische praktijk en 
aanbevelingen voor toekomstig onderzoek. 
Het bepalen van de cumarine dosering op 
basis van het genotype kan de behandeling 
van patiënten met atriumfibrilleren of 
veneuze trombose verbeteren. Daarnaast 
zijn ook de nieuwe antistollingsmiddelen 
veelbelovende alternatieven voor 
cumarinederivaten. Uit de resultaten 
van de kosteneffectiviteitsstudies in dit 
proefschrift blijkt dat het van belang is om 
land-specifieke kosteneffectiviteitsanalyses 
uit te voeren als er gekeken moet worden 
naar de economische gevolgen van het 
verbeteren van de antistollingsbehandeling.
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Daar is ie dan, mijn eigen proefschrift! Het voelt heerlijk om het nu af te hebben, na 4 jaar 
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heen die ik graag wil bedanken voor hun bijdrage.
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de andere stukken heb ik zeer veel aan je advies en prikkelende vragen gehad.
Voor het EU-PACT onderzoek was het prettig dat ik kon samenwerken met een heel 
fijn team hier in Nederland. Diane, jij was vanaf het begin bij het project betrokken en 
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meeste samenwerking op dit project was toch wel met jou, Rianne. Zoals jij al schreef in 
jouw proefschrift, ontmoetten we elkaar even voordat ik op het project startte, onderweg 
naar Newcastle. We waren snel maatjes en er volgden nog meer hele gezellige reisjes. 
Ook onze fietstochtjes van en naar de universiteit waren zowel gezellig als nuttig om alle 
werkzaken door te spreken. Ik vind het super dat je ook mijn paranimf wilt zijn.
The trial was a European project and I enjoyed working together with the international 
EU-PACT team also. Thank you Mia Wadelius, Farhad Kamali, Ann Daly, Vangelis 
Manolopoulos, Munir Pirmohamed, Rita Barallon, Julia Stingl and Elisabeth Haschke-Becher. 
Marcel Bouvy, bedankt voor het meedenken bij het uitzetten van de ‘beliefs about 
medicines’ vragenlijst vóór de start van de trial en bij het schrijven van het artikel 
hierover. Ook wil ik de onderzoekers van de Rotterdam studie, waaronder Loes Visser en 
Martina Teichert graag bedanken voor de samenwerking voor een van de artikelen in dit 
proefschrift. Daarnaast hebben ook Tom Schalekamp en Judith Wessels meegedacht met 
verschillende artikelen, bedankt hiervoor. Mary Geitona, Josep Darba, Dyfrig Hughes, 
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Het verzamelen van alle gegevens was nooit gelukt zonder medewerking van een aantal 
trombosediensten. Allereerst wil ik de medewerkers van de trombosedienst Medial in 
Hoofddorp bedanken voor hun gastvrijheid, eerst bij het pre-EU-PACT onderzoek, maar later 
mocht ik weer bij jullie terecht voor het ‘echte’ onderzoek. Caroline, Erik, Martin, Hanneke, 
Marja en alle dames van de trombosedienst, bedankt voor al jullie hulp en adviezen. Ook bij de 
trombosedienst Atal-mdc in Amsterdam heb ik veel tijd doorgebracht. Het was fijn dat ik welkom 
bleef ook bij uitloop van de studie en het ruimte gebrek binnen de trombosedienst. Speciaal wil 
ik bedanken Mary, Aref, Michelle, Yvonne, Huib en Danielle voor alle betrokkenheid. Hoewel 
ik niet veel in de trombosedienst in Leiden ben geweest, wil ik hier wel graag Felix van der Meer 
bedanken voor zijn betrokkenheid bij de trial en de verschillende studies.
Veel praktisch werk is me uit handen genomen door een aantal studenten, wie ik heb 
mogen begeleiden. Samira, Myrre, Miranda, Hoda, Brenda, Peter, Edwin, Arjan, 
Zamiera, Fazila, Siham en Inge, jullie hebben me heel erg geholpen met het includeren 
van de vele patiënten in de trombosediensten en alle vervolg visites, maar ook bij de 
verschillende onderzoeksprojecten in dit proefschrift. Wilma, wat was ik blij dat 
jij ons team kwam versterken. Het was zeer fijn samenwerken met zo’n gedreven 
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niet mogelijk geweest dit proefschrift te schrijven, dus mijn dank gaat ook uit naar alle 
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Miriam Bruggink, Nicky Michorius en Béate ten Bokum, bedankt voor al het advies 
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Ook de leden van de leescommissie wil ik bedanken voor hun bereidheid het manuscript 
te beoordelen: prof. dr. M.J. Postma, prof. dr. H. ten Cate, prof. dr. A.H. Zwinderman, 
prof. dr. A.C.G. Egberts en prof. dr. A.K. Daly.
Judith, bedankt voor het maken van de mooie cover. Ik waardeer het erg dat je deze voor 
mij wilde ontwerpen ook al werd je net opnieuw moeder. Het is nog leuker geworden dan 
ik had gedacht! 
Wanneer ik niet bij de trombosedienst hoefde te zijn, heb ik altijd een zeer fijne werkomgeving 
gehad bij de afdeling farmaco-epidemiologie en klinische farmacologie. Mijn dank gaat uit 
naar alle collega’s van de afdeling voor de gezellige en inspirerende gesprekken. Speciaal wil 
ik de dames van het secretariaat bedanken. Ineke, Suzanne en Anja, jullie behulpzaamheid 
en advies heb ik altijd heel erg gewaardeerd. Mijn kamergenoten in het Went gebouw, 
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één stuk door kletsen (als we niet aan het zingen waren). Bedankt voor je luisterend oor 
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gesprekken, grappige vragen en simpelweg voor je aanwezigheid.
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gehad. Jij bent altijd behulpzaam, helpen met solliciteren, presentaties voorbereiden, noem 
maar op. Lieve Sijmon, wat ben ik blij met zo’n lief neefje als jij! Lieve Simone, voor jou 
maakt het niet uit of ik nu promoveer of arts word of wat dan ook, ik blijf je zelfde zusje hè?!
Lieve papa en mama, bedankt voor al jullie betrokkenheid en vertrouwen in mijn kunnen 
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